QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered | ||
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ |
Smaller reporting company |
||||
Emerging growth company |
||||||
GUARDIAN PHARMACY SERVICES, INC.
FORM 10-Q
TABLE OF CONTENTS
1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “estimates,” “expects,” “intends,” “may,” “plans,” “seeks,” “should,” “will,” “would,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, some of which are beyond our control. For more information regarding these risks and uncertainties, as well as certain additional risks that we face, refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and the factors more fully described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q. Among the factors that could cause actual results to differ materially from those suggested by forward-looking statements are:
| • | our ability to effectively execute our business strategies, implement new initiatives and improve efficiency; |
| • | our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; |
| • | our relationships with pharmaceutical wholesalers and key manufacturers, long-term health care facilities (“LTCFs”) and health plan payors; |
| • | our ability to maintain and expand relationships with LTCF operators on favorable terms; |
| • | the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees and business and on our supply chain and the LTCFs we serve; |
| • | continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements; |
| • | changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; |
| • | further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; |
| • | our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; |
| • | our exposure to, and the results of, claims, legal proceedings and governmental inquiries; |
| • | our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); |
| • | product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; |
| • | the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; |
| • | the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; |
| • | the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and |
| • | the market price of shares of our Class A common stock has experienced, and may in the future experience, substantial volatility due to relatively lower trading volumes and a limited public float. |
New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in, or implied by, the forward-looking statements. Therefore, we caution you not to place undue reliance on any forward-looking statements or information. Any forward-looking statements only speak as of the date of this Quarterly Report on Form 10-Q. We undertake no obligation to update any forward-looking statements made in this report to reflect events or circumstances after the date of this report or to reflect new information or the occurrence of unanticipated events, except as may be required by law.
2
(In thousands, except share amounts) |
December 31, 2024 |
September 30, 2025 |
||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable, net |
||||||||
Inventories |
||||||||
Other current assets |
||||||||
Total current assets |
||||||||
Property and equipment, net |
||||||||
Intangible assets, net |
||||||||
Goodwill |
||||||||
Operating lease right-of-use |
||||||||
Deferred tax assets |
||||||||
Other assets |
||||||||
Total assets |
$ | $ | ||||||
Liabilities and equity |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued compensation |
||||||||
Operating leases, current portion |
||||||||
Other current liabilities |
||||||||
Total current liabilities |
||||||||
Operating leases, net of current portion |
||||||||
Other liabilities |
||||||||
Total liabilities |
$ | $ | ||||||
Commitments and contingencies (see Note 5) |
||||||||
Equity: |
||||||||
Class A common stock- |
||||||||
Class B common stock- |
||||||||
Additional paid-in capital |
||||||||
Retained earnings |
||||||||
Non-controlling interests |
||||||||
Total equity |
||||||||
Total liabilities and equity |
$ | $ | ||||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
(In thousands, except share and per share amounts) |
2024 |
2025 |
2024 |
2025 |
||||||||||||
| Revenues |
$ | $ | $ | $ | ||||||||||||
| Cost of goods sold |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Gross profit |
||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling, general, and administrative expenses |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating income (loss) |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other expenses (income): |
||||||||||||||||
| Interest expense |
||||||||||||||||
| Other expense (income), net |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total other expenses (income) |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Income (loss) before income taxes |
( |
) | ( |
) | ||||||||||||
| Provision for income taxes |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income (loss) |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization |
||||||||||||||||
| Less net income (loss) attributable to non-controlling interests |
( |
) | ( |
) | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Net income (loss) per share of Class A and Class B common stock 1 |
||||||||||||||||
| Basic |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| Diluted |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| Weighted-average Class A and Class B common shares outstanding |
||||||||||||||||
| Basic |
||||||||||||||||
| Diluted |
||||||||||||||||
1 |
See Note 6 Basic and Diluted Net Income Per Share |
(In thousands, except share amounts) |
Class A Shares |
Class B Shares |
Class A Amount |
Class B Amount |
Additional Paid-in capital |
Retained Earnings |
Non-Controlling Interests |
Total Equity |
||||||||||||||||||||||||
| Balance, December 31, 2024 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||
| Contributions |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Distributions |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Net income attributable to Guardian Pharmacy Services, Inc. |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interest |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Share-based compensation forfeitures |
— | ( |
) | — | — | ( |
) | — | — | ( |
) | |||||||||||||||||||||
| Share-based compensation expense |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Conversion of Class B Common Stock to Class A Common Stock |
( |
) | ( |
) | — | — | — | — | ||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance, March 31, 2025 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Contributions |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Non-cash equity contribution |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Distributions |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Net income attributable to Guardian Pharmacy Services, Inc. |
— | — | — | — | — | |||||||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interest |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Share-based compensation forfeitures |
( |
) | ( |
) | — | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
| Share-based compensation expense |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Issuance of Class A common stock associated with vested restricted stock units |
— | — | — | — | — | — | — | |||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance, June 30, 2025 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Contributions |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Non-cash equity contribution |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Distributions |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||
| Net income attributable to Guardian Pharmacy Services, Inc. |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Net income (loss) attributable to non-controlling interest |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
| Share-based compensation forfeitures |
( |
) | ( |
) | — | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||
| Share-based compensation expense |
— | — | — | — | — | — | ||||||||||||||||||||||||||
| Conversion of Class B Common Stock to Class A Common Stock |
( |
) | ( |
) | — | — | — | — | ||||||||||||||||||||||||
| Issuance of Class B Common Stock associated with acquisition |
— | — | — | — | ||||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Balance, September 30, 2025 |
$ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Guardian Pharmacy, LLC (Prior to Corporate Reorganization) |
Guardian Pharmacy Services, Inc. Stockholders’ Equity |
|||||||||||||||||||||||||||||||||||
(In thousands, except share amounts) |
Members’ Equity |
Class A Shares |
Class B Shares |
Class A Amount |
Class B Amount |
Additional Paid-in capital |
Retained Earnings |
Non-Controlling Interests |
Total Equity |
|||||||||||||||||||||||||||
Balance, December 31, 2023 |
$ | — | — | $ | — | $ | — | $ | — | $ | — | $ | $ | |||||||||||||||||||||||
Contributions |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net income |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Distributions |
( |
) | — | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||
Balance, March 31, 2024 |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Contributions |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Non-cash equity contribution |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net income |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Distributions |
( |
) | — | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||
Balance, June 30, 2024 |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Net income prior to Corporate Reorganization |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Contributions prior to Corporate Reorganization |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Distributions prior to Corporate Reorganization |
( |
) | — | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||
Impacts of Corporate Reorganization and IPO |
||||||||||||||||||||||||||||||||||||
Conversion of non-controlling interest into Guardian Pharmacy, LLC common units |
— | — | — | — | — | — | ( |
) | — | |||||||||||||||||||||||||||
Conversion of Restricted Interest Unit awards into Guardian Pharmacy, LLC common units |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Conversion of Guardian Pharmacy, LLC common units into Class B common stock of Guardian Pharmacy Services, Inc. |
( |
) | — | — | — | — | ||||||||||||||||||||||||||||||
Issuance of Class A common stock, net of costs |
— | — | — | — | — | |||||||||||||||||||||||||||||||
Payments to Class B common stock stockholders of $ |
— | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
Recognition of deferred tax asset, net from Corporate Reorganization |
||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Guardian Pharmacy Services, Inc. |
— | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||
Net income attributable to non-controlling interest subsequent to Corporate Reorganization |
||||||||||||||||||||||||||||||||||||
Equity-based compensation subsequent to Corporate Reorganization |
— | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Balance, September 30, 2024 |
$ | — | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||
Nine Months Ended September 30, |
||||||||
(In thousands) |
2024 |
2025 |
||||||
Operating activities |
||||||||
Net income (loss) |
$ | ( |
) | $ | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
||||||||
Share-based compensation expense |
||||||||
Provision for losses on accounts receivable |
||||||||
Change in deferred tax asset |
— | |||||||
Other |
( |
) | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
( |
) | ( |
) | ||||
Inventories |
( |
) | ( |
) | ||||
Other current assets |
||||||||
Accounts payable |
||||||||
Accrued compensation |
( |
) | ||||||
Other operating liabilities |
( |
) | ( |
) | ||||
Net cash provided by operating activities |
||||||||
Investing activities |
||||||||
Purchases of property and equipment |
( |
) | ( |
) | ||||
Payment for acquisitions |
( |
) | ( |
) | ||||
Other |
||||||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Financing activities |
||||||||
Proceeds from equity offering, net of underwriter fees |
||||||||
Repurchase of outstanding Class A common stock |
— | ( |
) | |||||
Payments of equity offering costs |
( |
) | ( |
) | ||||
Payments to Class B common stockholders |
( |
) | — | |||||
Borrowings from notes payable |
— | |||||||
Repayment of notes payable |
( |
) | ( |
) | ||||
Borrowings from line of credit |
— | |||||||
Repayments of line of credit |
( |
) | — | |||||
Principal payments on finance lease obligations |
( |
) | ( |
) | ||||
Contingent payments related to acquisitions |
— | ( |
) | |||||
Contributions from non-controlling interests |
||||||||
Distributions to non-controlling interests |
( |
) | ( |
) | ||||
Member distributions |
( |
) | — | |||||
Other |
( |
) | — | |||||
Net cash provided by (used in) financing activities |
( |
) | ||||||
Net change in cash and cash equivalents |
||||||||
Cash and cash equivalents, beginning of period |
||||||||
Cash and cash equivalents, end of period |
$ | $ | ||||||
Supplemental disclosure of cash flow information |
||||||||
Cash paid during the year for interest |
$ | $ | ||||||
Cash paid during the year for income taxes |
$ | — | $ | |||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Purchases of property and equipment through finance leases |
$ | $ | ||||||
Accrued and capitalized offering costs recorded to additional paid-in capital |
$ | $ | — | |||||
Non-cash equity contributions from non-controlling interests |
$ | $ | ||||||
1. |
Organization and Background |
| • | All Preferred Units in Guardian Pharmacy, LLC were converted into Common Units, resulting in Guardian Pharmacy, LLC having only Common Units outstanding; |
| • | The membership interests, including Restricted Interest Unit awards, held by members other than Guardian Pharmacy, LLC in our subsidiaries (other than certain subsidiaries that were not parties to the Corporate Reorganization, as discussed below) were converted into Common Units of Guardian Pharmacy, LLC. The subsidiaries that participated in the Corporate Reorganization are referred to as the “Converted Subsidiaries”, and the subsidiaries that were not parties to the Corporate Reorganization (including those which were formed or acquired subsequent to the Corporate Reorganization) are referred to as the Non-Converted Subsidiaries; and |
| • | Guardian Pharmacy, LLC became a wholly-owned subsidiary of the Company by participating in a merger with a transitory subsidiary of the Company. Pursuant to the merger, each Common Unit of Guardian Pharmacy, LLC was converted into (i) one share of the Company’s Class B common stock, par value $ |
2. |
Summary of Significant Accounting Policies |
New Accounting Standard Adopted | ||||||
ASU Number and Name |
Description |
Date of Adoption |
Effect on the unaudited interim Consolidated Financial Statements upon adoption | |||
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures |
ASU 2023-07 requires companies to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and are included within each reported measure of segment operating results. The standard also requires companies to disclose the total amount of any other items included in segment operating results which were not deemed to be significant expenses for separate disclosure, along with a qualitative description of the composition of these other items. In addition, the standard also requires disclosure of the CODM’s title and position, as well as detail on how the CODM uses the reported measure of segment operating results to evaluate segment performance and allocate resources. The standard also aligns interim segment reporting disclosure requirements with annual segment reporting disclosure requirements. The standard requires retrospective application to all prior periods presented. |
January 1, 2024 for annual disclosures. January 1, 2025 for interim disclosures. |
The Company adopted the standard on January 1, 2024 for annual disclosures, and January 1, 2025 for interim disclosures. See Note 8 Segments for new disclosures. | |||
2024-01, Scope Application of Profits Interest and Similar Awards |
ASU 2024-01 clarifies the scope application of profits interest and similar awards by adding illustrative guidance in ASC 718 - Compensation - Stock Compensation. |
January 1, 2025 for annual and interim disclosures |
The Company adopted the standard as of January 1, 2025, with no material impact on the Consolidated Financial Statements. | |||
New Accounting Standards Not Yet Effective | ||||||
ASU Number and Name |
Description |
Date of Adoption |
Effect on the unaudited interim Consolidated Financial Statements upon adoption | |||
2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures |
ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The standard requires the annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. |
January 1, 2025 for annual disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2025. The Company is currently evaluating the impact of the incremental income taxes information that will be required to be disclosed as well as the impact to the Income Taxes footnote in the Form 10-K. | |||
2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) |
ASU 2024-03 requires Public Business Entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items that are considered “relevant.” |
January 1, 2027 for annual disclosures; January 1, 2028 for interim disclosures |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2027. The Company is currently evaluating the impact of the incremental disaggregated expense information that will be required to be disclosed. | |||
2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810):Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity |
ASU 2025-03 revises the guidance in ASC 805 on identifying the accounting acquirer in a business combination in which the legal acquiree is a variable interest entity (VIE). The ASU is intended to improve comparability between business combinations that involve VIEs and those that do not. |
January 1, 2027 for annual disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2027. The Company is currently evaluating the impact of the new standard. | |||
2025-04, Compensation—StockCompensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer |
ASU 2025-04 clarifies the guidance in both ASC 606 and ASC 718 on the accounting for share-based payment awards that are granted by an entity as consideration payable to its customer. The ASU is intended to reduce diversity in practice and improve existing guidance, primarily by revising the definition of a “performance condition” and eliminating a forfeiture policy election for service conditions associated with share-based consideration payable to a customer. |
January 1, 2027 for annual disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2027. The Company is currently evaluating the impact of the new standard. | |||
2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets |
ASU 2025-05 amends ASC 326-202 to provide a practical expedient (for all entities) and an accounting policy election (for all entities, other than public business entities, that elect the practical expedient) related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. |
January 1, 2026 for annual and interim disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2026. The Company is currently evaluating the impact of the new standard. | |||
2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software |
ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs under ASC 350-40. |
January 1, 2028 for annual and interim disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2028. The Company is currently evaluating the impact of the new standard. | |||
2025-07—Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract |
ASU 2025-07 refines the scope of the guidance on derivatives in ASC 815 and clarifies the guidance on share-based payments from a customer in ASC 606. The ASU is intended to address concerns about the application of derivative accounting to contracts that have features based on the operations or activities of one of the parties to the contract and to reduce diversity in the accounting for share-based payments in revenue contracts. |
January 1, 2027 for annual and interim disclosures. |
The Company will adopt the new disclosures for the annual periods beginning on January 1, 2027. The Company is currently evaluating the impact of the new standard. | |||
3. |
Acquisitions |
| (in thousands) |
Fair Value |
|||
| Total purchase consideration |
$ | |||
| Net assets acquired: |
||||
| Inventory |
||||
| Other assets |
||||
| Intangible Assets |
||||
| Other liabilities |
( |
) | ||
| Non-controlling interest equity |
( |
) | ||
| |
|
|||
| Net assets acquired |
||||
| |
|
|||
| Goodwill |
$ | |||
| |
|
|||
| (in thousands) |
Fair Value |
|||
| Total purchase consideration |
$ | |||
| Net assets acquired: |
||||
| Inventory |
||||
| Other assets |
||||
| Intangible Assets |
||||
| Other liabilities |
( |
) | ||
| Non-controlling interest equity |
( |
) | ||
| |
|
|||
| Net assets acquired |
||||
| |
|
|||
| Goodwill |
$ | |||
| |
|
|||
4. |
Fair Value Measurements |
| • | Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. |
| • | Level 2 - Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. |
| • | Level 3 - Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs that market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk. |
Level 1 |
Level 2 |
Level 3 |
||||||||||
| December 31, 2024 |
||||||||||||
| Liabilities: |
||||||||||||
| Contingent consideration payable |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
| Fair value of financial instruments |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
Level 1 |
Level 2 |
Level 3 |
||||||||||
| September 30, 2025 |
||||||||||||
| Liabilities: |
||||||||||||
| Contingent consideration payable |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
| Fair value of financial instruments |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
| Balance at December 31, 2024 |
$ | |||
| |
|
|||
| Current year acquisitions |
||||
| Fair value adjustments |
||||
| Payments |
||||
| |
|
|||
| Balance at March 31, 2025 |
||||
| |
|
|||
| Current year acquisitions |
||||
| Fair value adjustments |
||||
| Payments |
( |
) | ||
| |
|
|||
| Balance at June 30, 2025 |
||||
| |
|
|||
| Current year acquisitions |
||||
| Fair value adjustments |
||||
| Payments |
||||
| |
|
|||
| Balance at September 30, 2025 |
$ | |||
| |
|
5. |
Commitments and Contingencies |
6. |
Basic and Diluted Net Income Per Share |
(in thousands) |
Three Months Ended September 30, 2024 |
Nine Months Ended September 30, 2024 |
Three Months Ended September 30, 2025 |
Nine Months Ended September 30, 2025 |
||||||||||||
Numerator: |
||||||||||||||||
Net income (loss) |
$ | ( |
) | $ | ( |
) | $ | $ | ||||||||
Less: Net income attributable to Guardian Pharmacy, LLC before Corporate Reorganization |
||||||||||||||||
Less net income (loss) attributable to non-controlling interests |
( |
) | ( |
) | ||||||||||||
Net income (loss) attributable to Guardian Pharmacy Services, Inc. |
$ | ( |
) | $ | ( |
) | $ | $ | ||||||||
Three Months Ended September 30, 2025 |
Nine Months Ended September 30, 2025 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Basic net income per share attributable to common stockholders |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income attributable to Guardian Pharmacy Services, Inc. |
$ | $ | $ | $ | ||||||||||||
Denominator: |
||||||||||||||||
Weighted average number of shares of Class A and Class B common stock outstanding |
||||||||||||||||
Basic net income per share attributable to common stockholders |
$ | $ | $ | $ | ||||||||||||
Diluted net income per share attributable to common stockholders |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income attributable to Guardian Pharmacy Services, Inc. |
$ | $ | $ | $ | ||||||||||||
Denominator: |
||||||||||||||||
Number of shares used in basic computation |
||||||||||||||||
Dilutive Restricted Stock Units and Class A and B Common Stock |
||||||||||||||||
Weighted average shares of Class A and Class B common stock outstanding used to calculate diluted net income per share |
||||||||||||||||
Diluted net income per share attributable to common stockholders |
$ | $ | $ | $ | ||||||||||||
Three Months Ended September 30, 2024 |
Nine Months Ended September 30, 2024 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Basic net income (loss) per share attributable to common stockholders |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income (loss) attributable to Guardian Pharmacy Inc. |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Denominator: |
||||||||||||||||
Weighted average number of shares of Class A and Class B common stock outstanding |
||||||||||||||||
Basic net income (loss) per share attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Diluted net income (loss) per share attributable to common stockholders |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income (loss) attributable to Guardian Pharmacy Inc. |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Denominator: |
||||||||||||||||
Number of shares used in basic computation |
||||||||||||||||
Dilutive Restricted Stock Units and Class B Common Stock |
||||||||||||||||
Weighted average shares of Class A and Class B common stock outstanding used to calculate diluted net income (loss) per share |
||||||||||||||||
Diluted net income (loss) per share attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
Three Months Ended September 30, 2024 |
Nine Months Ended September 30, 2024 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Anti-dilutive unvested Restricted Stock Units and Class B Common Stock |
||||||||||||||||
Total anti-dilutive securities |
||||||||||||||||
7. |
Share-based Compensation |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2024 |
2025 |
2024 |
2025 |
|||||||||||||
| Pre-IPO awards |
$ | $ | $ | $ | ||||||||||||
| Unvested Class A and B common stock |
||||||||||||||||
| Restricted stock units |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Total share-based compensation expense |
$ | $ | $ | $ | ||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
Amount |
Weighted Average Remaining Service Period (years) |
|||||||
| Restricted stock units |
||||||||
| |
|
|||||||
| Total unamortized share-based compensation cost |
$ | |||||||
| |
|
|||||||
8. |
Segments |
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
2024 |
2025 |
2024 |
2025 |
|||||||||||||
| Revenue |
$ | $ | $ | $ | ||||||||||||
| Less: |
||||||||||||||||
| Employee expenses (excluding share-based compensation expense) |
||||||||||||||||
| Share-based compensation expense |
||||||||||||||||
| Other segment items (1) |
||||||||||||||||
| Depreciation and amortization |
||||||||||||||||
| Interest expense |
||||||||||||||||
| Income taxes |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Segment net income (loss) |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconciliation of net income to consolidated statements of operations |
||||||||||||||||
| Adjustments and reconciling items |
||||||||||||||||
| Consolidated net income (loss) |
$ | ( |
) | $ | $ | ( |
) | $ | ||||||||
| |
|
|
|
|
|
|
|
|||||||||
| (1) | Other segment items included in operating segment net income include product expenses, legal expenses, rent and auto lease expenses, utilities expenses, maintenance expenses, and other overhead expenses. |
9. |
Income Taxes |
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and our audited consolidated financial statements and related notes thereto and the discussion under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2024.
This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions, that are based on the beliefs of our management. Our actual results could differ materially from those discussed in these forward-looking statements. See “Special Note Regarding Forward-Looking Statements.”
Unless the context otherwise requires, the terms “Guardian,” the “Company,” “we,” “us” and “our” when used in this report mean Guardian Pharmacy Services, Inc. and all subsidiaries included in our consolidated financial statements.
Overview
We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (“LTCFs”) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We enter into contracts directly with LTCFs to serve as the principal pharmacy provider for their residents. In this capacity, we offer high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”) and behavioral health facilities (“BHFs”). Additionally, our robust capabilities enable us to serve residents in all types of LTCFs. Our services include prescription intake and adjudication management, packaging drugs into unit dose and/or multi-dose compliance packaging that are organized by date and time of administration, and electronically tracking each drug from delivery through administration to LTCF residents. We also offer training to caregivers and conduct mock audits to ensure compliance with pharmacy administration requirements, billing claims processing, government regulation and other matters. As of September 30, 2025, our 53 pharmacies served approximately 204,000 residents in approximately 8,200 LTCFs across 38 states.
20
While our national competitors have primarily focused on skilled nursing facilities (“SNFs”), we believe we enjoy a strong competitive position as a large and purpose-built provider of pharmacy services to ALFs and BHFs. More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs, while the remainder has been generated primarily from residents of SNFs. LTCF industry trends, including aging demographics, increases in the number of assisted living residents, improving life expectancies and enhanced quality of care, have resulted in ALF and BHF resident populations that require assistance with their increasingly acute and complex healthcare needs. Through our value-added capabilities and local management model, we have been able to pass on to residents, LTCFs and health plan payors the benefits of our scale without compromising on the high-touch, localized customer service traditionally associated with an independent pharmacy. For this reason, we are well positioned to continue to serve ALFs and BHFs, which we believe to be the most attractive and highest growth sector of the LTCF market.
Our core growth strategy focuses on increasing the number of residents we serve through a combination of organic and acquired growth. Acquired growth represents growth in the number of residents served resulting from acquiring an operating pharmacy, which we measure using the number of residents served by the acquired pharmacy as of the acquisition date. Organic growth represents the increase in the number of residents served at existing pharmacies, our greenfield pharmacies, and acquired pharmacies subsequent to the acquisition date. We have generated organic growth through new and expanded LTCF relationships as well as increased resident adoption of our services in the facilities we already serve.
Corporate Reorganization and IPO
On September 27, 2024, the Company consummated its IPO of 8,000,000 shares of its Class A common stock, as described in the Prospectus. Also on September 27, 2024, the underwriters for the IPO exercised in full their option to purchase an additional 1,200,000 shares of Class A common stock. The 9,200,000 shares were issued at a public offering price of $14.00 per share, resulting in net proceeds to the Company of $119.8 million, after deducting underwriting discounts of $9.0 million. In addition to the underwriting discounts, the Company incurred $13.0 million of offering costs, which were recorded to additional paid-in capital.
Prior to the IPO, we conducted our business through Guardian Pharmacy, LLC, and its majority owned and wholly owned limited liability company subsidiaries, which were treated for income tax purposes as partnerships and disregarded entities, respectively. Immediately prior to the IPO, we completed a series of corporate reorganization transactions (the “Corporate Reorganization”), pursuant to which:
| • | All Preferred Units in Guardian Pharmacy, LLC were converted into Common Units, resulting in Guardian Pharmacy, LLC having only Common Units outstanding; |
| • | The membership interests, including Restricted Interest Unit awards, held by members other than Guardian Pharmacy, LLC in our subsidiaries (other than certain subsidiaries that were not parties to the Corporate Reorganization, as discussed below) were converted into Common Units of Guardian Pharmacy, LLC. The subsidiaries that participated in the Corporate Reorganization are referred to as the “Converted Subsidiaries”, and the subsidiaries that were not parties to the Corporate Reorganization (including those which were formed or acquired subsequent to the Corporate Reorganization) are referred to as the “Non-Converted Subsidiaries”; and |
| • | Guardian Pharmacy, LLC became a wholly-owned subsidiary of the Company by participating in a merger with a transitory subsidiary of the Company. Pursuant to the merger, each Common Unit of Guardian Pharmacy, LLC was converted into (i) one share of the Company’s Class B common stock, par value $0.001 per share (“Class B common stock”) and (ii) the right to receive $1.02 in cash per share, without interest (collectively, the “Merger Consideration”). In the merger, 54,094,232 shares of Class B common stock were issued in exchange for Common Units of Guardian Pharmacy, LLC. In accordance with the terms of the Company’s Amended and Restated Certificate of Incorporation, such issued shares of Class B common stock automatically convert on a one-for-one basis into shares of the Company’s Class A common stock, par value $0.001 per share (“Class A common stock”), with 25% of each holder’s shares of Class B common stock converting into shares of Class A common stock on each of the following dates: (i) March 28, 2025; (ii) September 27, 2025; (iii) March 28, 2026; and (iv) September 27, 2026. The Merger Consideration was $55,176 and was paid using the proceeds from the IPO. |
As a result of the Corporate Reorganization, the Company became a holding company with no material assets other than its 100% interest in Guardian Pharmacy, LLC, and the Converted Subsidiaries became wholly owned subsidiaries of Guardian Pharmacy, LLC. In addition, Guardian Pharmacy, LLC remained the majority owner of each of the Non-Converted Subsidiaries.
The Non-Converted Subsidiaries are (i) greenfield start-up pharmacies in various stages of development and integration with Guardian and do not currently have material operations or (ii) pharmacies that we recently acquired. After a period of time that would typically be sufficient to allow such pharmacies to adopt our operating practices and experience meaningful growth in residents served and earnings, we expect to acquire the minority membership interests of such Non-Converted Subsidiaries.
21
Conversion of Class B Common Stock to Class A Common stock
In accordance with the terms of the Company’s Amended and Restated Certificate of Incorporation and the conversion schedule described in the Corporate Reorganization and IPO section above, on March 28, 2025 and September 27, 2025, 13,519,946 and 13,523,285 shares, respectively, of the Company’s Class B common stock automatically converted, in accordance with the terms of such class and without any further action by their holders or the Company, into an equal number of shares of the Company’s Class A common stock.
Follow-On Offering
In May 2025, the Company completed an underwritten follow-on public offering (“Q2 2025 Offering”) of 1,440,447 shares of Class A common stock at an offering price of $21.00 per share. We used all of the net proceeds from the Q2 2025 Offering to purchase 1,440,447 shares of outstanding Class A common stock that were issued upon conversion of shares of our Class B common stock that were originally issued in connection with our Corporate Reorganization. The 1,440,447 shares of Class A common stock purchased by the Company were cancelled, resulting in no change to the total number of Class A common stock outstanding. We did not retain any of the proceeds from the sale of shares in the offering.
As part of the Q2 2025 offering, certain selling shareholders, consisting of the Company’s founders (the “Guardian Founders”), sold 6,059,553 shares of Class A common stock. We did not receive any proceeds from the sale of shares by the selling shareholders in this offering.
Factors Affecting the Comparability of Our Results of Operations
Our results of operations for the three and nine months ended September 30, 2025 and the corresponding period in 2024 have been affected by the following, among other factors, which must be understood to assess the comparability of our period-to-period financial performance and condition.
Acquisitions
Our growth strategy involves periodically acquiring institutional pharmacies servicing LTCFs and their residents as well as residents in other care settings. Our strategy includes the acquisition of freestanding institutional pharmacy businesses as well as other assets, generally less significant in size, which are combined with existing pharmacy operations to augment internal organic growth.
During 2024 and 2025, we completed acquisitions of various pharmacy operations (the “Acquisitions”). The operating results of the Acquisitions were a contributing factor in certain changes in the results of operations for the three and nine months ended September 30, 2025 compared to the corresponding periods in 2024. Acquisition impacts are considered when the beginning of the comparative period precedes the acquisition date.
Share-Based Compensation (in connection with the Corporate Reorganization and IPO)
In connection with the Corporate Reorganization and IPO, Restricted Interest Unit awards associated with the Converted Subsidiaries and Guardian Pharmacy, LLC were converted into Common Units of Guardian Pharmacy, LLC, and the Common Units in Guardian Pharmacy, LLC were then converted into Class B common stock of the Company. This conversion of Restricted Interest Units was treated as a modification, requiring the units to be marked to fair value on the modification date, resulting in the Company recognizing $122.4 million of incremental share-based compensation expense during the three and nine months period ended September 30, 2024.
Components of Results of Operations
Revenues. We recognize revenue at the time of delivery of prescriptions and other pharmacy services to the LTCF, at which time control has been transferred. Revenue recognized reflects the consideration we expect to receive in exchange for these goods and services.
Cost of goods sold. Cost of goods sold consists primarily of expenses associated with the fulfillment and delivery of the prescription. Cost of goods sold also includes associated pharmacy personnel-related expenses, including salaries and benefits, delivery charges and other supporting overhead costs (such as rent and depreciation and amortization of assets used in the fulfillment and delivery of the prescription).
22
Selling, general, and administrative expenses. Selling, general, and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, salaries and benefits, for our employees at the pharmacies and support services engaged in other pharmacy related activities including sales and marketing, finance, legal, human resources, purchasing and other administrative functions. Selling, general, and administrative expenses also include facilities-related expenses, software expenses, sales and marketing expenses, insurance premiums, professional services expenses, including for outside legal and accounting services, other overhead costs, changes in the fair value of contingent payments related to acquisitions, depreciation related to long lived assets, and amortization of intangible assets.
Prior to the Corporate Reorganization and IPO, share-based compensation expense primarily represented non-cash recognition of changes in the value of Restricted Interest Unit awards. These awards contained a cash settlement feature and were accounted for as a liability in accordance with generally accepted accounting principles in the United States of America (“GAAP”). These units remained in place until they were (a) forfeited (which occurs when the employee leaves before the units are fully vested), (b) paid out (we purchase the units at a calculated value upon termination of employment) or (c) converted into shares as a result of a major capital event such as a sale or public offering. These units vest in their entirety on the third anniversary of their grant date. The value of the units is recognized ratably over the vesting period and is remeasured and reported at the end of each quarter based on the change in calculated value pursuant to our Restricted Interest Purchase Agreements. The primary inputs used to value the units include the accumulated vesting status of the issued units, the trailing four quarters of our adjusted earnings, inclusive of share-based compensation expense, and our outstanding capital and debt obligations as of the quarterly measurement date. The liability and corresponding expense are adjusted on a quarterly basis. Based on the number of participants and units outstanding, trailing earnings, forfeitures and other factors, we have experienced volatility in our share-based compensation liability. This calculation has in turn had a significant impact on our net income for the periods presented.
In connection with the Corporate Reorganization and IPO, all outstanding Restricted Interest Unit awards, other than those issued by Non-Converted Subsidiaries, were converted into shares of Class B common stock and are no longer considered a liability. In addition to the unvested Class B common stock issued in connection with the Corporate Reorganization and IPO, the Company has share-based compensation awards in the form of restricted stock units, which are settled in shares of Class A common stock upon vesting and are considered equity-based awards.
Interest expense. Interest expense consists of interest on long-term debt and line of credit under our credit facility and finance leases.
Other expense (income), net. Other expense, net consists primarily of gain (loss) on asset disposals and interest income earned on cash deposits.
Provision for income taxes. Provision for income taxes consists primarily of income taxes in certain jurisdictions in which we conduct business.
23
Results of Operations for the Three and Nine Months Ended September 30, 2024 and 2025
The following table sets forth our consolidated statements of operations data for the three and nine months ended September 30, 2024 and 2025, respectively. The year-over-year comparison of results of operations is not necessarily indicative of results for future periods.
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| (in thousands) | 2024 | 2025 | 2024 | 2025 | ||||||||||||
| Revenues |
$ | 314,393 | $ | 377,427 | $ | 889,840 | $ | 1,051,069 | ||||||||
| Cost of goods sold |
253,515 | 302,706 | 712,573 | 843,853 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
60,878 | 74,721 | 177,267 | 207,216 | ||||||||||||
| Selling, general, and administrative expenses (1) |
165,491 | 58,367 | 256,942 | 165,277 | ||||||||||||
| Operating income (loss) |
(104,613 | ) | 16,354 | (79,675 | ) | 41,939 | ||||||||||
| Other expenses (income): |
||||||||||||||||
| Interest expense |
1,026 | 160 | 2,857 | 502 | ||||||||||||
| Other expense (income), net |
2 | (437 | ) | 166 | (887 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other expenses (income) |
1,028 | (277 | ) | 3,023 | (385 | ) | ||||||||||
| Income (loss) before income taxes |
(105,641 | ) | 16,631 | (82,698 | ) | 42,324 | ||||||||||
| Provision for income taxes |
176 | 7,038 | 176 | 14,631 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
(105,817 | ) | 9,593 | (82,874 | ) | 27,693 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization |
9,350 | — | 22,760 | — | ||||||||||||
| Less net income (loss) attributable to non-controlling interests (2) |
6,823 | (225 | ) | 16,356 | (603 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. |
$ | (121,990 | ) | $ | 9,818 | $ | (121,990 | ) | $ | 28,296 | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA (3) |
$ | 23,012 | $ | 27,275 | $ | 64,944 | $ | 75,659 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (1) | Included in selling, general, and administrative expenses is share-based compensation expense of $122,355 and $4,356 during the three months ended September 30, 2024 and 2025, respectively, and $128,029 and $12,770 during the nine months ended September 30, 2024 and 2025, respectively. For the three and nine months ended September 30, 2024, this share-based compensation expense primarily represents the incremental expense recognized for Restricted Interest Unit awards that were modified in connection with the Corporate Reorganization and IPO. For the three and nine months ended September 30, 2025, this share-based compensation expense primarily represents the incremental expense recognized for Restricted Interest Unit awards that were modified in connection with the Corporate Reorganization and IPO, and share-based compensation expense for Restricted Stock Units granted for Class A common stock. |
| (2) | For the three and nine months ended September 30, 2024, these figures, for both Converted Subsidiaries and Non-Converted Subsidiaries, reflect minority membership interests in our subsidiaries preceding the Corporate Reorganization and IPO. For the three and nine months ended September 30, 2025, these figures reflect the minority membership interest for the Non-Converted Subsidiaries subsequent to the Corporate Reorganization and IPO. |
| (3) | See “—Adjusted EBITDA and Other Non-GAAP Financial Measures” below for more information and for a reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP. |
Revenue
| Three Months Ended September 30, |
% Change | Nine Months Ended September 30, |
% Change | |||||||||||||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||
| Revenue |
$ | 314,393 | $ | 377,427 | 20.0 | % | $ | 889,840 | $ | 1,051,069 | 18.1 | % | ||||||||||||
24
Revenue for the three months ended September 30, 2025 increased by $63.0 million or 20.0% compared to the three months ended September 30, 2024. $20.0 million of the increase was attributable to revenue from the Acquisitions, with the remaining $43.0 million of the increase attributable to the organic growth of our business. Further, the increase was attributable to increases in the number of residents served from 180,000 residents during September 2024 to 204,000 residents during September 2025 and prescriptions dispensed from 6.4 million during the three months ended September 30, 2024 to 7.3 million during the three months ended September 30, 2025, as well as annual drug price inflation.
Revenue for the nine months ended September 30, 2025 increased by $161.2 million or 18.1% compared to the nine months ended September 30, 2024. $51.2 million of the increase was attributable to revenue from the Acquisitions, with the remaining $110.0 million of the increase attributable to the organic growth of our business. Further, the increase was attributable to increases in the number of residents served from 180,000 residents during September 2024 to 204,000 residents during September 2025 and prescriptions dispensed from 18.4 million during the nine months ended September 30, 2024 to 21.0 million during the nine months ended September 30, 2025, as well as annual drug price inflation.
Cost of goods sold
| Three Months Ended September 30, |
% Change | Nine Months Ended September 30, |
% Change | |||||||||||||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||
| Cost of goods sold |
$ | 253,515 | $ | 302,706 | 19.4 | % | $ | 712,573 | $ | 843,853 | 18.4 | % | ||||||||||||
| Percentage of revenue |
80.6 | % | 80.2 | % | 80.1 | % | 80.3 | % | ||||||||||||||||
Cost of goods sold for the three months ended September 30, 2025 increased by $49.2 million or 19.4% compared to the three months ended September 30, 2024. $18.1 million of the increase was attributable to the Acquisitions, with the remaining $31.1 million of the increase attributable to the organic growth of our business. Cost of goods sold as a percentage of revenue decreased from 80.6% to 80.2% during the three months ended September 30, 2025.
Cost of goods sold for the nine months ended September 30, 2025 increased by $131.3 million or 18.4% compared to the nine months ended September 30, 2024. $45.4 million of the increase was attributable to the Acquisitions, with the remaining $85.9 million of the increase attributable to the organic growth of our business. Cost of goods sold as a percentage of revenue increased from 80.1% to 80.3% during the nine months ended September 30, 2025.
Selling, general, and administrative expenses
| Three Months Ended September 30, |
% Change | Nine Months Ended September 30, |
% Change | |||||||||||||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||
| Selling, general, and administrative expenses |
$ | 165,491 | $ | 58,367 | (64.7 | )% | $ | 256,942 | $ | 165,277 | (35.7 | )% | ||||||||||||
| Percentage of revenue |
52.6 | % | 15.5 | % | 28.9 | % | 15.7 | % | ||||||||||||||||
Selling, general and administrative expenses decreased $107.1 million or (64.7)% for the three months ended September 30, 2025 compared to the three months ended September 30, 2024. $118.0 million of the decrease was driven by decreases in share-based compensation expense, as the three months ended September 30, 2024 included significant share-based compensation expense recognized in connection with the Corporate Reorganization and IPO. This decrease was offset by a $10.9 million increase in expense due to an increase in average employee headcount, with $8.2 million resulting from organic growth and $2.7 million resulting from the Acquisitions. Selling, general and administrative expenses as a percentage of revenue decreased from 52.6% to 15.5% based primarily on decreases to share-based compensation expense described above.
25
Selling, general and administrative expenses decreased $91.7 million or (35.7)% for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. $115.3 million of the decrease was driven by decreases in share-based compensation expense, as the nine months ended September 30, 2024 included significant share-based compensation expense recognized in connection with the Corporate Reorganization and IPO. This decrease was offset by a $23.6 million increase in expense due to an increase in average employee headcount, with $16.3 million resulting from organic growth and $7.3 million resulting from the Acquisitions. Selling, general and administrative expenses as a percentage of revenue decreased from 28.9% to 15.7% based primarily on decreases to share-based compensation expense described above.
Interest expense
| Three Months Ended September 30, |
% Change | Nine Months Ended September 30, |
% Change | |||||||||||||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||
| Interest expense |
$ | 1,026 | $ | 160 | (84.4 | )% | $ | 2,857 | $ | 502 | (82.4 | )% | ||||||||||||
Interest expense decreased by $0.9 million or (84.4)% for the three months ended September 30, 2025 compared to the three months ended September 30, 2024. The decrease was due to having no balances outstanding under the Credit Facility (see “-Liquidity and Capital Resources” below) during the three months ended September 30, 2025.
Interest expense decreased by $2.4 million or (82.4)% for the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024. The decrease was due to having no balances outstanding under the Credit Facility (see “-Liquidity and Capital Resources” below) during the nine months ended September 30, 2025.
Provision for income taxes
| Three Months Ended September 30, |
% Change | Nine Months Ended September 30, |
% Change | |||||||||||||||||||||
| 2024 | 2025 | 2024 | 2025 | |||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||
| Provision for income taxes |
$ | 176 | $ | 7,038 | N/M | $ | 176 | $ | 14,631 | N/M | ||||||||||||||
Income tax expense increased by $6.8 million and $14.4 million for the three and nine months ended September 30, 2025, respectively, when compared to the prior year. Prior to the IPO, we conducted our business through Guardian Pharmacy, LLC, and its majority-owned and wholly-owned limited liability company subsidiaries, which were treated for income tax purposes as partnerships and disregarded entities, respectively. As such, minimal income tax expense was recorded during the three and nine months ended September 30, 2024.
Adjusted EBITDA and Other Non-GAAP Financial Measures
To supplement the results presented in our consolidated financial statements in accordance with GAAP, we also present Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A, which are financial measures not based on any standardized methodology prescribed by GAAP.
We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, acquisition accounting adjustments, certain legal and regulatory items, financing-related and other activities, payor-reimbursement matters, and certain tax matters related to the Corporate Reorganization and IPO.
We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, the income tax impact of the adjustments, and certain tax matters related to the Corporate Reorganization and IPO.
26
We define Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A and Class B common stock.
We define Adjusted SG&A as GAAP selling, general, and administrative expenses adjusted to exclude the impact of share-based compensation, expenses relating to certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.
Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A may not be the same as, or comparable to, similarly titled measures used by other companies.
We use Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.
There are a number of limitations related to the use of Adjusted EBITDA, Adjusted EPS, and Adjusted SG&A rather than the most directly comparable GAAP financial measure, including:
| • | Adjusted EBITDA does not reflect interest and income tax payments that represent a reduction in cash available to us; |
| • | Depreciation and amortization are non-cash charges and the assets being depreciated may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; |
| • | Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS does not reflect changes in, or cash requirements for, our working capital needs; |
| • | Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A do not consider the impact of share-based compensation; and |
| • | Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A exclude the impact of certain legal and regulatory items, and payor-reimbursement matters which can affect our current and future cash requirements. |
Because of these limitations, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A alongside other financial measures, including net income, diluted EPS, GAAP selling, general, and administrative expense and our other financial results presented in accordance with GAAP.
27
A reconciliation of Adjusted EBITDA to net income, of Adjusted Net Income to Net Income Attributable to Guardian Pharmacy Services, Inc., and of Adjusted SG&A to GAAP selling, general, and administrative expense, the most directly comparable GAAP financial measures, are set forth below.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (in thousands) | 2024 | 2025 | 2024 | 2025 | ||||||||||||
| Net income (loss) |
(105,817 | ) | 9,593 | (82,874 | ) | 27,693 | ||||||||||
| Add: |
||||||||||||||||
| Interest expense (income), net |
1,026 | (133 | ) | 2,857 | (203 | ) | ||||||||||
| Depreciation and amortization |
4,994 | 5,838 | 14,619 | 16,594 | ||||||||||||
| Provision for income taxes |
176 | 7,038 | 176 | 14,631 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| EBITDA |
$ | (99,621 | ) | $ | 22,336 | $ | (65,222 | ) | $ | 58,715 | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Share-based compensation (1) |
122,355 | 4,356 | 128,029 | 12,770 | ||||||||||||
| Certain legal & other regulatory matters (2) |
278 | 435 | 3,807 | 1,057 | ||||||||||||
| Financing-related and other activities (3) |
— | 110 | — | 1,924 | ||||||||||||
| Payor-reimbursement matters (4) |
$ | — | $ | 38 | $ | (1,670 | ) | $ | 1,193 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | 23,012 | $ | 27,275 | $ | 64,944 | $ | 75,659 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income as a percentage of revenue |
(33.7 | )% | 2.5 | % | (9.3 | )% | 2.6 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA as a percentage of revenue |
7.3 | % | 7.2 | % | 7.3 | % | 7.2 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net Income (loss) attributable to Guardian Pharmacy Services, Inc. |
(121,990 | ) | 9,818 | (121,990 | ) | 28,296 | ||||||||||
| Share-based compensation (1) |
N/M | 4,356 | N/M | 12,770 | ||||||||||||
| Certain legal & other regulatory matters (2) |
N/M | 435 | N/M | 1,057 | ||||||||||||
| Financing-related and other activities (3) |
N/M | 110 | N/M | 1,924 | ||||||||||||
| Payor-reimbursement matters (4) |
N/M | 38 | N/M | 1,193 | ||||||||||||
| Acquisition-related intangible asset amortization (5) |
N/M | 978 | N/M | 2,687 | ||||||||||||
| Income tax impact of adjustments (7) |
N/M | (1,759 | ) | N/M | (5,854 | ) | ||||||||||
| Certain tax matters related to Corporate Reorganization and IPO (6) |
— | 1,725 | — | 1,725 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net income |
N/M | (8) | $ | 15,701 | N/M | (8) | $ | 43,798 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding used in calculating diluted U.S. GAAP net income per share |
61,143,311 | 63,432,468 | 61,143,311 | 63,179,784 | ||||||||||||
| Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per share |
N/M | 63,432,468 | N/M | 63,179,784 | ||||||||||||
| Diluted EPS |
$ | (2.00 | ) | $ | 0.15 | $ | (2.00 | ) | $ | 0.45 | ||||||
| Adjusted EPS |
N/M | (8) | $ | 0.25 | N/M | (8) | $ | 0.69 | ||||||||
| GAAP selling, general, and administrative expenses |
$ | 165,491 | $ | 58,367 | $ | 256,942 | $ | 165,277 | ||||||||
| Subtract: |
||||||||||||||||
| Share-based compensation (1) |
122,355 | 4,356 | 128,029 | 12,770 | ||||||||||||
| Certain legal & other regulatory matters (2) |
278 | 435 | 3,807 | 1,057 | ||||||||||||
| Financing-related and other activities (3) |
— | 110 | — | 1,924 | ||||||||||||
| Payor-reimbursement matters (4) |
$ | — | $ | 1,668 | $ | — | $ | 2,806 | ||||||||
| Adjusted SG&A |
$ | 42,858 | $ | 51,798 | $ | 125,106 | $ | 146,703 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP selling, general, and administrative expenses as a percentage of revenue |
52.6 | % | 15.5 | % | 28.9 | % | 15.7 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted SG&A as a percentage of revenue |
13.6 | % | 13.7 | % | 14.1 | % | 14.0 | % | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
28
| (1) | Prior to the Corporate Reorganization and IPO, our share-based compensation expense primarily represented non-cash recognition of changes in the value of Restricted Interest Unit awards, which had historically been recorded as a liability using a cash settlement methodology as calculated on a quarterly basis. In connection with the Corporate Reorganization and IPO, certain Restricted Interest Unit awards were modified, resulting in share-based compensation expense of $122.4 million, based on the fair value of the modified awards. Share-based compensation expense for the three and nine months ended September 30, 2025 relates to equity-classified awards. |
| (2) | Represents non-recurring attorney’s fees, settlement costs and other expenses associated with certain legal proceedings. The Company excludes such charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations. |
| (3) | Represents non-recurring costs associated with various financing-related activities and costs to transition to a public company. |
| (4) | Represents proceeds and legal expenses associated with payor reimbursement matters. |
Proceeds received associated with payor reimbursement matters, recorded as revenue, were $1.6 million during the three and nine months ended September 30, 2025, and $0.0 million and $1.7 million during the three and nine months ended September 30, 2024, respectively.
Legal expenses associated with payor reimbursement matters during the three and nine months ended September 30, 2025 were $1.7 million and $2.8 million, respectively and $0.0 million during the three and nine months ended September 30, 2024.
| (5) | Represents amortization expense associated with the acquisition-related intangible assets, such as customer lists and trademarks. |
| (6) | Represents non-recurring income tax expense associated with the Corporate Reorganization and IPO. The Company excludes such charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion allows for consistent evaluation of operations. |
| (7) | Represents the income tax impact of non-GAAP adjustments, calculated using the estimated tax rate for the respective non-GAAP adjustment. |
| (8) | Adjusted net income and Adjusted EPS are not calculated for the three and nine months ended September 30, 2024, as the net income attributable to Guardian Pharmacy Services, Inc. only includes net income for the three days in the period subsequent to our IPO on September 27, 2024. As such, we do not think the non-GAAP measures for adjusted net income and adjusted EPS are meaningful for these periods. |
Liquidity and Capital Resources
We have historically financed our business and acquisitions primarily through cash from operations and borrowings under our credit facility and, more recently, sales of our Class A common stock in our IPO. We use cash in the ordinary course of our operations primarily for prescription drug acquisition costs, capital expenditures, and personnel costs. As of September 30, 2025, we had $36.5 million in cash and cash equivalents. Our cash primarily consists of demand deposits held with a large regional financial institution.
On May 13, 2024, the Company entered into the Sixth Amendment to the Third Amended and Restated Loan and Security Agreement (the “2024 Amendment”) to the existing credit facility with Regions Bank (the “Credit Facility”). The Credit Facility provides for term loans (the “Term Loan”) and a line of credit. The 2024 Amendment extended the maturity date of the Credit Facility from April 23, 2025 to April 23, 2027. The line of credit under the Credit Facility bears an interest rate equal to the one-month Secured Overnight Financing Rate (“SOFR”) plus an additional rate of 1.80% to 2.80% based on certain financial ratios maintained by the Company. The total amount available under the line of credit as of September 30, 2025 is $40 million and we have the ability to increase our overall Credit Facility up to $75 million.
29
As of September 30, 2025, we had no amounts of principal outstanding under the Term Loan and no borrowings outstanding under the line of credit.
We believe our existing cash and cash equivalents, expected cash flows provided by our operations, and the amounts available under our Credit Facility will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months and for the foreseeable future, though we may require additional capital resources in the future.
Net Cash Flows
For the nine months ended September 30, 2024 and 2025, respectively, our net cash flows provided by / (used in) were as follows:
| Nine Months Ended September 30, |
||||||||
| (in thousands) | 2024 | 2025 | ||||||
| Operating activities |
$ | 35,623 | $ | 65,655 | ||||
|
|
|
|
|
|||||
| Investing activities |
(23,783 | ) | (27,515 | ) | ||||
|
|
|
|
|
|||||
| Financing activities |
24,629 | (6,313 | ) | |||||
Operating Activities
Cash flows provided by operating activities consist of our net income principally adjusted for certain non-cash items, such as depreciation and amortization, provision for losses on accounts receivable, changes in deferred tax asset, and share-based compensation expense. Cash flows used in operating activities consist primarily of changes in our operating assets and liabilities. Subsequent to the Corporate Reorganization and IPO, income tax payments and receivables are presented as changes in operating assets and liabilities within operating activities.
Net cash provided by operating activities for the nine months ended September 30, 2025 increased by $30.0 million compared to the corresponding period in 2024. The increase was primarily attributable to increases in accounts payable and accrued compensation, lower accounts receivable growth, and decreases in the use of cash for other operating liabilities when compared to the corresponding period in 2024.
Investing Activities
Cash flows provided by investing activities consist primarily of proceeds from disposition of property and equipment. Cash flows used in investing activities consist primarily of acquisitions and capital expenditures relating to our new and existing pharmacy locations.
Net cash used in investing activities for the six months ended September 30, 2025 increased by $3.7 million compared to the corresponding period in 2024. The increase was primarily due to the increase in cash paid for purchases of property plant and equipment of $3.5 million compared to the corresponding period in 2024.
Financing Activities
Cash flows provided by financing activities consist primarily of borrowings from the line of credit and sale of our common stock. Cash flows used in financing activities consist primarily of repayment of borrowings from the term loan (recorded as repayment of notes payable) and the line of credit, and payment of equity offering costs associated with the IPO. Prior to the Corporate Reorganization and IPO, cash flows used in financing activities included significant distributions to equity holders (inclusive of non-controlling interests) of Guardian Pharmacy, LLC, mostly consisting of distributions to fund income tax liabilities and operational distributions, as well as return of capital.
Net cash used in financing activities for the nine months ended June 30, 2025 increased by $30.9 million compared to the corresponding period in 2024.
30
Cash flows used in financing activities were $6.3 million for the nine months ended September 30, 2025, primarily due to $3.4 million in payments for finance lease obligations, $1.6 million of payments for equity offering costs, $2.2 million in payments for contingent payments associated with acquisitions, offset by $1.6 million in contributions from non-controlling interests.
Cash flows provided by financing activities were $24.6 million for the nine months ended September 30, 2024, primarily due to net proceeds received from the IPO of $119.8 million and the 2024 Amendment resulting in $15.0 million being added to the Credit Facility, offset by the Merger Consideration payment to holders of Class B common stock of $55.2 million in connection with the Corporate Reorganization and IPO, and distributions to equity holders (inclusive of non-controlling interest) of $50.4 million.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in accordance with GAAP. Preparing our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses as well as related disclosures. Because these estimates and judgments may change from period to period, actual results could differ materially, which may negatively affect our financial condition or results of operations. We base our estimates and judgments on historical experience and various other assumptions that we consider reasonable, and we evaluate these estimates and judgments on an ongoing basis.
See the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K, filed for the year ended December 31, 2024, for further discussion of critical accounting estimates. There were no material changes to our critical accounting policies with which the estimates are developed since December 31, 2024.
Recent Accounting Pronouncements
Refer to Note 2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for accounting pronouncements adopted and recent accounting pronouncements not yet adopted as of the date of this Quarterly Report on Form 10-Q.
JOBS Act Accounting Election
The JOBS Act permits EGCs to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.
We could remain an “emerging growth company” until the last day of the fiscal year following the fifth anniversary of our IPO, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion, (b) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common equity that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (c) the date on which we have issued more than $1.0 billion in non-convertible debt securities during any three-year period.
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents of $36.5 million as of September 30, 2025, which primarily consist of demand deposits held with financial institutions. Changes in interest rates affect the interest income we earn on our cash and cash equivalents and the fair value of our cash equivalents. Historical fluctuations in interest rates have not had a significant impact on our financial condition or results of operations, and a hypothetical 100 basis point increase or decrease in interest rates would not have a material impact on the value of our cash and cash equivalents or on our future financial condition or results of operations.
31
ITEM 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2025.
Based on management’s evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2025, our disclosure controls and procedures were designed, and were effective, to provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management as appropriate to allow timely decisions regarding required disclosures.
In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Changes in Internal Control over Financial Reporting
During the three and nine months ended September 30, 2025, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
32
ITEM 6. Exhibits
35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Guardian Pharmacy Services, Inc. | ||||||
| Date: November 10, 2025 | By: | /s/ David K. Morris | ||||
| David K. Morris | ||||||
| Executive Vice President and Chief Financial Officer | ||||||
| (Principal Financial and Accounting Officer) | ||||||
36
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Fred P. Burke, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Guardian Pharmacy Services, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 10, 2025
| /s/ Fred P. Burke |
| Fred P. Burke |
| President and Chief Executive Officer |
| (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, David K. Morris, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Guardian Pharmacy Services, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 10, 2025
| /s/ David K. Morris |
| David K. Morris |
| Executive Vice President and Chief Financial Officer |
| (Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Guardian Pharmacy Services, Inc. (the “Company”), does hereby certify, to such officer’s knowledge, that the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ Fred P. Burke | ||||||
| Dated: November 10, 2025 | Fred P. Burke Title: President and Chief Executive Officer | |||||
| (Principal Executive Officer) |
The foregoing certification is furnished and is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not deemed to be incorporated by reference into any filing of Guardian Pharmacy Services, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Guardian Pharmacy Services, Inc. specifically incorporates it by reference.
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Guardian Pharmacy Services, Inc. (the “Company”), do hereby certify, to such officer’s knowledge, that the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ David K. Morris | ||||||
| Dated: November 10, 2025 | David K. Morris Title: Executive Vice President and Chief Financial Officer | |||||
| (Principal Financial Officer) |
The foregoing certification is furnished and is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not deemed to be incorporated by reference into any filing of Guardian Pharmacy Services, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Guardian Pharmacy Services, Inc. specifically incorporates it by reference.
Consolidated Balance Sheets (Parenthetical) - $ / shares |
Sep. 30, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Class A common stock [Member] | ||
| Common stock, par or stated value per share | $ 0.001 | |
| Common Stock [Member] | Class A common stock [Member] | ||
| Common stock, shares authorized | 700,000,000 | 700,000,000 |
| Common stock, par or stated value per share | $ 0.001 | $ 0.001 |
| Common stock, shares, issued | 36,253,744 | 9,200,000 |
| Common stock, shares, outstanding | 36,253,744 | 9,200,000 |
| Common Stock [Member] | Class B common stock [Member] | ||
| Common stock, shares authorized | 100,000,000 | 100,000,000 |
| Common stock, par or stated value per share | $ 0.001 | $ 0.001 |
| Common stock, shares, issued | 27,066,890 | 54,087,158 |
| Common stock, shares, outstanding | 27,066,890 | 54,087,158 |
Consolidated Statements of Operations - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|||
| Revenues | $ 377,427 | $ 314,393 | $ 1,051,069 | $ 889,840 | ||
| Cost of goods sold | 302,706 | 253,515 | 843,853 | 712,573 | ||
| Gross profit | 74,721 | 60,878 | 207,216 | 177,267 | ||
| Selling, general, and administrative expenses | 58,367 | 165,491 | 165,277 | 256,942 | ||
| Operating income (loss) | 16,354 | (104,613) | 41,939 | (79,675) | ||
| Other expenses (income): | ||||||
| Interest expense | 160 | 1,026 | 502 | 2,857 | ||
| Other expense (income), net | (437) | 2 | (887) | 166 | ||
| Total other expenses (income) | (277) | 1,028 | (385) | 3,023 | ||
| Income (loss) before income taxes | 16,631 | (105,641) | 42,324 | (82,698) | ||
| Provision for income taxes | 7,038 | 176 | 14,631 | 176 | ||
| Net income (loss) | 9,593 | (105,817) | 27,693 | (82,874) | ||
| Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization | 0 | 9,350 | 0 | 22,760 | ||
| Less net income (loss) attributable to non-controlling interests | (225) | 6,823 | (603) | 16,356 | ||
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. | $ 9,818 | $ (121,990) | $ 28,296 | $ (121,990) | ||
| Class A and Class B common stock [Member] | ||||||
| Net income (loss) per share of Class A and Class B common stock | ||||||
| Basic | [1] | $ 0.16 | $ (2) | $ 0.46 | $ (2) | |
| Diluted | [1] | $ 0.15 | $ (2) | $ 0.45 | $ (2) | |
| Weighted-average Class A and Class B common shares outstanding | ||||||
| Basic | 62,124,010 | 61,143,311 | 62,071,370 | 61,143,311 | ||
| Diluted | 63,432,468 | 61,143,311 | 63,179,784 | 61,143,311 | ||
| ||||||
Consolidated Statements of Changes in Members' Equity and Stockholders' Equity (Parenthetical) |
9 Months Ended |
|---|---|
|
Sep. 30, 2025
$ / shares
| |
| Statement of Stockholders' Equity [Abstract] | |
| Payment to common stock per share | $ 1.02 |
Pay vs Performance Disclosure - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Pay vs Performance Disclosure | ||||||
| Net Income (Loss) | $ 9,818 | $ 9,030 | $ 9,448 | $ (121,990) | $ 28,296 | $ (121,990) |
Insider Trading Arrangements |
9 Months Ended |
|---|---|
Sep. 30, 2025 | |
| Trading Arrangements, by Individual | |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
Organization and Background |
9 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||
| Organization and Background |
Business Guardian Pharmacy Services, Inc. (the “Company”) is a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (“LTCFs”) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We enter into contracts directly with LTCFs to serve as the principal pharmacy provider for their residents. In this capacity, we offer high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities, and behavioral health facilities and group homes. Additionally, our robust suite of capabilities enables us to serve residents in all types of LTCFs. We are a trusted partner to residents, LTCFs and health plan payors because we help reduce errors in drug administration, manage and ensure adherence to drug regimens, and lower overall healthcare costs. Organization The Company was incorporated in the state of Delaware on November 16, 2021. The Company was formed for the purpose of completing an initial public offering (“IPO”) of its common stock and related corporate reorganization transactions in order to carry on the business of Guardian Pharmacy, LLC, which was formed on July 21, 2003 as an Indiana limited liability company, as a publicly-traded entity. Corporate Reorganization Prior to the IPO, we conducted our business through Guardian Pharmacy, LLC, and its majority owned and wholly owned limited liability company subsidiaries, which were treated for income tax purposes as partnerships and disregarded entities, respectively. Immediately prior to the IPO, we completed a series of corporate reorganization transactions (the “Corporate Reorganization”), pursuant to which:
As a result of the Corporate Reorganization, the Company became a holding company with no material assets other than its 100% interest in Guardian Pharmacy, LLC, and the Converted Subsidiaries became wholly owned subsidiaries of Guardian Pharmacy, LLC. In addition, Guardian Pharmacy, LLC remained the majority owner of each of the Non-Converted Subsidiaries. The Non-Converted Subsidiaries are (i) greenfield start-up pharmacies in various stages of development and integration with Guardian and do not currently have material operations or (ii) pharmacies that we recently acquired. After a period of time that would typically be sufficient to allow such pharmacies to adopt our operating practices and experience meaningful growth in residents served and earnings, we expect to acquire the minority membership interests of such Non-Converted Subsidiaries. As a result of the Corporate Reorganization, the Company recorded deferred tax assets and liabilities attributable to the business of Guardian Pharmacy, LLC. In addition, the Company received tax basis for the $55,176 in cash payments related to the Merger Consideration, which are amortizable for tax purposes. To reflect this new taxability at the corporate level and the tax step-up, the Company recorded an incremental net deferred tax asset through additional paid-in capital of $5,973 on September 27, 2024. See Note 9 for further discussion. Initial Public Offering On September 27, 2024, the Company consummated its IPO of 8,000,000 shares of its Class A common stock, as described in the Company’s final prospectus dated September 25, 2024, filed with the Securities and Exchange Commission (“SEC”) on September 26, 2024, pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Prospectus”). Also on September 27, 2024, the underwriters for the IPO exercised in full their option to purchase an additional 1,200,000 shares of Class A common stock. The 9,200,000 shares were issued at a public offering price of $14.00 per share, resulting in net proceeds to the Company of $119,784, after deducting underwriting discounts of $9,016. In addition to the underwriting discounts, the Company incurred $13,023 of offering costs, which were recorded to additional paid-in capital. Conversion of Class B Common Stock to Class A Common Stock In accordance with the terms of the Company’s Amended and Restated Certificate of Incorporation and the conversion schedule described in the Corporate Reorganization section above, on March 28, 2025 and September 27, 2025, 13,519,946 shares and 13,523,285 shares, respectively, of the Company’s Class B common stock automatically converted, in accordance with the terms of such class and without any further action by their holders or the Company, into an equal number of shares of the Company’s Class A common stock. Follow-On Offering In May 2025, the Company completed an underwritten follow-on public offering (“Q2 2025 Offering”) of 1,440,447 shares of Class A common stock at an offering price of $21.00 per share. We used all of the net proceeds from the Q2 2025 Offering to purchase 1,440,447 shares of outstanding Class A common stock that were issued upon conversion of shares of our Class B common stock that were originally issued in connection with our Corporate Reorganization. The 1,440,447 shares of Class A common stock purchased by the Company were cancelled, resulting in no change to the total number of Class A common stock outstanding. We did not retain any of the proceeds from the sale of shares in the offering. As part of the Q2 2025 Offering, certain selling shareholders, consisting of the Company’s founders (the “Guardian Founders”), sold 6,059,553 shares of Class A common stock. We did not receive any proceeds from the sale of shares by the selling shareholders in this offering.
|
Summary of Significant Accounting Policies |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Significant Accounting Policies |
Principles of consolidation The accompanying unaudited interim consolidated financial statements include the accounts of the Company and all controlled subsidiaries (collectively, the “Company”). All intercompany transactions and accounts have been eliminated. Results of operations of the Company’s controlled subsidiaries have been included from the date of acquisition. Basis of Presentation The accompanying unaudited interim consolidated financial statements are prepared in conformity with the generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting. Accordingly, these unaudited interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. Certain footnote disclosures have been omitted that would substantially duplicate the disclosures in the Company’s audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2024, unless information contained in those disclosures materially changed or is required by U.S. GAAP to be included in interim financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair presentation of the unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2024 and 2025 have been recorded. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2025, or any other period. These interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2024, as filed with the SEC on March 26, 2025. The Corporate Reorganization was accounted for as a combination of entities under common control. As a result, the financial reports filed with the SEC by the Company subsequent to the Corporate Reorganization are prepared “as if” Guardian Pharmacy, LLC is the accounting predecessor of the Company. The historical operations of Guardian Pharmacy, LLC are deemed to be those of the Company. Thus, the financial statements included in this report reflect (i) the historical operating results of Guardian Pharmacy, LLC prior to the Corporate Reorganization; (ii) the consolidated results of the Company and Guardian Pharmacy, LLC following the Corporate Reorganization; (iii) the assets and liabilities of the Company and Guardian Pharmacy, LLC at their historical cost; and (iv) the Company’s equity structure for all periods presented. No step-up basis of intangible assets or goodwill was recorded. Guardian Pharmacy, LLC has been determined to be our predecessor for accounting purposes and, accordingly, the consolidated financial statements for periods prior to the Corporate Reorganization have been adjusted to combine the previously separate entities for presentation purposes. The Company had no material operations prior to the Corporate Reorganization, and is acting as a holding company, with 100% ownership interest in Guardian Pharmacy, LLC, subsequent to the Corporate Reorganization. Thus, the Company’s financial position, results of operations and cash flows effectively represent those of Guardian Pharmacy, LLC as of and for all periods presented. New Accounting Pronouncements The following table provides a description of recent accounting pronouncements that are applicable to the Company’s unaudited interim consolidated financial statements:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Acquisitions |
The Company’s growth strategy involves periodically acquiring institutional pharmacies servicing LTCFs and their residents as well as residents in other care settings. The Company’s strategy includes the acquisition of freestanding institutional pharmacy businesses as well as other assets, generally less significant in size, which are combined with existing pharmacy operations to augment internal organic growth. 2025 Acquisitions During the nine months ended September 30, 2025, the Company completed acquisitions of various pharmacy operations (the “2025 Acquisitions”). 13,230, 24,075 shares of Class B common stock with a fair value of $441, and contingent earnout payments of up to $2,600 if certain revenue and earnings targets are achieved during the first full four quarters subsequent to the acquisition date. The fair value of the shares of Class B common stock issued was determined based on the closing share price of the Company’s Class A common stock on the acquisition date, discounted for a lack of registration, as the Class B common stock remains unregistered. The fair value of the contingent consideration arrangements at the acquisition dates and at September 30, 2025 was $2,600. (see Note 4 Fair Value Measurements The 2025 Acquisitions included non-controlling interests, for which the fair value was estimated to be $3,609. The fair value of the non-controlling interests was estimated by utilizing the implied fair value of the non-controlling interest, determined based on the acquisition purchase price, and considering discounts necessary due to the lack of marketability and lack of control associated with the non-controlling interest. We incurred an immaterial amount of acquisition costs in connection with the 2025 Acquisitions. The 2025 Acquisitions were treated as a purchase in accordance with ASC 805, Business Combinations The preliminary recognition of assets acquired and liabilities assumed for the 2025 Acquisitions as of September 30, 2025 is as follows:
Goodwill and Intangible Assets Goodwill represents the excess of the purchase price over the estimated fair value of the identifiable net assets acquired in the 2025 Acquisitions. Goodwill represents future economic benefits expected to arise from the Company’s expanded presence in the long-term care pharmacy industry, the assembled workforce acquired, expected revenue synergies, as well as operating efficiencies and cost savings. Of the $10,275 of goodwill recorded related to the 2025 Acquisitions, $8,016 is expected to be deductible for tax purposes. Intangible assets are comprised of customer lists and trademarks. The fair values for the customer lists and trademarks were $6,400 and $290, respectively. The weighted average useful lives for the customer lists and trademarks were 10 years and 5 years, respectively. Consolidated Results of Operations The results of operations for the 2025 Acquisitions have been included in the consolidated financial statements since the date of acquisition. During the three months and nine months ended September 30, 2025, the Company’s consolidated statements of operations included $16,167 and $20,772 of revenue associated with the 2025 Acquisitions, respectively. Net income related to the 2025 Acquisitions was not material to the consolidated financial statements. The comparable prior period results of operations associated with the 2025 Acquisitions are not material to the consolidated financial statements, and as such, supplemental pro forma financial information is not presented. 2024 Acquisitions In 2024, the Company completed acquisitions of various pharmacy operations (the “2024 Acquisitions”). Total consideration for the 2024 Acquisitions included cash of $14,710, and contingent earnout payments of up to $2,700 if certain revenue and earnings targets are achieved by certain acquired entities during the two-year period subsequent to the respective acquisition dates. The fair value of the contingent consideration arrangement at the acquisition dates and as of December 31, 2024 was $2,700, and at September 30, 2025 was $750. During the nine months ended September 30, 2025, we made payments totaling $1,950 to settle a portion of the contingent consideration (see Note 4 Fair Value Measurements The 2024 Acquisitions included non-controlling interests, for which the fair value was estimated to be $5,371 at the time of the Acquisitions. The fair value of the non-controlling interests was estimated by utilizing the implied fair value of the non-controlling interests, determined based on the acquisition price, and considering discounts necessary due to the lack of marketability and lack of control associated with the non-controlling interests. During 2024, we incurred an immaterial amount of acquisition costs in connection with the 2024 Acquisitions. The 2024 Acquisitions were treated as a purchase in accordance with ASC 805, Business Combinations, which requires recognition of the estimated fair values of assets acquired and liabilities assumed in a transaction. Our recognition of the assets acquired and liabilities assumed was based on management’s judgment after evaluating several factors, including a valuation assessment. There were no material measurement period adjustments recognized in periods subsequent to the 2024 Acquisitions. The recognition of the assets and liabilities of the 2024 Acquisitions was as follows during 2024:
Goodwill and Intangible Assets Goodwill represents the excess of the purchase price over the estimated fair value of the identifiable net assets acquired in the 2024 Acquisitions. Goodwill represents future economic benefits expected to arise from the Company’s expanded presence in the long-term care pharmacy industry, the assembled workforce acquired, expected revenue synergies, as well as operating efficiencies and cost savings. Of the $13,250 of goodwill recorded related to the 2024 Acquisitions, $9,957 is expected to be deductible for tax purposes. Intangible assets are comprised of customer lists and trademarks. The fair values for the customer lists and trademarks were $5,686 and $550, respectively. The weighted average useful lives for the customer lists and trademarks were 10 years and 5 years, respectively. Consolidated Results of Operations The results of operations for the 2024 Acquisitions have been included in the consolidated financial statements since the dates of acquisition. The comparable prior period results of operations associated with the 2024 Acquisitions are not material to the consolidated financial statements, and as such, supplemental pro forma financial information is not presented.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measurements |
The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:
Financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, line of credit, and notes payable. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term maturity of these instruments. The following table summarizes the valuation of liabilities measured at fair value on a recurring basis on the Company’s Consolidated Balance Sheets:
The fair value measurement of the contingent consideration obligations arising from acquisitions is based upon Level 3 unobservable inputs including, in part, the estimate of future cash flows based upon the likelihood of achieving the various criteria triggering the payment of the obligations. The fair values of the liabilities associated with contingent consideration obligations were derived using the income approach with unobservable inputs, which included future earnings forecasts for which there is no market data. Fair value measurement using unobservable inputs is inherently uncertain, and a change in significant inputs could result in different fair values. During the three and nine months ended September 30, 2025, there were no material gains or losses related to liabilities classified as Level 3 as a result of fair value adjustments. Changes in the fair value of the contingent consideration obligations are recorded within Selling, general and administrative expenses. The following table provides a reconciliation of the activity for the Level 3 contingent consideration fair value measurements during the nine-month period ended September 30, 2025:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2025 | |||
| Commitments and Contingencies Disclosure [Abstract] | |||
| Commitments and Contingencies |
The Company is subject to legal proceedings and claims that arise in the ordinary course of business. The Company may have exposure to loss contingencies arising from pending or threatened litigation for which assessing and estimating the outcomes of these matters involve substantial uncertainties. The Company evaluates contingencies on an ongoing basis and establishes loss provisions for matters in which losses are probable and the amount of loss can be reasonably estimated. Legal expenses include attorneys’ fees, litigation expenses and settlements. The Company recorded legal expenses totaling $4,745 and $4,479 for the nine months ended September 30, 2024 and 2025, respectively.
|
Basic and Diluted Net Income Per Share |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic and Diluted Net Income Per Share |
Basic earnings per share of Class A and Class B common stock is computed by dividing net income attributable to Guardian Pharmacy Services, Inc. by the weighted-average number of shares of Class A and Class B common stock outstanding during the period. The Class A and Class B common stock are identical in their rights and privileges, except that shares of Class B common stock are subject to transfer restrictions prior to their conversion into shares of Class A common stock. Therefore, the basic earnings per share for Class A and Class B common stock will be equal. Diluted earnings per share of Class A and Class B common stock is computed by dividing net income attributable to Guardian Pharmacy Services, Inc. by the weighted-average number of shares of Class A and Class B common stock outstanding, adjusted to give effect to potentially dilutive elements. The Company analyzed the calculation of earnings per unit, related to units of Guardian Pharmacy, LLC, for periods prior to the IPO and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Further, the Company had no operations prior to the Corporate Reorganization and the number of shares issued prior to the Corporate Reorganization was 100, which we have determined is not meaningful. Therefore, earnings per share information has not been presented for periods preceding the Corporate Reorganization and IPO in the three and nine months ended September 30, 2024. The following table sets forth (in thousands) the computation of net income attributable to the Company used to compute basic net income per share of Class A and Class B common stock for the three and nine months ended September 30, 2025 and 2024.
The following table sets forth the computation of basic and diluted net income per share of Class A and Class B common stock (in thousands, except share amounts, and per share amounts):
The following potentially dilutive shares were not included in the calculation of diluted shares outstanding as the effect would have been anti-dilutive:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Compensation |
Restricted Interest Units Conversion In connection with the Corporate Reorganization and IPO, Restricted Interest Unit awards associated with the Converted Subsidiaries and Guardian Pharmacy, LLC were converted into Common Units of Guardian Pharmacy, LLC, and the Common Units of Guardian Pharmacy, LLC were then converted into 12,321,282 shares of Class B common stock of the Company, some of which are subject to additional service vesting requirements (see Note 1 Organization and Background above for further discussion of the Corporate Reorganization and IPO). As of September 30, 2025, these awards are fully vested. 2025 Long-Term Incentive Program Awards On February 5, 2025, the Compensation Committee of the Company’s Board of Directors approved the Company’s 2025 long-term incentive program (“2025 LTIP”), consisting of restricted stock unit awards granted under the Company’s 2024 Equity and Incentive Compensation Plan. Restricted Stock Units (“RSU”) Awards During February 2025, and under the 2025 LTIP, the Company granted RSU awards to certain executive and management employees of 619,638 shares. The stock price used to determine the award value was the closing price on the grant date of the award. These awards cliff vest three years subsequent to the grant date of each award and upon vesting are settled in shares of Class A common stock. Share-based compensation expense Share-based compensation expense is recorded to selling, general, and administrative expenses in the consolidated statements of operations, and is as follows for the periods indicated:
As of September 30, 2025, unamortized share-based compensation costs related to share-based incentive awards is as follows (in thousands, except for the remaining service period):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segments |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segments |
General Information The Company’s single operating segment derives its revenues primarily through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States. Measure of segment profit or loss and assets The chief operating decision maker (“CODM”) assesses performance of the operating segment and decides how to allocate resources based on net income, which also is reported on the consolidated statements of operations as net income. In addition to comparing net income against forecasted net income, the CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the operating segment or expansion of the operating segment through acquisitions. The measure of operating segment assets is reported on the Consolidated Balance Sheets as total assets. The accounting policies of the operating segment are the same as those of the Company. Reportable segment reconciliation The following reconciliation presents operating segment revenue, net income, and significant segment expenses:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2025 | |||
| Income Tax Disclosure [Abstract] | |||
| Income Taxes |
Guardian Pharmacy Services, Inc. is taxed as a corporation and is subject to paying corporate federal and state and local taxes on the income allocated to it from its 100% ownership of Guardian Pharmacy, LLC, which includes economic interest held in the Non-Converted Subsidiaries, as well as any stand-alone income or loss it generates. The Non-Converted Subsidiaries are treated as a partnership for U.S. federal and most applicable state and local income tax purposes. Prior to the Corporate Reorganization, the Guardian Pharmacy, LLC business was comprised of entities treated as partnerships for income tax purposes. As a partnership it was not subject to U.S. federal and certain state and local income taxes. As a result of the Corporate Reorganization, the Company is subject to federal and state corporate income taxes beginning on September 27, 2024.Income tax expense for the three months ended September 30, 2024 and 2025 was $176 and $7,038, respectively. This reflects effective tax rates for the three months ended September 30, 2024 and 2025 of -0.1% and 42.3% , respectively. Income tax expense for the nine months ended September 30, 2024 and 2025 was $176 and $14,631, respectively. This reflects effective tax rates for the nine months ended September 30, 2024 and 2025 of -0.1% and 34.6% , respectively. The comparison of the Company’s effective tax rate to the U.S. statutory rate of 21% was primarily due to state income taxes and certain 2024 tax filing matters relating to the Corporate Reorganization and IPO, including the incremental share-based compensation charge (see Note 7—Share-based Compensation for further detail on the share-based compensation charge). These compensation costs are not deductible for federal and state income taxes due to prior Section 83(b) elections. On July 4, 2025, H.R. 1, commonly referred to as the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes significant provisions, such as the permanent extension of certain expiring business tax provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have assessed that this will have an immaterial impact on our consolidated financial statements and effective tax rate. |
Summary of Significant Accounting Policies (Policies) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Principles of consolidation | Principles of consolidation The accompanying unaudited interim consolidated financial statements include the accounts of the Company and all controlled subsidiaries (collectively, the “Company”). All intercompany transactions and accounts have been eliminated. Results of operations of the Company’s controlled subsidiaries have been included from the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of Presentation | Basis of Presentation The accompanying unaudited interim consolidated financial statements are prepared in conformity with the generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting. Accordingly, these unaudited interim consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. Certain footnote disclosures have been omitted that would substantially duplicate the disclosures in the Company’s audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2024, unless information contained in those disclosures materially changed or is required by U.S. GAAP to be included in interim financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair presentation of the unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2024 and 2025 have been recorded. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2025, or any other period. These interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes as of and for the year ended December 31, 2024, as filed with the SEC on March 26, 2025. The Corporate Reorganization was accounted for as a combination of entities under common control. As a result, the financial reports filed with the SEC by the Company subsequent to the Corporate Reorganization are prepared “as if” Guardian Pharmacy, LLC is the accounting predecessor of the Company. The historical operations of Guardian Pharmacy, LLC are deemed to be those of the Company. Thus, the financial statements included in this report reflect (i) the historical operating results of Guardian Pharmacy, LLC prior to the Corporate Reorganization; (ii) the consolidated results of the Company and Guardian Pharmacy, LLC following the Corporate Reorganization; (iii) the assets and liabilities of the Company and Guardian Pharmacy, LLC at their historical cost; and (iv) the Company’s equity structure for all periods presented. No step-up basis of intangible assets or goodwill was recorded. Guardian Pharmacy, LLC has been determined to be our predecessor for accounting purposes and, accordingly, the consolidated financial statements for periods prior to the Corporate Reorganization have been adjusted to combine the previously separate entities for presentation purposes. The Company had no material operations prior to the Corporate Reorganization, and is acting as a holding company, with 100% ownership interest in Guardian Pharmacy, LLC, subsequent to the Corporate Reorganization. Thus, the Company’s financial position, results of operations and cash flows effectively represent those of Guardian Pharmacy, LLC as of and for all periods presented.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| New Accounting Pronouncements | New Accounting Pronouncements The following table provides a description of recent accounting pronouncements that are applicable to the Company’s unaudited interim consolidated financial statements:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisitions (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Combinations [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Preliminary Recognition of the Assets and Liabilities of the Acquisitions | The preliminary recognition of assets acquired and liabilities assumed for the 2025 Acquisitions as of September 30, 2025 is as follows:
|
The recognition of the assets and liabilities of the 2024 Acquisitions was as follows during 2024:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Liabilities Measured at Fair Value on a Recurring Basis on the Company's Consolidated Balance Sheets | The following table summarizes the valuation of liabilities measured at fair value on a recurring basis on the Company’s Consolidated Balance Sheets:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Reconciliation of the Activity for the Level 3 Contingent Consideration Fair Value Measurements | The following table provides a reconciliation of the activity for the Level 3 contingent consideration fair value measurements during the nine-month period ended September 30, 2025:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Diluted Net Income Per Share (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Basic Net Income Per Share of Class A and Class B Common Stock | The following table sets forth (in thousands) the computation of net income attributable to the Company used to compute basic net income per share of Class A and Class B common stock for the three and nine months ended September 30, 2025 and 2024.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Basic and Diluted Net Income Per Share of Class A and Class B Common Stock | The following table sets forth the computation of basic and diluted net income per share of Class A and Class B common stock (in thousands, except share amounts, and per share amounts):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Diluted Shares Outstanding as the Effect would have been Anti-Dilutive | The following potentially dilutive shares were not included in the calculation of diluted shares outstanding as the effect would have been anti-dilutive:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Share-based Compensation Expense | Share-based compensation expense is recorded to selling, general, and administrative expenses in the consolidated statements of operations, and is as follows for the periods indicated:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Unamortized Share Based Compensation Incentive Awards | As of September 30, 2025, unamortized share-based compensation costs related to share-based incentive awards is as follows (in thousands, except for the remaining service period):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segments (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Operating Segment Revenue, Net Income | The following reconciliation presents operating segment revenue, net income, and significant segment expenses:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies - Additional Information (Detail) |
Sep. 30, 2025 |
|---|---|
| Guardian Pharmacy LLC [Member] | |
| Accounting Policies [Line Items] | |
| Subsidiary, ownership percentage, parent | 100.00% |
Acquisitions - Summary of Preliminary Recognition of the Assets and Liabilities of the Acquisitions (Detail) - USD ($) $ in Thousands |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Dec. 31, 2024 |
|
| Net assets acquired: | |||
| Goodwill | $ 79,570 | $ 69,296 | |
| Pharmacy Operations [Member] | |||
| Business Acquisition [Line Items] | |||
| Total purchase consideration | 16,271 | $ 17,410 | |
| Net assets acquired: | |||
| Inventory | 1,641 | 2,671 | |
| Other assets | 4,326 | 2,446 | |
| Intangible Assets | 6,690 | 6,236 | |
| Other liabilities | (3,052) | (1,822) | |
| Non-controlling interest equity | (3,609) | (5,371) | |
| Net assets acquired | 5,996 | 4,160 | |
| Goodwill | $ 10,275 | $ 13,250 | |
Fair Value Measurements - Summary of Liabilities Measured at Fair Value on a Recurring Basis on the Company's Consolidated Balance Sheets (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands |
Sep. 30, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Level 1 [Member] | ||
| Liabilities: | ||
| Contingent consideration payable | ||
| Fair value of financial instruments | ||
| Level 2 [Member] | ||
| Liabilities: | ||
| Contingent consideration payable | ||
| Fair value of financial instruments | ||
| Level 3 [Member] | ||
| Liabilities: | ||
| Contingent consideration payable | 3,350 | 2,700 |
| Fair value of financial instruments | $ 3,350 | $ 2,700 |
Fair Value Measurements - Summary of Reconciliation of the Activity for the Level 3 Contingent Consideration Fair Value Measurements (Detail) - Level 3 [Member] - USD ($) $ in Thousands |
3 Months Ended | ||
|---|---|---|---|
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
|
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |||
| Beginning balance | $ 2,450 | $ 2,700 | $ 2,700 |
| Current year acquisitions | 900 | 1,700 | |
| Fair value adjustments | |||
| Payments | (1,950) | ||
| Ending balance | $ 3,350 | $ 2,450 | $ 2,700 |
Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands |
9 Months Ended | |
|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Commitments and Contingencies Disclosure [Abstract] | ||
| Legal expenses | $ 4,479 | $ 4,745 |
Basic and Diluted Net Income Per Share - Additional Information (Detail) |
Sep. 30, 2025
shares
|
|---|---|
| Prior to the Corporate Reorganization [Member] | |
| Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] | |
| Shares, issued | 100 |
Basic and Diluted Net Income Per Share - Summary of Basic Net Income (Loss) Per Share of Class A and Class B Common Stock (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Numerator: | ||||||||
| Net income (loss) | $ 9,593 | $ (105,817) | $ 15,848 | $ 7,095 | $ 27,693 | $ (82,874) | ||
| Less: Net income attributable to Guardian Pharmacy, LLC before Corporate Reorganization | 0 | 9,350 | 0 | 22,760 | ||||
| Less net income (loss) attributable to non-controlling interests | (225) | $ (203) | $ (175) | 6,823 | (603) | 16,356 | ||
| Net income (loss) attributable to Guardian Pharmacy Services, Inc. | $ 9,818 | $ 9,030 | $ 9,448 | $ (121,990) | $ 28,296 | $ (121,990) | ||
Basic and Diluted Net Income Per Share - Summary of Diluted Shares Outstanding as the Effect would have been Anti-Dilutive (Detail) - shares |
3 Months Ended | 9 Months Ended |
|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2024 |
|
| Common Class A [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Anti-dilutive securities | 60,543 | 60,543 |
| Common Class B [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Anti-dilutive securities | 385,460 | 385,460 |
| Restricted Stock [Member] | Common Class A [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Anti-dilutive securities | 60,543 | 60,543 |
| Restricted Stock [Member] | Common Class B [Member] | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
| Anti-dilutive securities | 385,460 | 385,460 |
Share-based Compensation - Additional Information (Detail) |
9 Months Ended |
|---|---|
|
Sep. 30, 2025
shares
| |
| Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Nonemployee [Member] | |
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
| Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted | 619,638 |
| Common Class B [Member] | Restricted Interest Units Conversion [Member] | |
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
| Conversion of stock, shares converted | 12,321,282 |
Share-based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation expense | $ 4,356 | $ 122,355 | $ 12,770 | $ 128,029 |
| Pre-IPO awards | ||||
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation expense | 0 | 122,243 | 0 | 127,917 |
| Unvested Class A and B common stock | ||||
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation expense | 3,269 | 112 | 10,036 | $ 112 |
| Restricted stock units | ||||
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
| Total share-based compensation expense | $ 1,087 | $ 0 | $ 2,734 | |
Share-based Compensation - Schedule of Unamortized Share Based Compensation Incentive Awards (Detail) $ in Thousands |
9 Months Ended |
|---|---|
|
Sep. 30, 2025
USD ($)
| |
| Schedule of Unamortized Share Based Compensation Incentive Awards [Line Items] | |
| Unamortized share-based compensation costs related to each share-based incentive award (in dollars) | $ 9,914 |
| Restricted stock units | |
| Schedule of Unamortized Share Based Compensation Incentive Awards [Line Items] | |
| Unamortized share-based compensation costs related to each share-based incentive award (in dollars) | $ 9,914 |
| Unamortize share-based compensation costs related to each share-based incentive award (years) | 2 years 3 months 18 days |
Segments - Summary of Operating Segment Revenue, Net Income (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|||
| Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||||||||
| Revenue | $ 377,427 | $ 314,393 | $ 1,051,069 | $ 889,840 | ||||||
| Share-based compensation expense | 4,356 | 122,355 | 12,770 | 128,029 | ||||||
| Depreciation and amortization | 16,594 | 14,619 | ||||||||
| Income taxes | 7,038 | 176 | 14,631 | 176 | ||||||
| Segment net income (loss) | 9,593 | (105,817) | $ 15,848 | $ 7,095 | 27,693 | (82,874) | ||||
| Net Income (Loss) | 9,818 | $ 9,030 | $ 9,448 | (121,990) | 28,296 | (121,990) | ||||
| Corporate Segment [Member] | ||||||||||
| Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | ||||||||||
| Revenue | 377,427 | 314,393 | 1,051,069 | 889,840 | ||||||
| Employee expenses (excluding share-based compensation expense) | 80,496 | 70,078 | 228,518 | 197,733 | ||||||
| Share-based compensation expense | 4,356 | 122,355 | 12,770 | 128,029 | ||||||
| Other segment items | [1] | 269,946 | 221,581 | 750,361 | 629,300 | |||||
| Depreciation and amortization | 5,838 | 4,994 | 16,594 | 14,619 | ||||||
| Interest expense | 160 | 1,026 | 502 | 2,857 | ||||||
| Income taxes | 7,038 | 176 | 14,631 | 176 | ||||||
| Segment net income (loss) | 9,593 | (105,817) | 27,693 | (82,874) | ||||||
| Adjustments and reconciling items | 0 | 0 | 0 | 0 | ||||||
| Net Income (Loss) | $ 9,593 | $ (105,817) | $ 27,693 | $ (82,874) | ||||||
| ||||||||||
Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Income Taxes [Line Items] | ||||
| Effective income tax rate reconciliation, percent | 42.30% | (0.10%) | 34.60% | 0.10% |
| Effective income tax rate reconciliation, at federal statutory income tax rate, percent | 21.00% | |||
| Income taxes | $ 7,038 | $ 176 | $ 14,631 | $ 176 |
| Guardian Pharmacy, LLC [Member] | ||||
| Income Taxes [Line Items] | ||||
| Subsidiary, ownership percentage, parent | 100.00% | 100.00% | ||
{
"version": "2.2",
"instance": {
"d946258d10q.htm": {
"nsprefix": "grdn",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"dts": {
"inline": {
"local": [
"d946258d10q.htm"
]
},
"schema": {
"local": [
"grdn-20250930.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/2023/calculation-1.1.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
"https://xbrl.sec.gov/country/2024/country-2024.xsd",
"https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
"https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
"https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
"https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
"https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
]
}
},
"keyStandard": 183,
"keyCustom": 29,
"axisStandard": 14,
"axisCustom": 0,
"memberStandard": 18,
"memberCustom": 13,
"hidden": {
"total": 4,
"http://xbrl.sec.gov/dei/2024": 4
},
"contextCount": 161,
"entityCount": 1,
"segmentCount": 32,
"elementCount": 443,
"unitCount": 5,
"baseTaxonomies": {
"http://fasb.org/us-gaap/2024": 565,
"http://xbrl.sec.gov/dei/2024": 32,
"http://xbrl.sec.gov/ecd/2024": 4
},
"report": {
"R1": {
"role": "http://www.guardianpharmacy.com/role/CoverPage",
"longName": "1001 - Document - Cover Page",
"shortName": "Cover Page",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R2": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"longName": "1002 - Statement - Consolidated Balance Sheets",
"shortName": "Consolidated Balance Sheets",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "2",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R3": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
"shortName": "Consolidated Balance Sheets (Parenthetical)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "parenthetical",
"menuCat": "Statements",
"order": "3",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025_CommonClassAMemberusgaapStatementClassOfStockAxis",
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"unitRef": "Unit_USD_per_Share",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"div",
"td",
"tr",
"table",
"us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis",
"name": "us-gaap:CommonStockSharesAuthorized",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "INF",
"ancestors": [
"div",
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R4": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"longName": "1004 - Statement - Consolidated Statements of Operations",
"shortName": "Consolidated Statements of Operations",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "4",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:Revenues",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:CostOfGoodsAndServicesSold",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R5": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"longName": "1005 - Statement - Consolidated Statements of Changes in Members' Equity and Stockholders' Equity",
"shortName": "Consolidated Statements of Changes in Members' Equity and Stockholders' Equity",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "5",
"firstAnchor": {
"contextRef": "PAsOn12_31_2023",
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2024To03_31_2024",
"name": "us-gaap:PartnersCapitalAccountContributions",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R6": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquityParenthetical",
"longName": "1006 - Statement - Consolidated Statements of Changes in Members' Equity and Stockholders' Equity (Parenthetical)",
"shortName": "Consolidated Statements of Changes in Members' Equity and Stockholders' Equity (Parenthetical)",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "parenthetical",
"menuCat": "Statements",
"order": "6",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "grdn:PaymentToCommonStockPerShare",
"unitRef": "Unit_USD_per_Share",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"div",
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "grdn:PaymentToCommonStockPerShare",
"unitRef": "Unit_USD_per_Share",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"div",
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R7": {
"role": "http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"longName": "1007 - Statement - Consolidated Statements of Cash Flows",
"shortName": "Consolidated Statements of Cash Flows",
"isDefault": "false",
"groupType": "statement",
"subGroupType": "",
"menuCat": "Statements",
"order": "7",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R8": {
"role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"longName": "995410 - Disclosure - Pay vs Performance Disclosure",
"shortName": "Pay vs Performance Disclosure",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "8",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:NetIncomeLoss",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": null
},
"R9": {
"role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"longName": "995445 - Disclosure - Insider Trading Arrangements",
"shortName": "Insider Trading Arrangements",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "9",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "ecd:Rule10b51ArrAdoptedFlag",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ecd:NonRule10b51ArrAdoptedFlag",
"ecd:Rule10b51ArrTrmntdFlag",
"ecd:NonRule10b51ArrTrmntdFlag",
"div",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "ecd:Rule10b51ArrAdoptedFlag",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ecd:NonRule10b51ArrAdoptedFlag",
"ecd:Rule10b51ArrTrmntdFlag",
"ecd:NonRule10b51ArrTrmntdFlag",
"div",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R10": {
"role": "http://www.guardianpharmacy.com/role/OrganizationAndBackground",
"longName": "999001 - Disclosure - Organization and Background",
"shortName": "Organization and Background",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "10",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R11": {
"role": "http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPolicies",
"longName": "999002 - Disclosure - Summary of Significant Accounting Policies",
"shortName": "Summary of Significant Accounting Policies",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "11",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R12": {
"role": "http://www.guardianpharmacy.com/role/Acquisitions",
"longName": "999003 - Disclosure - Acquisitions",
"shortName": " Acquisitions",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "12",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:BusinessCombinationDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R13": {
"role": "http://www.guardianpharmacy.com/role/FairValueMeasurements",
"longName": "999004 - Disclosure - Fair Value Measurements",
"shortName": "Fair Value Measurements",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "13",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R14": {
"role": "http://www.guardianpharmacy.com/role/CommitmentsAndContingencies",
"longName": "999005 - Disclosure - Commitments and Contingencies",
"shortName": "Commitments and Contingencies",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "14",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R15": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShare",
"longName": "999006 - Disclosure - Basic and Diluted Net Income Per Share",
"shortName": "Basic and Diluted Net Income Per Share",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "15",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:EarningsPerShareTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:EarningsPerShareTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R16": {
"role": "http://www.guardianpharmacy.com/role/ShareBasedCompensation",
"longName": "999007 - Disclosure - Share-based Compensation",
"shortName": "Share-based Compensation",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "16",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R17": {
"role": "http://www.guardianpharmacy.com/role/Segments",
"longName": "999008 - Disclosure - Segments",
"shortName": "Segments",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "17",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R18": {
"role": "http://www.guardianpharmacy.com/role/IncomeTaxes",
"longName": "999009 - Disclosure - Income Taxes",
"shortName": "Income Taxes",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "",
"menuCat": "Notes",
"order": "18",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R19": {
"role": "http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
"longName": "999010 - Disclosure - Summary of Significant Accounting Policies (Policies)",
"shortName": "Summary of Significant Accounting Policies (Policies)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "policies",
"menuCat": "Policies",
"order": "19",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ConsolidationPolicyTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ConsolidationPolicyTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R20": {
"role": "http://www.guardianpharmacy.com/role/AcquisitionsTables",
"longName": "999011 - Disclosure - Acquisitions (Tables)",
"shortName": " Acquisitions (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "20",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R21": {
"role": "http://www.guardianpharmacy.com/role/FairValueMeasurementsTables",
"longName": "999012 - Disclosure - Fair Value Measurements (Tables)",
"shortName": "Fair Value Measurements (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "21",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R22": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareTables",
"longName": "999013 - Disclosure - Basic and Diluted Net Income Per Share (Tables)",
"shortName": "Basic and Diluted Net Income Per Share (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "22",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R23": {
"role": "http://www.guardianpharmacy.com/role/ShareBasedCompensationTables",
"longName": "999014 - Disclosure - Share-based Compensation (Tables)",
"shortName": "Share-based Compensation (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "23",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R24": {
"role": "http://www.guardianpharmacy.com/role/SegmentsTables",
"longName": "999015 - Disclosure - Segments (Tables)",
"shortName": "Segments (Tables)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "tables",
"menuCat": "Tables",
"order": "24",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R25": {
"role": "http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"longName": "999016 - Disclosure - Organization and Background - Additional Information (Detail)",
"shortName": "Organization and Background - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "25",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:ConversionOfStockSharesIssued1",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"div",
"td",
"tr",
"table",
"us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:PaymentsForMergerRelatedCosts",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"div",
"td",
"tr",
"table",
"us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R26": {
"role": "http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"longName": "999017 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
"shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "26",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025_GuardianPharmacyLLCMembersrtOwnershipAxis",
"name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
"unitRef": "Unit_pure",
"xsiNil": "false",
"lang": null,
"decimals": "2",
"ancestors": [
"div",
"us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": null
},
"R27": {
"role": "http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"longName": "999018 - Disclosure - Acquisitions - Additional Information (Detail)",
"shortName": " Acquisitions - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "27",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:Goodwill",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2024_PharmacyOperationsMemberusgaapBusinessAcquisitionAxis",
"name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"div",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R28": {
"role": "http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail",
"longName": "999019 - Disclosure - Acquisitions - Summary of Preliminary Recognition of the Assets and Liabilities of the Acquisitions (Detail)",
"shortName": "Acquisitions - Summary of Preliminary Recognition of the Assets and Liabilities of the Acquisitions (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "28",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:Goodwill",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025_PharmacyOperationsMemberusgaapBusinessAcquisitionAxis",
"name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R29": {
"role": "http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail",
"longName": "999020 - Disclosure - Fair Value Measurements - Summary of Liabilities Measured at Fair Value on a Recurring Basis on the Company's Consolidated Balance Sheets (Detail)",
"shortName": "Fair Value Measurements - Summary of Liabilities Measured at Fair Value on a Recurring Basis on the Company's Consolidated Balance Sheets (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "29",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
"name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
"unitRef": "Unit_USD",
"xsiNil": "true",
"lang": null,
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
"name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
"unitRef": "Unit_USD",
"xsiNil": "true",
"lang": null,
"decimals": null,
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R30": {
"role": "http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail",
"longName": "999021 - Disclosure - Fair Value Measurements - Summary of Reconciliation of the Activity for the Level 3 Contingent Consideration Fair Value Measurements (Detail)",
"shortName": "Fair Value Measurements - Summary of Reconciliation of the Activity for the Level 3 Contingent Consideration Fair Value Measurements (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "30",
"firstAnchor": {
"contextRef": "PAsOn06_30_2025_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "PAsOn12_31_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R31": {
"role": "http://www.guardianpharmacy.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"longName": "999022 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
"shortName": "Commitments and Contingencies - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "31",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:LegalFees",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"div",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025",
"name": "us-gaap:LegalFees",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"div",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R32": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail",
"longName": "999023 - Disclosure - Basic and Diluted Net Income Per Share - Additional Information (Detail)",
"shortName": "Basic and Diluted Net Income Per Share - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "32",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025_PriorToTheCorporateReorganizationMemberusgaapNonmonetaryTransactionTypeAxis",
"name": "us-gaap:SharesIssued",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025_PriorToTheCorporateReorganizationMemberusgaapNonmonetaryTransactionTypeAxis",
"name": "us-gaap:SharesIssued",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R33": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail",
"longName": "999024 - Disclosure - Basic and Diluted Net Income Per Share - Summary of Basic Net Income (Loss) Per Share of Class A and Class B Common Stock (Detail)",
"shortName": "Basic and Diluted Net Income Per Share - Summary of Basic Net Income (Loss) Per Share of Class A and Class B Common Stock (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "33",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:ProfitLoss",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": null
},
"R34": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"longName": "999025 - Disclosure - Basic and Diluted Net Income Per Share - Summary of Basic and Diluted Net Income Per Share of Class A and Class B Common Stock (Detail)",
"shortName": "Basic and Diluted Net Income Per Share - Summary of Basic and Diluted Net Income Per Share of Class A and Class B Common Stock (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "34",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:NetIncomeLoss",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2025To09_30_2025_CommonClassAMemberusgaapStatementClassOfStockAxis",
"name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R35": {
"role": "http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail",
"longName": "999026 - Disclosure - Basic and Diluted Net Income Per Share - Summary of Diluted Shares Outstanding as the Effect would have been Anti-Dilutive (Detail)",
"shortName": "Basic and Diluted Net Income Per Share - Summary of Diluted Shares Outstanding as the Effect would have been Anti-Dilutive (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "35",
"firstAnchor": {
"contextRef": "P07_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R36": {
"role": "http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail",
"longName": "999027 - Disclosure - Share-based Compensation - Additional Information (Detail)",
"shortName": "Share-based Compensation - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "36",
"firstAnchor": {
"contextRef": "P01_01_2025To09_30_2025_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"div",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P01_01_2025To09_30_2025_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedPaymentArrangementNonemployeeMemberusgaapGranteeStatusAxis",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
"unitRef": "Unit_shares",
"xsiNil": "false",
"lang": null,
"decimals": "0",
"ancestors": [
"div",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R37": {
"role": "http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
"longName": "999028 - Disclosure - Share-based Compensation - Summary of Share-based Compensation Expense (Detail)",
"shortName": "Share-based Compensation - Summary of Share-based Compensation Expense (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "37",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2025To09_30_2025_PreIpoawardsMemberusgaapIncomeStatementLocationAxis",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R38": {
"role": "http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail",
"longName": "999029 - Disclosure - Share-based Compensation - Schedule of Unamortized Share Based Compensation Incentive Awards (Detail)",
"shortName": "Share-based Compensation - Schedule of Unamortized Share Based Compensation Incentive Awards (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "38",
"firstAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"grdn:ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "PAsOn09_30_2025",
"name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"grdn:ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTextBlock",
"ix:continuation",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
},
"R39": {
"role": "http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail",
"longName": "999030 - Disclosure - Segments - Summary of Operating Segment Revenue, Net Income (Detail)",
"shortName": "Segments - Summary of Operating Segment Revenue, Net Income (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "39",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:Revenues",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"div",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2025To09_30_2025_CorporateMemberusgaapStatementBusinessSegmentsAxis",
"name": "us-gaap:Revenues",
"unitRef": "Unit_USD",
"xsiNil": "false",
"lang": null,
"decimals": "-3",
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"us-gaap:SegmentReportingDisclosureTextBlock",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"unique": true
}
},
"R40": {
"role": "http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"longName": "999031 - Disclosure - Income Taxes - Additional Information (Detail)",
"shortName": "Income Taxes - Additional Information (Detail)",
"isDefault": "false",
"groupType": "disclosure",
"subGroupType": "details",
"menuCat": "Details",
"order": "40",
"firstAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"unitRef": "Unit_pure",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"div",
"us-gaap:IncomeTaxDisclosureTextBlock",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "P07_01_2025To09_30_2025",
"name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"unitRef": "Unit_pure",
"xsiNil": "false",
"lang": null,
"decimals": "3",
"ancestors": [
"div",
"us-gaap:IncomeTaxDisclosureTextBlock",
"div",
"div",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d946258d10q.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"us-gaap_AccountingPoliciesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccountingPoliciesAbstract",
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"auth_ref": []
},
"grdn_AccountingPoliciesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AccountingPoliciesLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Line Items]"
}
}
},
"auth_ref": []
},
"grdn_AccountingPoliciesTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AccountingPoliciesTable",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Table]"
}
}
},
"auth_ref": []
},
"us-gaap_AccountsPayableCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccountsPayableCurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 14.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable",
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
}
}
},
"auth_ref": [
"r48",
"r547"
]
},
"us-gaap_AccountsReceivableNetCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccountsReceivableNetCurrent",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Accounts receivable, net",
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
}
}
},
"auth_ref": [
"r669"
]
},
"grdn_AccruedAndCapitalizedOfferingCostsRecordedToAdditionalpaidIncapital": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AccruedAndCapitalizedOfferingCostsRecordedToAdditionalpaidIncapital",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Accrued And Capitalized Offering Costs Recorded To AdditionalPaid InCapital",
"terseLabel": "Accrued and capitalized offering costs recorded to additional\u00a0paid-in\u00a0capital",
"documentation": "Accrued and capitalized offering costs recorded to additional\u00a0paid in\u00a0capital."
}
}
},
"auth_ref": []
},
"grdn_AdditionOfUnderwritingDiscountsIncurredOfOfferingCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AdditionOfUnderwritingDiscountsIncurredOfOfferingCosts",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Addition Of Underwriting Discounts Incurred Of Offering Costs",
"terseLabel": "Addition of underwriting discounts incurred of offering costs",
"documentation": "Addition of underwriting discounts incurred of offering costs."
}
}
},
"auth_ref": []
},
"ecd_Additional402vDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Additional402vDisclosureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Additional 402(v) Disclosure [Text Block]",
"terseLabel": "Additional 402(v) Disclosure"
}
}
},
"auth_ref": [
"r596"
]
},
"us-gaap_AdditionalPaidInCapital": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdditionalPaidInCapital",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0,
"order": 22.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Paid in Capital",
"terseLabel": "Additional\u00a0paid-in\u00a0capital",
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
}
}
},
"auth_ref": [
"r58",
"r547",
"r761"
]
},
"us-gaap_AdditionalPaidInCapitalMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdditionalPaidInCapitalMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional Paid-in capital [Member]",
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
}
}
},
"auth_ref": [
"r436",
"r657",
"r658",
"r659",
"r660",
"r719",
"r762"
]
},
"ecd_AdjToCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Compensation Amount",
"terseLabel": "Adjustment to Compensation, Amount"
}
}
},
"auth_ref": [
"r609"
]
},
"ecd_AdjToCompAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToCompAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Compensation [Axis]",
"terseLabel": "Adjustment to Compensation:"
}
}
},
"auth_ref": [
"r609"
]
},
"ecd_AdjToNonPeoNeoCompFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToNonPeoNeoCompFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
"terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
}
}
},
"auth_ref": [
"r609"
]
},
"ecd_AdjToPeoCompFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AdjToPeoCompFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment To PEO Compensation, Footnote [Text Block]",
"terseLabel": "Adjustment To PEO Compensation, Footnote"
}
}
},
"auth_ref": [
"r609"
]
},
"grdn_AdjustmentOfDeferredTaxAssetLiabilityThroughAdditionalPaidInCapital": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AdjustmentOfDeferredTaxAssetLiabilityThroughAdditionalPaidInCapital",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustment of Deferred Tax Asset Liability Through Additional Paid in Capital",
"terseLabel": "Adjustment of deferred tax asset liability through additional paid in capital",
"documentation": "Adjustment of deferred tax asset liability through additional paid in capital."
}
}
},
"auth_ref": []
},
"grdn_AdjustmentsAndReconcilingItems": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "AdjustmentsAndReconcilingItems",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments And Reconciling Items",
"terseLabel": "Adjustments and reconciling items",
"documentation": "Adjustments and reconciling items."
}
}
},
"auth_ref": []
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
"verboseLabel": "Share-based compensation expense",
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r31",
"r32",
"r261"
]
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
}
}
},
"auth_ref": []
},
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
}
}
},
"auth_ref": [
"r642"
]
},
"ecd_AggtErrCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Erroneous Compensation Amount",
"terseLabel": "Aggregate Erroneous Compensation Amount"
}
}
},
"auth_ref": [
"r568",
"r578",
"r588",
"r620"
]
},
"ecd_AggtErrCompNotYetDeterminedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtErrCompNotYetDeterminedTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
"terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
}
}
},
"auth_ref": [
"r571",
"r581",
"r591",
"r623"
]
},
"ecd_AggtPnsnAdjsSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AggtPnsnAdjsSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Pension Adjustments Service Cost [Member]",
"terseLabel": "Aggregate Pension Adjustments Service Cost"
}
}
},
"auth_ref": [
"r643"
]
},
"ecd_AllAdjToCompMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllAdjToCompMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Adjustments to Compensation [Member]",
"terseLabel": "All Adjustments to Compensation"
}
}
},
"auth_ref": [
"r609"
]
},
"ecd_AllExecutiveCategoriesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllExecutiveCategoriesMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Executive Categories [Member]",
"terseLabel": "All Executive Categories"
}
}
},
"auth_ref": [
"r616"
]
},
"ecd_AllIndividualsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllIndividualsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Individuals [Member]",
"terseLabel": "All Individuals"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r616",
"r624",
"r628",
"r636"
]
},
"ecd_AllTradingArrangementsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AllTradingArrangementsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "All Trading Arrangements [Member]",
"terseLabel": "All Trading Arrangements"
}
}
},
"auth_ref": [
"r634"
]
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AllocatedShareBasedCompensationExpense",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Expense",
"verboseLabel": "Total share-based compensation expense",
"definitionGuidance": "Share-based compensation expense",
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
}
}
},
"auth_ref": [
"r290",
"r295"
]
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AmendmentFlag",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"verboseLabel": "Anti-dilutive securities",
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
}
}
},
"auth_ref": [
"r162"
]
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Antidilutive Securities [Axis]",
"documentation": "Information by type of antidilutive security."
}
}
},
"auth_ref": [
"r26"
]
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesNameDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Antidilutive Securities, Name [Domain]",
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
}
}
},
"auth_ref": [
"r26"
]
},
"us-gaap_Assets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Assets",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Assets",
"totalLabel": "Total assets",
"documentation": "Amount of asset recognized for present right to economic benefit."
}
}
},
"auth_ref": [
"r92",
"r101",
"r115",
"r137",
"r166",
"r174",
"r192",
"r196",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r326",
"r330",
"r363",
"r393",
"r468",
"r516",
"r517",
"r547",
"r559",
"r685",
"r686",
"r728"
]
},
"us-gaap_AssetsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"auth_ref": []
},
"us-gaap_AssetsCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrent",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current",
"totalLabel": "Total current assets",
"documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
}
}
},
"auth_ref": [
"r110",
"r121",
"r137",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r326",
"r330",
"r363",
"r547",
"r685",
"r686",
"r728"
]
},
"us-gaap_AssetsCurrentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsCurrentAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"auth_ref": []
},
"ecd_AwardExrcPrice": {
"xbrltype": "perShareItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardExrcPrice",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Exercise Price",
"terseLabel": "Exercise Price"
}
}
},
"auth_ref": [
"r631"
]
},
"ecd_AwardGrantDateFairValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardGrantDateFairValue",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Grant Date Fair Value",
"terseLabel": "Fair Value as of Grant Date"
}
}
},
"auth_ref": [
"r632"
]
},
"ecd_AwardTmgDiscLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgDiscLineItems",
"lang": {
"en-us": {
"role": {
"label": "Award Timing Disclosures [Line Items]",
"terseLabel": "Award Timing Disclosures"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgHowMnpiCnsdrdTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing, How MNPI Considered [Text Block]",
"terseLabel": "Award Timing, How MNPI Considered"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_AwardTmgMethodTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMethodTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing Method [Text Block]",
"terseLabel": "Award Timing Method"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_AwardTmgMnpiCnsdrdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing MNPI Considered [Flag]",
"terseLabel": "Award Timing MNPI Considered"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_AwardTmgMnpiDiscTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing MNPI Disclosure [Text Block]",
"terseLabel": "Award Timing MNPI Disclosure"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_AwardTmgPredtrmndFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgPredtrmndFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Timing Predetermined [Flag]",
"terseLabel": "Award Timing Predetermined"
}
}
},
"auth_ref": [
"r627"
]
},
"us-gaap_AwardTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AwardTypeAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Type [Axis]",
"terseLabel": "Award Type",
"documentation": "Information by type of award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"ecd_AwardUndrlygSecuritiesAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardUndrlygSecuritiesAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Award Underlying Securities Amount",
"terseLabel": "Underlying Securities"
}
}
},
"auth_ref": [
"r630"
]
},
"ecd_AwardsCloseToMnpiDiscIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r629"
]
},
"ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures [Table]",
"terseLabel": "Awards Close in Time to MNPI Disclosures"
}
}
},
"auth_ref": [
"r628"
]
},
"ecd_AwardsCloseToMnpiDiscTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
"terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
}
}
},
"auth_ref": [
"r628"
]
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"lang": {
"en-us": {
"role": {
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation",
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
}
}
},
"auth_ref": []
},
"us-gaap_BusinessAcquisitionAcquireeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionAcquireeDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Acquisition, Acquiree [Domain]",
"documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
}
}
},
"auth_ref": [
"r219",
"r220",
"r221",
"r222",
"r223",
"r319",
"r528",
"r529"
]
},
"us-gaap_BusinessAcquisitionAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Acquisition [Axis]",
"documentation": "Information by business combination or series of individually immaterial business combinations."
}
}
},
"auth_ref": [
"r33",
"r34",
"r219",
"r220",
"r221",
"r222",
"r223",
"r319",
"r528",
"r529"
]
},
"us-gaap_BusinessAcquisitionLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Acquisition [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r319"
]
},
"us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
"terseLabel": "Business acquisition, goodwill, expected tax deductible amount",
"documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
}
}
},
"auth_ref": [
"r41"
]
},
"us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"weight": -1.0,
"order": 5.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
"verboseLabel": "Business combination, acquisition of less than 100 percent, noncontrolling interest, fair value",
"negatedLabel": "Non-controlling\u00a0interest equity",
"documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date."
}
}
},
"auth_ref": [
"r37"
]
},
"us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationAndAssetAcquisitionAbstract",
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_BusinessCombinationConsiderationTransferred1": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationConsiderationTransferred1",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Consideration Transferred",
"presentationGuidance": "Business combination, consideration transferred",
"terseLabel": "Total purchase consideration",
"documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
}
}
},
"auth_ref": [
"r0",
"r1",
"r9"
]
},
"us-gaap_BusinessCombinationContingentConsiderationLiability": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationContingentConsiderationLiability",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Contingent Consideration, Liability",
"terseLabel": "Business combination, contingent consideration, liability",
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
}
}
},
"auth_ref": [
"r40",
"r88",
"r321",
"r344",
"r345",
"r346"
]
},
"us-gaap_BusinessCombinationDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationDisclosureTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/Acquisitions"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination Disclosure [Text Block]",
"terseLabel": "Acquisitions",
"documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
}
}
},
"auth_ref": [
"r86",
"r320"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
"terseLabel": "Other assets",
"documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
}
}
},
"auth_ref": [
"r36"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
"terseLabel": "Intangible Assets",
"documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
}
}
},
"auth_ref": [
"r36"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
"terseLabel": "Inventory",
"documentation": "The amount of inventory recognized as of the acquisition date."
}
}
},
"auth_ref": [
"r35",
"r36"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"weight": -1.0,
"order": 4.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
"negatedLabel": "Other liabilities",
"documentation": "Amount of liabilities assumed at the acquisition date."
}
}
},
"auth_ref": [
"r36"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
"totalLabel": "Net assets acquired",
"documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree."
}
}
},
"auth_ref": [
"r36"
]
},
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]",
"terseLabel": "Net assets acquired:"
}
}
},
"auth_ref": []
},
"us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Fair Value",
"verboseLabel": "Business combination, achieved in stages, preacquisition equity interest in acquiree, fair value",
"documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
}
}
},
"auth_ref": [
"r12"
]
},
"us-gaap_BusinessCombinationsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Business Combinations [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashAndCashEquivalentsAtCarryingValue",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents",
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
}
}
},
"auth_ref": [
"r17",
"r112",
"r506"
]
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodStartLabel": "Cash and cash equivalents, beginning of period",
"periodEndLabel": "Cash and cash equivalents, end of period",
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": [
"r17",
"r76",
"r135"
]
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net change in cash and cash equivalents",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
}
}
},
"auth_ref": [
"r2",
"r76"
]
},
"us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
"terseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0investing and financing activities"
}
}
},
"auth_ref": []
},
"us-gaap_CashMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Cash [Member]",
"documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
}
}
},
"auth_ref": [
"r112"
]
},
"grdn_ChangeInDeferredTaxAsset": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ChangeInDeferredTaxAsset",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 13.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Change In Deferred Tax Asset",
"terseLabel": "Change in deferred tax asset",
"documentation": "Change in deferred tax asset."
}
}
},
"auth_ref": []
},
"ecd_ChangedPeerGroupFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChangedPeerGroupFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Changed Peer Group, Footnote [Text Block]",
"terseLabel": "Changed Peer Group, Footnote"
}
}
},
"auth_ref": [
"r607"
]
},
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
"terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
}
}
},
"auth_ref": [
"r604"
]
},
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
"terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
}
}
},
"auth_ref": [
"r602"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CityAreaCode",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"us-gaap_ClassOfStockDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/CoverPage",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Class of Stock [Domain]",
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
}
}
},
"auth_ref": [
"r105",
"r116",
"r117",
"r118",
"r137",
"r156",
"r157",
"r159",
"r161",
"r168",
"r169",
"r204",
"r237",
"r239",
"r240",
"r241",
"r244",
"r245",
"r247",
"r248",
"r249",
"r250",
"r251",
"r363",
"r428",
"r429",
"r430",
"r431",
"r436",
"r437",
"r438",
"r439",
"r440",
"r441",
"r442",
"r443",
"r444",
"r445",
"r446",
"r447",
"r456",
"r477",
"r495",
"r498",
"r499",
"r500",
"r501",
"r502",
"r647",
"r654",
"r661"
]
},
"ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Company Selected Measure Amount",
"terseLabel": "Company Selected Measure Amount"
}
}
},
"auth_ref": [
"r608"
]
},
"ecd_CoSelectedMeasureName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Company Selected Measure Name",
"terseLabel": "Company Selected Measure Name"
}
}
},
"auth_ref": [
"r608"
]
},
"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r324"
]
},
"us-gaap_CommitmentsAndContingencies": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingencies",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies (see Note 5)",
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
}
}
},
"auth_ref": [
"r54",
"r93",
"r394",
"r455"
]
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/CommitmentsAndContingencies"
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies",
"documentation": "The entire disclosure for commitments and contingencies."
}
}
},
"auth_ref": [
"r81",
"r235",
"r236",
"r504",
"r683",
"r684"
]
},
"grdn_CommonClassAAndClassBMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "CommonClassAAndClassBMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Common Class A And Class B [Member]",
"verboseLabel": "Class A and Class B common stock [Member]",
"documentation": "Common class A and Class B."
}
}
},
"auth_ref": []
},
"us-gaap_CommonClassAMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonClassAMember",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/CoverPage",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Common Class A [Member]",
"terseLabel": "Class A common stock [Member]",
"verboseLabel": "Class A [Member]",
"documentation": "Classification of common stock representing ownership interest in a corporation."
}
}
},
"auth_ref": [
"r762"
]
},
"us-gaap_CommonClassBMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonClassBMember",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/CoverPage",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Common Class B [Member]",
"verboseLabel": "Class B common stock [Member]",
"definitionGuidance": "Class B [Member]",
"terseLabel": "Common Class B [Member]",
"presentationGuidance": "Common Class B [Member]",
"documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
}
}
},
"auth_ref": [
"r762"
]
},
"us-gaap_CommonStockMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]",
"documentation": "Stock that is subordinate to all other stock of the issuer."
}
}
},
"auth_ref": [
"r549",
"r550",
"r551",
"r553",
"r554",
"r555",
"r556",
"r657",
"r658",
"r660",
"r719",
"r760",
"r762"
]
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockParOrStatedValuePerShare",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par or stated value per share",
"documentation": "Face amount or stated value per share of common stock."
}
}
},
"auth_ref": [
"r57"
]
},
"us-gaap_CommonStockSharesAuthorized": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesAuthorized",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized",
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
}
}
},
"auth_ref": [
"r57",
"r456"
]
},
"us-gaap_CommonStockSharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesIssued",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock, shares, issued",
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
}
}
},
"auth_ref": [
"r57"
]
},
"us-gaap_CommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesOutstanding",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Common stock, shares, outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
}
}
},
"auth_ref": [
"r10",
"r57",
"r456",
"r474",
"r762",
"r763"
]
},
"us-gaap_CommonStockValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockValue",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0,
"order": 21.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock",
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
}
}
},
"auth_ref": [
"r57",
"r395",
"r547"
]
},
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
}
}
},
"auth_ref": [
"r613"
]
},
"ecd_CompActuallyPaidVsNetIncomeTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsNetIncomeTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Net Income [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Net Income"
}
}
},
"auth_ref": [
"r612"
]
},
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsOtherMeasureTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Other Measure [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Other Measure"
}
}
},
"auth_ref": [
"r614"
]
},
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
"terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
}
}
},
"auth_ref": [
"r611"
]
},
"us-gaap_ConsolidationPolicyTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConsolidationPolicyTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation, Policy [Policy Text Block]",
"terseLabel": "Principles of consolidation",
"documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
}
}
},
"auth_ref": [
"r44",
"r508"
]
},
"grdn_ContingentEarnoutPaymentMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ContingentEarnoutPaymentMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Contingent Earnout Payment [Member]",
"documentation": "Contingent earnout payment."
}
}
},
"auth_ref": []
},
"grdn_ConversionOfGuardianPharmacyLLCCommonUnitsInToClassBCommonStockOfGuardianPharmacyServicesInc": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ConversionOfGuardianPharmacyLLCCommonUnitsInToClassBCommonStockOfGuardianPharmacyServicesInc",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion Of Guardian Pharmacy LLC Common Units In To Class B Common Stock Of Guardian Pharmacy Services Inc",
"verboseLabel": "Conversion of Guardian Pharmacy, LLC common units into Class\u00a0B common stock of Guardian Pharmacy Services, Inc.",
"documentation": "Conversion of guardian pharmacy LLC common units in to class b common stock of guardian pharmacy services inc."
}
}
},
"auth_ref": []
},
"grdn_ConversionOfGuardianPharmacyLLCCommonUnitsInToClassBCommonStockOfGuardianPharmacyServicesIncShares": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ConversionOfGuardianPharmacyLLCCommonUnitsInToClassBCommonStockOfGuardianPharmacyServicesIncShares",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion Of Guardian Pharmacy LLC Common Units In To Class B Common Stock Of Guardian Pharmacy Services Inc Shares",
"verboseLabel": "Conversion of Guardian Pharmacy, LLC common units into Class\u00a0B common stock of Guardian Pharmacy Services, Inc. (Shares)",
"documentation": "Conversion of guardian pharmacy LLC common units in to class B common stock of guardian pharmacy services inc shares."
}
}
},
"auth_ref": []
},
"grdn_ConversionOfNonControllingInterestIntoGuardianPharmacyLLCCommonUnits": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ConversionOfNonControllingInterestIntoGuardianPharmacyLLCCommonUnits",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion Of Non Controlling Interest Into Guardian Pharmacy LLC Common Units",
"terseLabel": "Conversion of\u00a0non-controlling\u00a0interest into Guardian Pharmacy, LLC common units",
"documentation": "conversion of non controlling interest into guardian pharmacy llc common units."
}
}
},
"auth_ref": []
},
"grdn_ConversionOfRestrictedInterestUnitAwardsIntoGuardianPharmacyLlcCommonUnits": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ConversionOfRestrictedInterestUnitAwardsIntoGuardianPharmacyLlcCommonUnits",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion Of Restricted Interest Unit Awards Into Guardian Pharmacy LLC Common Units",
"terseLabel": "Conversion of Restricted Interest Unit awards into Guardian Pharmacy, LLC common units",
"documentation": "Conversion of restricted interest unit awards into guardian pharmacy llc common units."
}
}
},
"auth_ref": []
},
"grdn_ConversionOfStockPerSharesConverted": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ConversionOfStockPerSharesConverted",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion Of Stock Per Shares Converted",
"terseLabel": "Conversion of stock per shares converted",
"documentation": "Conversion of stock per shares converted."
}
}
},
"auth_ref": []
},
"us-gaap_ConversionOfStockSharesConverted1": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConversionOfStockSharesConverted1",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion of Stock, Shares Converted",
"terseLabel": "Conversion of stock, shares converted",
"documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
}
}
},
"auth_ref": [
"r19",
"r20",
"r21"
]
},
"us-gaap_ConversionOfStockSharesIssued1": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ConversionOfStockSharesIssued1",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Conversion of Stock, Shares Issued",
"terseLabel": "Conversion of stock, shares issued",
"documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
}
}
},
"auth_ref": [
"r19",
"r20",
"r21"
]
},
"us-gaap_CorporateMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CorporateMember",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Corporate Segment [Member]",
"documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items."
}
}
},
"auth_ref": [
"r664"
]
},
"us-gaap_CostOfGoodsAndServicesSold": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CostOfGoodsAndServicesSold",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0,
"order": 6.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of goods sold",
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
}
}
},
"auth_ref": [
"r66",
"r67",
"r384"
]
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"us-gaap_CustomerListsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CustomerListsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Customer Lists [Member]",
"documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information."
}
}
},
"auth_ref": [
"r39",
"r673",
"r674",
"r675",
"r676",
"r678",
"r679",
"r681",
"r682"
]
},
"us-gaap_DeferredIncomeTaxAssetsNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredIncomeTaxAssetsNet",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 10.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Deferred Income Tax Assets, Net",
"terseLabel": "Deferred tax assets",
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
}
}
},
"auth_ref": [
"r297",
"r298"
]
},
"us-gaap_DepreciationDepletionAndAmortization": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DepreciationDepletionAndAmortization",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and amortization",
"definitionGuidance": "Depreciation and amortization",
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
}
}
},
"auth_ref": [
"r7",
"r166",
"r179",
"r196",
"r516",
"r517"
]
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensation"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement [Text Block]",
"terseLabel": "Share-based Compensation",
"documentation": "The entire disclosure for share-based payment arrangement."
}
}
},
"auth_ref": [
"r259",
"r263",
"r291",
"r292",
"r294",
"r530"
]
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement [Abstract]"
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"dei_DocumentInformationTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentInformationTable",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Information [Table]",
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r563"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentTransitionReport",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r595"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentType",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
"terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
}
}
},
"auth_ref": [
"r606"
]
},
"us-gaap_EarningsPerShareAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]",
"terseLabel": "Net income (loss) per share of Class A and Class B common stock"
}
}
},
"auth_ref": []
},
"us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareBasic",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic",
"terseLabel": "Basic",
"verboseLabel": "Basic net income (loss) per share attributable to common stockholders",
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
}
}
},
"auth_ref": [
"r128",
"r144",
"r145",
"r146",
"r147",
"r148",
"r149",
"r154",
"r156",
"r159",
"r160",
"r161",
"r165",
"r317",
"r323",
"r339",
"r340",
"r389",
"r405",
"r509"
]
},
"us-gaap_EarningsPerShareBasicAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareBasicAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic [Abstract]",
"terseLabel": "Numerator:"
}
}
},
"auth_ref": []
},
"us-gaap_EarningsPerShareBasicLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareBasicLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r156",
"r157",
"r159"
]
},
"us-gaap_EarningsPerShareDiluted": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareDiluted",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Diluted",
"terseLabel": "Diluted",
"verboseLabel": "Diluted net income (loss) per share attributable to common stockholders",
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
}
}
},
"auth_ref": [
"r128",
"r144",
"r145",
"r146",
"r147",
"r148",
"r149",
"r156",
"r159",
"r160",
"r161",
"r165",
"r317",
"r323",
"r339",
"r340",
"r389",
"r405",
"r509"
]
},
"us-gaap_EarningsPerShareDilutedAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareDilutedAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Diluted [Abstract]",
"terseLabel": "Numerator:"
}
}
},
"auth_ref": []
},
"us-gaap_EarningsPerShareTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShare"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Basic and Diluted Net Income Per Share",
"documentation": "The entire disclosure for earnings per share."
}
}
},
"auth_ref": [
"r153",
"r162",
"r163",
"r164"
]
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Effective Income Tax Rate Reconciliation, Percent",
"terseLabel": "Effective income tax rate reconciliation, percent",
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
}
}
},
"auth_ref": [
"r300",
"r531"
]
},
"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
"terseLabel": "Effective income tax rate reconciliation, at federal statutory income tax rate, percent",
"documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
}
}
},
"auth_ref": [
"r138",
"r300",
"r308",
"r531"
]
},
"grdn_EmployeeBenefitsAndShareBasedCompensationSubsequentToCorporateReorganization": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "EmployeeBenefitsAndShareBasedCompensationSubsequentToCorporateReorganization",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Employee Benefits and Share Based Compensation Subsequent to Corporate Reorganization",
"terseLabel": "Equity-based compensation subsequent to Corporate Reorganization",
"documentation": "Employee benefits and share based compensation subsequent to corporate reorganization."
}
}
},
"auth_ref": []
},
"grdn_EmployeeExpenses": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "EmployeeExpenses",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Employee Expenses",
"terseLabel": "Employee expenses (excluding share-based compensation expense)",
"documentation": "Employee expenses."
}
}
},
"auth_ref": []
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeRelatedLiabilitiesCurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 17.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Employee-related Liabilities, Current",
"terseLabel": "Accrued compensation",
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
}
}
},
"auth_ref": [
"r50"
]
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Unamortize share-based compensation costs related to each share-based incentive award (years)",
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": [
"r293"
]
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unamortized share-based compensation costs related to each share-based incentive award (in dollars)",
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
}
}
},
"auth_ref": [
"r713"
]
},
"us-gaap_EmployeeStockOptionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeStockOptionMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Employee Stock Option [Member]",
"terseLabel": "Employee Stock Option",
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Ex Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r646"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityFileNumber",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityFilerCategory",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r645"
]
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityRegistrantName",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityShellCompany",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r561"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r561"
]
},
"ecd_EqtyAwrdsAdjFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments, Footnote [Text Block]",
"terseLabel": "Equity Awards Adjustments, Footnote"
}
}
},
"auth_ref": [
"r600"
]
},
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
"terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
}
}
},
"auth_ref": [
"r641"
]
},
"ecd_EqtyAwrdsAdjsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjsMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments"
}
}
},
"auth_ref": [
"r641"
]
},
"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
}
}
},
"auth_ref": [
"r641"
]
},
"us-gaap_EquityComponentDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityComponentDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Component [Domain]",
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
}
}
},
"auth_ref": [
"r10",
"r106",
"r124",
"r125",
"r126",
"r139",
"r140",
"r141",
"r143",
"r148",
"r150",
"r152",
"r167",
"r205",
"r206",
"r228",
"r252",
"r306",
"r307",
"r314",
"r315",
"r316",
"r318",
"r322",
"r323",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r372",
"r380",
"r404",
"r420",
"r421",
"r422",
"r436",
"r495"
]
},
"ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EquityValuationAssumptionDifferenceFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
"terseLabel": "Equity Valuation Assumption Difference, Footnote"
}
}
},
"auth_ref": [
"r610"
]
},
"ecd_ErrCompAnalysisTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompAnalysisTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Erroneous Compensation Analysis [Text Block]",
"terseLabel": "Erroneous Compensation Analysis"
}
}
},
"auth_ref": [
"r568",
"r578",
"r588",
"r620"
]
},
"ecd_ErrCompRecoveryTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompRecoveryTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Erroneously Awarded Compensation Recovery [Table]",
"terseLabel": "Erroneously Awarded Compensation Recovery"
}
}
},
"auth_ref": [
"r565",
"r575",
"r585",
"r617"
]
},
"ecd_ExecutiveCategoryAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ExecutiveCategoryAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Executive Category [Axis]",
"terseLabel": "Executive Category:"
}
}
},
"auth_ref": [
"r616"
]
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r342",
"r343",
"r356",
"r534"
]
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Recurring and Nonrecurring [Table]",
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
}
}
},
"auth_ref": [
"r342",
"r343",
"r356",
"r534"
]
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueByFairValueHierarchyLevelAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail",
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Hierarchy and NAV [Axis]",
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
}
}
},
"auth_ref": [
"r246",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r341",
"r343",
"r344",
"r345",
"r346",
"r355",
"r356",
"r358",
"r381",
"r382",
"r383",
"r523",
"r524",
"r525",
"r526",
"r527",
"r534",
"r537"
]
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueByMeasurementFrequencyAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Measurement Frequency [Axis]",
"documentation": "Information by measurement frequency."
}
}
},
"auth_ref": [
"r342",
"r343",
"r344",
"r346",
"r534",
"r723",
"r726"
]
},
"us-gaap_FairValueDisclosuresAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueDisclosuresAbstract",
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_FairValueDisclosuresTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueDisclosuresTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurements"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Text Block]",
"verboseLabel": "Fair Value Measurements",
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
}
}
},
"auth_ref": [
"r351",
"r353",
"r354",
"r355",
"r358",
"r359",
"r360",
"r361",
"r362",
"r387",
"r534",
"r538"
]
},
"us-gaap_FairValueInputsLevel1Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueInputsLevel1Member",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1 [Member]",
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
}
}
},
"auth_ref": [
"r246",
"r253",
"r258",
"r343",
"r356",
"r381",
"r525",
"r526",
"r527",
"r534"
]
},
"us-gaap_FairValueInputsLevel2Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueInputsLevel2Member",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2 [Member]",
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
}
}
},
"auth_ref": [
"r246",
"r253",
"r258",
"r343",
"r344",
"r356",
"r382",
"r523",
"r524",
"r525",
"r526",
"r527",
"r534"
]
},
"us-gaap_FairValueInputsLevel3Member": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueInputsLevel3Member",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail",
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3 [Member]",
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
}
}
},
"auth_ref": [
"r246",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r343",
"r344",
"r345",
"r346",
"r356",
"r383",
"r523",
"r524",
"r525",
"r526",
"r527",
"r534",
"r537"
]
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
}
}
},
"auth_ref": []
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r347",
"r348",
"r349",
"r350",
"r351",
"r352"
]
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
"documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
}
}
},
"auth_ref": [
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r357"
]
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsTables"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
"terseLabel": "Summary of Reconciliation of the Activity for the Level 3 Contingent Consideration Fair Value Measurements",
"documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
}
}
},
"auth_ref": [
"r347",
"r352",
"r357"
]
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementFrequencyDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Measurement Frequency [Domain]",
"documentation": "Measurement frequency."
}
}
},
"auth_ref": [
"r342",
"r343",
"r344",
"r346",
"r534",
"r723",
"r726"
]
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
"verboseLabel": "Current year acquisitions",
"documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
}
}
},
"auth_ref": [
"r350",
"r357"
]
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
"verboseLabel": "Payments",
"documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
}
}
},
"auth_ref": [
"r350",
"r357"
]
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
"periodStartLabel": "Beginning balance",
"periodEndLabel": "Ending balance",
"documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
}
}
},
"auth_ref": [
"r347",
"r357"
]
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail",
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Hierarchy and NAV [Domain]",
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
}
}
},
"auth_ref": [
"r246",
"r253",
"r254",
"r255",
"r256",
"r257",
"r258",
"r341",
"r343",
"r344",
"r345",
"r346",
"r355",
"r356",
"r358",
"r381",
"r382",
"r383",
"r523",
"r524",
"r525",
"r526",
"r527",
"r534",
"r537"
]
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementsRecurringMember",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Recurring [Member]",
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
}
}
},
"auth_ref": [
"r534",
"r720",
"r721",
"r722",
"r723",
"r724",
"r726"
]
},
"us-gaap_FinanceLeasePrincipalPayments": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FinanceLeasePrincipalPayments",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 27.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Finance Lease, Principal Payments",
"negatedLabel": "Principal payments on finance lease obligations",
"documentation": "Amount of cash outflow for principal payment on finance lease."
}
}
},
"auth_ref": [
"r375",
"r376"
]
},
"us-gaap_FinancialLiabilitiesFairValueDisclosure": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FinancialLiabilitiesFairValueDisclosure",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Financial Liabilities Fair Value Disclosure",
"verboseLabel": "Contingent consideration payable",
"documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
}
}
},
"auth_ref": [
"r720",
"r721",
"r725"
]
},
"us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
"xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetUsefulLife",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Finite-Lived Intangible Asset, Useful Life",
"terseLabel": "Finite-lived intangible asset, useful life",
"documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
}
}
},
"auth_ref": []
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Finite-Lived Intangible Assets by Major Class [Axis]",
"documentation": "Information by major type or class of finite-lived intangible assets."
}
}
},
"auth_ref": [
"r218",
"r219",
"r220",
"r221",
"r223",
"r224",
"r225",
"r226",
"r385",
"r386",
"r505"
]
},
"us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Finite-Lived Intangible Assets, Fair Value Disclosure",
"terseLabel": "Finite-lived intangible assets, fair value disclosure",
"documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life."
}
}
},
"auth_ref": [
"r720",
"r721",
"r725"
]
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
}
}
},
"auth_ref": [
"r218",
"r219",
"r220",
"r221",
"r223",
"r224",
"r225",
"r226",
"r505"
]
},
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
"terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r624"
]
},
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Expense of Enforcement, Amount",
"terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r624"
]
},
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery due to Violation of Home Country Law, Amount",
"terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r624"
]
},
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
"terseLabel": "Forgone Recovery, Explanation of Impracticability"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r624"
]
},
"ecd_ForgoneRecoveryIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Forgone Recovery, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r624"
]
},
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
"terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
}
}
},
"auth_ref": [
"r605"
]
},
"us-gaap_Goodwill": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Goodwill",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 8.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill",
"terseLabel": "Goodwill",
"documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
}
}
},
"auth_ref": [
"r113",
"r208",
"r388",
"r517",
"r521",
"r535",
"r547",
"r671",
"r672"
]
},
"us-gaap_GranteeStatusAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GranteeStatusAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Grantee Status [Axis]",
"documentation": "Information by status of recipient to whom award is granted."
}
}
},
"auth_ref": [
"r260",
"r262",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"us-gaap_GranteeStatusDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GranteeStatusDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Grantee Status [Domain]",
"documentation": "Status of recipient to whom award is granted."
}
}
},
"auth_ref": [
"r260",
"r262",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"us-gaap_GrossProfit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GrossProfit",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Gross Profit",
"totalLabel": "Gross profit",
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
}
}
},
"auth_ref": [
"r63",
"r68",
"r100",
"r137",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r363",
"r511",
"r516",
"r663",
"r665",
"r666",
"r667",
"r668",
"r685"
]
},
"grdn_GuardianPharmacyLLCMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "GuardianPharmacyLLCMember",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Guardian Pharmacy LLC [Member]",
"terseLabel": "Guardian Pharmacy, LLC [Member]"
}
}
},
"auth_ref": []
},
"us-gaap_IPOMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IPOMember",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "IPO [Member]",
"documentation": "First sale of stock by a private company to the public."
}
}
},
"auth_ref": []
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_ProfitLoss",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"totalLabel": "Income (loss) before income taxes",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
}
}
},
"auth_ref": [
"r64",
"r96",
"r100",
"r391",
"r400",
"r511",
"r516",
"r663",
"r665",
"r666",
"r667",
"r668"
]
},
"us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 2.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
"terseLabel": "Net income (loss)",
"documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
}
}
},
"auth_ref": [
"r90",
"r100",
"r137",
"r142",
"r148",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r317",
"r323",
"r340",
"r363",
"r400",
"r511",
"r663",
"r665",
"r666",
"r667",
"r668",
"r685"
]
},
"us-gaap_IncomeStatementAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementAbstract",
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_IncomeStatementLocationAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementLocationAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Income Location, Balance [Axis]",
"documentation": "Information by location in statement of income where disaggregated amount has been reported."
}
}
},
"auth_ref": [
"r229",
"r231",
"r232",
"r348",
"r352",
"r357",
"r418",
"r419",
"r480",
"r505",
"r536",
"r731"
]
},
"us-gaap_IncomeStatementLocationDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementLocationDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Income Location, Balance [Domain]",
"documentation": "Location in statement of income where disaggregated amount has been reported."
}
}
},
"auth_ref": [
"r231",
"r232",
"r348",
"r352",
"r357",
"r418",
"r419",
"r480",
"r505",
"r536",
"r731"
]
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxDisclosureAbstract",
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxDisclosureTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxes"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes",
"documentation": "The entire disclosure for income tax."
}
}
},
"auth_ref": [
"r138",
"r296",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r309",
"r311",
"r312",
"r313",
"r433",
"r531"
]
},
"us-gaap_IncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxExpenseBenefit",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_ProfitLoss",
"weight": -1.0,
"order": 11.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Expense (Benefit)",
"terseLabel": "Provision for income taxes",
"verboseLabel": "Income taxes",
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
}
}
},
"auth_ref": [
"r103",
"r104",
"r151",
"r152",
"r166",
"r182",
"r196",
"r299",
"r300",
"r310",
"r406",
"r531"
]
},
"grdn_IncomeTaxesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "IncomeTaxesLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Income Taxes [Line Items]"
}
}
},
"auth_ref": []
},
"us-gaap_IncomeTaxesPaid": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxesPaid",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Income Taxes Paid",
"definitionGuidance": "Cash paid during the year for income taxes",
"documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
}
}
},
"auth_ref": [
"r18",
"r78",
"r653",
"r714",
"r715"
]
},
"grdn_IncomeTaxesTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "IncomeTaxesTable",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Income Taxes [Table]"
}
}
},
"auth_ref": []
},
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsPayable",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 10.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Accounts Payable",
"terseLabel": "Accounts payable",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
}
}
},
"auth_ref": [
"r6"
]
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsReceivable",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 7.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Accounts Receivable",
"negatedLabel": "Accounts receivable",
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
}
}
},
"auth_ref": [
"r6"
]
},
"us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 11.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Employee Related Liabilities",
"terseLabel": "Accrued compensation",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
}
}
},
"auth_ref": [
"r6"
]
},
"us-gaap_IncreaseDecreaseInInventories": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInInventories",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 8.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Inventories",
"negatedLabel": "Inventories",
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
}
}
},
"auth_ref": [
"r6"
]
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"auth_ref": []
},
"us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOtherCurrentAssets",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 9.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Other Current Assets",
"negatedLabel": "Other current assets",
"documentation": "Amount of increase (decrease) in current assets classified as other."
}
}
},
"auth_ref": [
"r652"
]
},
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInOtherOperatingLiabilities",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 12.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Other Operating Liabilities",
"terseLabel": "Other operating liabilities",
"documentation": "Amount of increase (decrease) in operating liabilities classified as other."
}
}
},
"auth_ref": [
"r6"
]
},
"ecd_IndividualAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "IndividualAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Individual [Axis]",
"terseLabel": "Individual:"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r616",
"r624",
"r628",
"r636"
]
},
"ecd_InsiderTradingArrLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingArrLineItems",
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Arrangements [Line Items]",
"terseLabel": "Insider Trading Arrangements:"
}
}
},
"auth_ref": [
"r634"
]
},
"ecd_InsiderTradingPoliciesProcLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingPoliciesProcLineItems",
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures [Line Items]",
"terseLabel": "Insider Trading Policies and Procedures:"
}
}
},
"auth_ref": [
"r564",
"r640"
]
},
"ecd_InsiderTrdPoliciesProcAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
],
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures Adopted [Flag]",
"terseLabel": "Insider Trading Policies and Procedures Adopted"
}
}
},
"auth_ref": [
"r564",
"r640"
]
},
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
],
"lang": {
"en-us": {
"role": {
"label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted"
}
}
},
"auth_ref": [
"r564",
"r640"
]
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IntangibleAssetsNetExcludingGoodwill",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 7.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Intangible Assets, Net (Excluding Goodwill)",
"terseLabel": "Intangible assets, net",
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
}
}
},
"auth_ref": [
"r218",
"r679",
"r680"
]
},
"us-gaap_InterestExpenseNonoperating": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestExpenseNonoperating",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0,
"order": 9.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Interest Expense, Nonoperating",
"terseLabel": "Interest expense",
"documentation": "Amount of interest expense classified as nonoperating."
}
}
},
"auth_ref": [
"r178",
"r651"
]
},
"us-gaap_InterestExpenseOperating": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestExpenseOperating",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Interest Expense, Operating",
"terseLabel": "Interest expense",
"documentation": "Amount of interest expense classified as operating."
}
}
},
"auth_ref": [
"r178",
"r390",
"r650"
]
},
"us-gaap_InterestPaidNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestPaidNet",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Cash paid during the year for interest",
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
}
}
},
"auth_ref": [
"r130",
"r133",
"r134"
]
},
"us-gaap_InventoryNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InventoryNet",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Inventory, Net",
"terseLabel": "Inventories",
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
}
}
},
"auth_ref": [
"r119",
"r507",
"r547"
]
},
"us-gaap_LegalFees": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LegalFees",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Legal Fees",
"terseLabel": "Legal expenses",
"documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
}
}
},
"auth_ref": [
"r648"
]
},
"us-gaap_Liabilities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Liabilities",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0,
"order": 12.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities",
"totalLabel": "Total liabilities",
"documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
}
}
},
"auth_ref": [
"r13",
"r49",
"r50",
"r51",
"r52",
"r53",
"r54",
"r55",
"r137",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r327",
"r330",
"r331",
"r363",
"r454",
"r510",
"r559",
"r685",
"r728",
"r729"
]
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquity",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
}
}
},
"auth_ref": [
"r62",
"r95",
"r398",
"r547",
"r656",
"r670",
"r727"
]
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and equity"
}
}
},
"auth_ref": []
},
"us-gaap_LiabilitiesCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 13.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities",
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
}
}
},
"auth_ref": [
"r51",
"r111",
"r137",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r327",
"r330",
"r331",
"r363",
"r547",
"r685",
"r728",
"r729"
]
},
"us-gaap_LiabilitiesCurrentAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrentAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"auth_ref": []
},
"us-gaap_LiabilitiesFairValueAdjustment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesFairValueAdjustment",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfReconciliationOfTheActivityForTheLevel3ContingentConsiderationFairValueMeasurementsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Fair Value Adjustment",
"verboseLabel": "Fair value adjustments",
"documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
}
}
},
"auth_ref": []
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesFairValueDisclosure",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Fair Value Disclosure",
"verboseLabel": "Fair value of financial instruments",
"documentation": "Fair value of financial and nonfinancial obligations."
}
}
},
"auth_ref": [
"r343",
"r720"
]
},
"us-gaap_LiabilitiesFairValueDisclosureAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesFairValueDisclosureAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsSummaryOfLiabilitiesMeasuredAtFairValueOnARecurringBasisOnTheCompanySConsolidatedBalanceSheetsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Fair Value Disclosure [Abstract]",
"terseLabel": "Liabilities:"
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"ecd_MeasureAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Measure [Axis]",
"terseLabel": "Measure:"
}
}
},
"auth_ref": [
"r608"
]
},
"ecd_MeasureName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Measure Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r608"
]
},
"grdn_MembersEquityMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "MembersEquityMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Members Equity [Member]",
"terseLabel": "Members' Equity [Member]",
"documentation": "Members equity."
}
}
},
"auth_ref": []
},
"us-gaap_MinorityInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MinorityInterest",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0,
"order": 24.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Equity, Attributable to Noncontrolling Interest",
"terseLabel": "Non-controlling\u00a0interests",
"documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
}
}
},
"auth_ref": [
"r61",
"r94",
"r137",
"r204",
"r237",
"r239",
"r240",
"r241",
"r244",
"r245",
"r363",
"r397",
"r458"
]
},
"us-gaap_MinorityInterestOwnershipPercentageByParent": {
"xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MinorityInterestOwnershipPercentageByParent",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Subsidiary, Ownership Percentage, Parent",
"terseLabel": "Subsidiary, ownership percentage, parent",
"documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
}
}
},
"auth_ref": []
},
"ecd_MnpiDiscTimedForCompValFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MnpiDiscTimedForCompValFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "MNPI Disclosure Timed for Compensation Value [Flag]",
"terseLabel": "MNPI Disclosure Timed for Compensation Value"
}
}
},
"auth_ref": [
"r627"
]
},
"ecd_MtrlTermsOfTrdArrTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MtrlTermsOfTrdArrTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Material Terms of Trading Arrangement [Text Block]",
"terseLabel": "Material Terms of Trading Arrangement"
}
}
},
"auth_ref": [
"r635"
]
},
"ecd_NamedExecutiveOfficersFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NamedExecutiveOfficersFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Named Executive Officers, Footnote [Text Block]",
"terseLabel": "Named Executive Officers, Footnote"
}
}
},
"auth_ref": [
"r609"
]
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInFinancingActivities",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 18.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by (used in) financing activities",
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
}
}
},
"auth_ref": [
"r132"
]
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Financing activities"
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInInvestingActivities",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 14.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in investing activities",
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
}
}
},
"auth_ref": [
"r132"
]
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Investing activities"
}
}
},
"auth_ref": []
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInOperatingActivities",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash provided by operating activities",
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
}
}
},
"auth_ref": [
"r76",
"r77",
"r79"
]
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Operating activities"
}
}
},
"auth_ref": []
},
"us-gaap_NetIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
},
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail": {
"parentTag": null,
"weight": null,
"order": null,
"root": true
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"totalLabel": "Net income (loss) attributable to Guardian Pharmacy Services, Inc.",
"definitionGuidance": "Net income (loss) attributable to Guardian Pharmacy Services, Inc.",
"presentationGuidance": "Allocation of net income (loss) attributable to Guardian Pharmacy Inc.",
"label": "Net Income (Loss)",
"terseLabel": "Net Income (Loss)",
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
}
}
},
"auth_ref": [
"r69",
"r79",
"r97",
"r109",
"r122",
"r123",
"r126",
"r137",
"r142",
"r144",
"r145",
"r146",
"r147",
"r148",
"r151",
"r152",
"r158",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r317",
"r323",
"r340",
"r363",
"r403",
"r476",
"r493",
"r494",
"r557",
"r685"
]
},
"grdn_NetIncomeLossAttributableToLlcPriorToCooperateReorganization": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "NetIncomeLossAttributableToLlcPriorToCooperateReorganization",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0,
"order": 3.0
},
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0,
"order": 12.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income Loss Attributable To LLC Prior To Cooperate Reorganization",
"verboseLabel": "Less net income attributable to Guardian Pharmacy, LLC prior to the Corporate Reorganization",
"terseLabel": "Less: Net income attributable to Guardian Pharmacy, LLC before Corporate Reorganization",
"documentation": "Net income loss attributable to LLC prior to cooperate reorganization."
}
}
},
"auth_ref": []
},
"us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLossAttributableToNoncontrollingInterest",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0,
"order": 2.0
},
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0,
"order": 13.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income (Loss) Attributable to Noncontrolling Interest",
"terseLabel": "Less net income (loss) attributable to non-controlling interests",
"presentationGuidance": "Net income (loss) attributable to non-controlling interest",
"verboseLabel": "Less net income (loss) attributable to non-controlling interests",
"documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
}
}
},
"auth_ref": [
"r46",
"r91",
"r122",
"r123",
"r148",
"r151",
"r152",
"r402",
"r649"
]
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
"terseLabel": "Numerator:",
"verboseLabel": "Basic net income per share attributable to common stockholders"
}
}
},
"auth_ref": []
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
"terseLabel": "Diluted net income per share attributable to common stockholders"
}
}
},
"auth_ref": []
},
"grdn_NetIncomePriorToCorporateReorganizationValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "NetIncomePriorToCorporateReorganizationValue",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income Prior To Corporate Reorganization Value",
"terseLabel": "Net income prior to Corporate Reorganization",
"documentation": "Net income prior to corporate reorganization value."
}
}
},
"auth_ref": []
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
],
"lang": {
"en-us": {
"role": {
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "New Accounting Pronouncements",
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
}
}
},
"auth_ref": []
},
"grdn_NonCashequityContributionsFromnonControllingmembers": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "NonCashequityContributionsFromnonControllingmembers",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Non CashEquity Contributions FromNon ControllingMembers",
"terseLabel": "Non-cash\u00a0equity contributions from\u00a0non-controlling\u00a0interests",
"documentation": "Non cash\u00a0equity contributions from\u00a0non controlling\u00a0members."
}
}
},
"auth_ref": []
},
"ecd_NonGaapMeasureDescriptionTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonGaapMeasureDescriptionTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-GAAP Measure Description [Text Block]",
"terseLabel": "Non-GAAP Measure Description"
}
}
},
"auth_ref": [
"r608"
]
},
"ecd_NonNeosMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonNeosMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-NEOs [Member]",
"terseLabel": "Non-NEOs"
}
}
},
"auth_ref": [
"r572",
"r582",
"r592",
"r616",
"r624"
]
},
"ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgCompActuallyPaidAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO Average Compensation Actually Paid Amount",
"terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
}
}
},
"auth_ref": [
"r599"
]
},
"ecd_NonPeoNeoAvgTotalCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoAvgTotalCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO Average Total Compensation Amount",
"terseLabel": "Non-PEO NEO Average Total Compensation Amount"
}
}
},
"auth_ref": [
"r598"
]
},
"ecd_NonPeoNeoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonPeoNeoMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Non-PEO NEO [Member]",
"terseLabel": "Non-PEO NEO"
}
}
},
"auth_ref": [
"r616"
]
},
"ecd_NonRule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
}
}
},
"auth_ref": [
"r635"
]
},
"ecd_NonRule10b51ArrTrmntdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
}
}
},
"auth_ref": [
"r635"
]
},
"us-gaap_NoncashContributionExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NoncashContributionExpense",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Noncash Contribution Expense",
"definitionGuidance": "Non-cash equity contribution",
"documentation": "Noncash charitable contributions made by the entity during the period."
}
}
},
"auth_ref": [
"r79"
]
},
"us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
"terseLabel": "Purchases of property and equipment through finance leases",
"documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
}
}
},
"auth_ref": [
"r19",
"r20",
"r21"
]
},
"us-gaap_NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable",
"terseLabel": "Net income attributable to non-controlling interest subsequent to Corporate Reorganization",
"documentation": "Amount after tax of income (loss) attributable to other redeemable noncontrolling equity holder."
}
}
},
"auth_ref": [
"r65"
]
},
"us-gaap_NoncontrollingInterestMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NoncontrollingInterestMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Noncontrolling Interest [Member]",
"terseLabel": "Non-Controlling Interests [Member]",
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
}
}
},
"auth_ref": [
"r42",
"r252",
"r657",
"r658",
"r659",
"r660",
"r762"
]
},
"us-gaap_NonmonetaryTransactionTypeAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NonmonetaryTransactionTypeAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Nonmonetary Transaction Type [Axis]",
"documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
}
}
},
"auth_ref": [
"r378",
"r379",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545",
"r546"
]
},
"us-gaap_NonmonetaryTransactionTypeDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NonmonetaryTransactionTypeDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Nonmonetary Transaction Type [Domain]",
"documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
}
}
},
"auth_ref": [
"r378",
"r379",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545",
"r546"
]
},
"us-gaap_NonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NonoperatingIncomeExpense",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0,
"order": 8.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Nonoperating Income (Expense)",
"negatedTotalLabel": "Total other expenses (income)",
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
}
}
},
"auth_ref": [
"r71"
]
},
"us-gaap_OperatingIncomeLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingIncomeLoss",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0,
"order": 3.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Operating Income (Loss)",
"totalLabel": "Operating income (loss)",
"documentation": "The net result for the period of deducting operating expenses from operating revenues."
}
}
},
"auth_ref": [
"r100",
"r511",
"r663",
"r665",
"r666",
"r667",
"r668"
]
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseLiabilityCurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 15.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Operating Lease, Liability, Current",
"terseLabel": "Operating leases, current portion",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
}
}
},
"auth_ref": [
"r374"
]
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseLiabilityNoncurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 18.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Operating leases, net of current portion",
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
}
}
},
"auth_ref": [
"r374"
]
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeaseRightOfUseAsset",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 9.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease\u00a0right-of-use\u00a0assets",
"documentation": "Amount of lessee's right to use underlying asset under operating lease."
}
}
},
"auth_ref": [
"r373"
]
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackground"
],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"terseLabel": "Organization and Background",
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
}
}
},
"auth_ref": [
"r47",
"r89",
"r425",
"r426"
]
},
"us-gaap_OtherAssetsCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsCurrent",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0,
"order": 5.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Other Assets, Current",
"terseLabel": "Other current assets",
"documentation": "Amount of current assets classified as other."
}
}
},
"auth_ref": [
"r120",
"r547"
]
},
"us-gaap_OtherAssetsNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsNoncurrent",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 11.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Other Assets, Noncurrent",
"terseLabel": "Other assets",
"documentation": "Amount of noncurrent assets classified as other."
}
}
},
"auth_ref": [
"r114"
]
},
"us-gaap_OtherLiabilitiesCurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesCurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0,
"order": 16.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Other Liabilities, Current",
"terseLabel": "Other current liabilities",
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
}
}
},
"auth_ref": [
"r50",
"r547"
]
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesNoncurrent",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Liabilities",
"weight": 1.0,
"order": 19.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other liabilities",
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
}
}
},
"auth_ref": [
"r53"
]
},
"us-gaap_OtherNoncashIncomeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherNoncashIncomeExpense",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0,
"order": 6.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Other Noncash Income (Expense)",
"negatedLabel": "Other",
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
}
}
},
"auth_ref": [
"r79"
]
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherNonoperatingIncomeExpense",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0,
"order": 10.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Other Nonoperating Income (Expense)",
"negatedLabel": "Other expense (income), net",
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
}
}
},
"auth_ref": [
"r72"
]
},
"us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherNonoperatingIncomeExpenseAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Other Nonoperating Income (Expense) [Abstract]",
"terseLabel": "Other expenses (income):"
}
}
},
"auth_ref": []
},
"ecd_OtherPerfMeasureAmt": {
"xbrltype": "decimalItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OtherPerfMeasureAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Other Performance Measure, Amount",
"terseLabel": "Other Performance Measure, Amount"
}
}
},
"auth_ref": [
"r608"
]
},
"ecd_OutstandingAggtErrCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingAggtErrCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Aggregate Erroneous Compensation Amount",
"terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
}
}
},
"auth_ref": [
"r570",
"r580",
"r590",
"r622"
]
},
"ecd_OutstandingRecoveryCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Recovery Compensation Amount",
"terseLabel": "Compensation Amount"
}
}
},
"auth_ref": [
"r573",
"r583",
"r593",
"r625"
]
},
"ecd_OutstandingRecoveryIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Outstanding Recovery, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r573",
"r583",
"r593",
"r625"
]
},
"srt_OwnershipAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024",
"localname": "OwnershipAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Axis]"
}
}
},
"auth_ref": []
},
"srt_OwnershipDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024",
"localname": "OwnershipDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/IncomeTaxesAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Domain]"
}
}
},
"auth_ref": []
},
"us-gaap_PartnersCapitalAccountContributions": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PartnersCapitalAccountContributions",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Partners' Capital Account, Contributions",
"terseLabel": "Contributions",
"documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners)."
}
}
},
"auth_ref": [
"r82",
"r83"
]
},
"ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PayVsPerformanceDisclosureLineItems",
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance Disclosure [Line Items]",
"terseLabel": "Pay vs Performance Disclosure"
}
}
},
"auth_ref": [
"r597"
]
},
"us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 30.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payment for Contingent Consideration Liability, Financing Activities",
"negatedLabel": "Contingent payments related to acquisitions",
"verboseLabel": "Payment for contingent consideration liability financing activities",
"documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
}
}
},
"auth_ref": [
"r4"
]
},
"grdn_PaymentOfUnderwritingDiscounts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PaymentOfUnderwritingDiscounts",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Payment of Underwriting Discounts",
"terseLabel": "Payment of underwriting discounts",
"documentation": "Payment of underwriting discounts."
}
}
},
"auth_ref": []
},
"grdn_PaymentToCommonStockPerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PaymentToCommonStockPerShare",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquityParenthetical"
],
"lang": {
"en-us": {
"role": {
"label": "Payment To Common Stock Per Share",
"terseLabel": "Payment to common stock per share",
"documentation": "Payment to common stock per share."
}
}
},
"auth_ref": []
},
"grdn_PaymentToCommonStockShareholder": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PaymentToCommonStockShareholder",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Payment To Common Stock Shareholder",
"terseLabel": "Payments to Class\u00a0B common stock stockholders of $1.02 per share",
"documentation": "Payment to common stock shareholder."
}
}
},
"auth_ref": []
},
"us-gaap_PaymentsForMergerRelatedCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsForMergerRelatedCosts",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Payments for Merger Related Costs",
"terseLabel": "Payments for merger related costs",
"documentation": "The amount of cash paid during the reporting period for charges associated with the mergers."
}
}
},
"auth_ref": [
"r5"
]
},
"us-gaap_PaymentsForRepurchaseOfCommonStock": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsForRepurchaseOfCommonStock",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 31.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments for Repurchase of Common Stock",
"negatedLabel": "Payments for repurchase of common stock",
"documentation": "The cash outflow to reacquire common stock during the period."
}
}
},
"auth_ref": [
"r74"
]
},
"us-gaap_PaymentsForRepurchaseOfOtherEquity": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsForRepurchaseOfOtherEquity",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 26.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments for Repurchase of Other Equity",
"negatedLabel": "Other",
"documentation": "Amount of cash outflow to reacquire equity classified as other."
}
}
},
"auth_ref": [
"r74"
]
},
"us-gaap_PaymentsOfStockIssuanceCosts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsOfStockIssuanceCosts",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 20.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments of Stock Issuance Costs",
"negatedLabel": "Payments of equity offering costs",
"documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
}
}
},
"auth_ref": [
"r16"
]
},
"us-gaap_PaymentsToAcquireProductiveAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsToAcquireProductiveAssets",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0,
"order": 15.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments to Acquire Productive Assets",
"negatedLabel": "Payment for acquisitions",
"documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
}
}
},
"auth_ref": [
"r102",
"r716",
"r717",
"r718"
]
},
"grdn_PaymentsToMemberDistributions": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PaymentsToMemberDistributions",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 29.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments To Member Distributions",
"negatedLabel": "Member distributions",
"documentation": "Payments to member distributions."
}
}
},
"auth_ref": []
},
"us-gaap_PaymentsToMinorityShareholders": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsToMinorityShareholders",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 28.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Payments to Noncontrolling Interests",
"negatedLabel": "Distributions to\u00a0non-controlling\u00a0interests",
"documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
}
}
},
"auth_ref": [
"r16"
]
},
"ecd_PeerGroupIssuersFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupIssuersFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Peer Group Issuers, Footnote [Text Block]",
"terseLabel": "Peer Group Issuers, Footnote"
}
}
},
"auth_ref": [
"r607"
]
},
"ecd_PeerGroupTotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupTotalShareholderRtnAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Peer Group Total Shareholder Return Amount",
"terseLabel": "Peer Group Total Shareholder Return Amount"
}
}
},
"auth_ref": [
"r607"
]
},
"ecd_PeoActuallyPaidCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Actually Paid Compensation Amount",
"terseLabel": "PEO Actually Paid Compensation Amount"
}
}
},
"auth_ref": [
"r599"
]
},
"ecd_PeoMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO [Member]",
"terseLabel": "PEO"
}
}
},
"auth_ref": [
"r616"
]
},
"ecd_PeoName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Name",
"terseLabel": "PEO Name"
}
}
},
"auth_ref": [
"r609"
]
},
"ecd_PeoTotalCompAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoTotalCompAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "PEO Total Compensation Amount",
"terseLabel": "PEO Total Compensation Amount"
}
}
},
"auth_ref": [
"r598"
]
},
"grdn_PercentageOfConversionOfShare": {
"xbrltype": "percentItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PercentageOfConversionOfShare",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Percentage Of Conversion Of Share",
"terseLabel": "Percentage Of Conversion Of Share",
"documentation": "Percentage of conversion of share."
}
}
},
"auth_ref": []
},
"grdn_PharmacyOperations2024AcquisitionsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PharmacyOperations2024AcquisitionsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Pharmacy Operations 2024 Acquisitions [Member]",
"documentation": "Pharmacy operations 2024 acquisitions."
}
}
},
"auth_ref": []
},
"grdn_PharmacyOperations2025AcquisitionsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PharmacyOperations2025AcquisitionsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Pharmacy Operations 2025 Acquisitions [Member]",
"documentation": "Pharmacy operations 2025 acquisitions."
}
}
},
"auth_ref": []
},
"grdn_PharmacyOperationsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PharmacyOperationsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Pharmacy Operations [Member]",
"documentation": "Pharmacy operations."
}
}
},
"auth_ref": []
},
"us-gaap_PlanNameAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PlanNameAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Plan Name [Axis]",
"documentation": "Information by plan name for share-based payment arrangement."
}
}
},
"auth_ref": [
"r687",
"r688",
"r689",
"r690",
"r691",
"r692",
"r693",
"r694",
"r695",
"r696",
"r697",
"r698",
"r699",
"r700",
"r701",
"r702",
"r703",
"r704",
"r705",
"r706",
"r707",
"r708",
"r709",
"r710",
"r711",
"r712"
]
},
"us-gaap_PlanNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PlanNameDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Plan Name [Domain]",
"documentation": "Plan name for share-based payment arrangement."
}
}
},
"auth_ref": [
"r687",
"r688",
"r689",
"r690",
"r691",
"r692",
"r693",
"r694",
"r695",
"r696",
"r697",
"r698",
"r699",
"r700",
"r701",
"r702",
"r703",
"r704",
"r705",
"r706",
"r707",
"r708",
"r709",
"r710",
"r711",
"r712"
]
},
"ecd_PnsnAdjsPrrSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsPrrSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Adjustments Prior Service Cost [Member]",
"terseLabel": "Pension Adjustments Prior Service Cost"
}
}
},
"auth_ref": [
"r600"
]
},
"ecd_PnsnAdjsSvcCstMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsSvcCstMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Adjustments Service Cost [Member]",
"terseLabel": "Pension Adjustments Service Cost"
}
}
},
"auth_ref": [
"r644"
]
},
"ecd_PnsnBnftsAdjFnTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnBnftsAdjFnTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pension Benefits Adjustments, Footnote [Text Block]",
"terseLabel": "Pension Benefits Adjustments, Footnote"
}
}
},
"auth_ref": [
"r599"
]
},
"grdn_PreIpoawardsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PreIpoawardsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Pre IpoAwards [Member]",
"terseLabel": "Pre-IPO awards",
"documentation": "Pre-ipo\u00a0awards."
}
}
},
"auth_ref": []
},
"grdn_PriorToTheCorporateReorganizationMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PriorToTheCorporateReorganizationMember",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Prior to the Corporate Reorganization [Member]",
"documentation": "Prior to the corporate reorganization."
}
}
},
"auth_ref": []
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromIssuanceOfCommonStock",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0,
"order": 19.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from equity offering, net of underwriter fees",
"documentation": "The cash inflow from the additional capital contribution to the entity."
}
}
},
"auth_ref": [
"r3"
]
},
"us-gaap_ProceedsFromLinesOfCredit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromLinesOfCredit",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0,
"order": 23.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from Lines of Credit",
"terseLabel": "Borrowings from line of credit",
"documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
}
}
},
"auth_ref": [
"r15",
"r655"
]
},
"us-gaap_ProceedsFromMinorityShareholders": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromMinorityShareholders",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0,
"order": 25.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from Noncontrolling Interests",
"terseLabel": "Contributions from\u00a0non-controlling\u00a0interests",
"documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership."
}
}
},
"auth_ref": [
"r14"
]
},
"us-gaap_ProceedsFromNotesPayable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromNotesPayable",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0,
"order": 21.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from Notes Payable",
"terseLabel": "Borrowings from notes payable",
"documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
}
}
},
"auth_ref": [
"r15"
]
},
"us-gaap_ProceedsFromSaleOfOtherProductiveAssets": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromSaleOfOtherProductiveAssets",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0,
"order": 16.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Proceeds from Sale of Other Productive Assets",
"terseLabel": "Other",
"documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other."
}
}
},
"auth_ref": [
"r73"
]
},
"us-gaap_ProfitLoss": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProfitLoss",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0,
"order": 1.0
},
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0,
"order": 1.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicNetIncomeLossPerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
"totalLabel": "Net income (loss)",
"terseLabel": "Net income",
"verboseLabel": "Net income (loss)",
"definitionGuidance": "Segment net income (loss)",
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
}
}
},
"auth_ref": [
"r109",
"r122",
"r123",
"r131",
"r137",
"r142",
"r148",
"r151",
"r152",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r317",
"r323",
"r325",
"r328",
"r329",
"r340",
"r363",
"r391",
"r401",
"r435",
"r476",
"r493",
"r494",
"r532",
"r533",
"r558",
"r649",
"r685"
]
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentNet",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Assets",
"weight": 1.0,
"order": 6.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net",
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
}
}
},
"auth_ref": [
"r8",
"r377",
"r392",
"r399",
"r547"
]
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProvisionForDoubtfulAccounts",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 5.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Accounts Receivable, Credit Loss Expense (Reversal)",
"terseLabel": "Provision for losses on accounts receivable",
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
}
}
},
"auth_ref": [
"r129",
"r207"
]
},
"grdn_PurchasesOfPropertyAndEquipment": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "PurchasesOfPropertyAndEquipment",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0,
"order": 17.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Purchases of Property And Equipment",
"negatedLabel": "Purchases of property and equipment",
"documentation": "Purchases of property and equipment."
}
}
},
"auth_ref": []
},
"ecd_PvpTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance Disclosure [Table]",
"terseLabel": "Pay vs Performance Disclosure"
}
}
},
"auth_ref": [
"r597"
]
},
"ecd_PvpTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table"
}
}
},
"auth_ref": [
"r597"
]
},
"grdn_RecognitionOfDeferredTaxAssetNetFromCorporateReorganization": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "RecognitionOfDeferredTaxAssetNetFromCorporateReorganization",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Recognition Of Deferred Tax Asset Net From Corporate Reorganization",
"terseLabel": "Recognition of deferred tax asset, net from Corporate Reorganization",
"documentation": "Recognition of deferred tax asset net from corporate reorganization."
}
}
},
"auth_ref": []
},
"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
"documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
}
}
},
"auth_ref": [
"r28",
"r29"
]
},
"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsTables"
],
"lang": {
"en-us": {
"role": {
"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
"terseLabel": "Summary of Operating Segment Revenue, Net Income",
"documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
}
}
},
"auth_ref": [
"r28",
"r29"
]
},
"ecd_RecoveryOfErrCompDisclosureLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems",
"lang": {
"en-us": {
"role": {
"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
"terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
}
}
},
"auth_ref": [
"r565",
"r575",
"r585",
"r617"
]
},
"us-gaap_RepaymentsOfLinesOfCredit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RepaymentsOfLinesOfCredit",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 24.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Repayments of Lines of Credit",
"negatedLabel": "Repayments of line of credit",
"documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
}
}
},
"auth_ref": [
"r75",
"r655"
]
},
"us-gaap_RepaymentsOfNotesPayable": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RepaymentsOfNotesPayable",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0,
"order": 22.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Repayments of Notes Payable",
"negatedLabel": "Repayment of notes payable",
"documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
}
}
},
"auth_ref": [
"r75"
]
},
"ecd_RestatementDateAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDateAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Determination Date [Axis]",
"terseLabel": "Restatement Determination Date:"
}
}
},
"auth_ref": [
"r566",
"r576",
"r586",
"r618"
]
},
"ecd_RestatementDeterminationDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDeterminationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Determination Date",
"terseLabel": "Restatement Determination Date"
}
}
},
"auth_ref": [
"r567",
"r577",
"r587",
"r619"
]
},
"ecd_RestatementDoesNotRequireRecoveryTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDoesNotRequireRecoveryTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Restatement Does Not Require Recovery [Text Block]",
"terseLabel": "Restatement does not require Recovery"
}
}
},
"auth_ref": [
"r574",
"r584",
"r594",
"r626"
]
},
"grdn_RestrictedInterestUnitsConversionMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "RestrictedInterestUnitsConversionMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Restricted Interest Units Conversion [Member]",
"documentation": "Restricted interest units conversion."
}
}
},
"auth_ref": []
},
"us-gaap_RestrictedStockMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestrictedStockMember",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Restricted Stock [Member]",
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
}
}
},
"auth_ref": [
"r26"
]
},
"grdn_RestrictedStockUnitsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "RestrictedStockUnitsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Restricted Stock Units [Member]",
"terseLabel": "Restricted stock units",
"documentation": "Restricted stock units."
}
}
},
"auth_ref": []
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestrictedStockUnitsRSUMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Restricted Stock Units (RSUs) [Member]",
"verboseLabel": "Restricted stock units",
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
}
}
},
"auth_ref": []
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0,
"order": 23.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Retained earnings",
"documentation": "Amount of accumulated undistributed earnings (deficit)."
}
}
},
"auth_ref": [
"r59",
"r83",
"r396",
"r423",
"r424",
"r432",
"r457",
"r547"
]
},
"us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RetainedEarningsMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Retained Earnings [Member]",
"terseLabel": "Retained Earnings [Member]",
"documentation": "Accumulated undistributed earnings (deficit)."
}
}
},
"auth_ref": [
"r106",
"r139",
"r140",
"r141",
"r143",
"r148",
"r150",
"r152",
"r205",
"r206",
"r228",
"r306",
"r307",
"r314",
"r315",
"r316",
"r318",
"r322",
"r323",
"r332",
"r334",
"r335",
"r337",
"r338",
"r370",
"r372",
"r420",
"r422",
"r436",
"r762"
]
},
"grdn_RevenueAssociatedWithTheAcquisitions": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "RevenueAssociatedWithTheAcquisitions",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Revenue Associated with the Acquisitions",
"terseLabel": "Revenue associated with the acquisitions",
"documentation": "Revenue associated with the acquisitions."
}
}
},
"auth_ref": []
},
"us-gaap_Revenues": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Revenues",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0,
"order": 5.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Revenues",
"terseLabel": "Revenues",
"verboseLabel": "Revenue",
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
}
}
},
"auth_ref": [
"r98",
"r99",
"r127",
"r137",
"r166",
"r175",
"r176",
"r190",
"r196",
"r199",
"r201",
"r202",
"r204",
"r237",
"r238",
"r239",
"r240",
"r241",
"r242",
"r243",
"r244",
"r245",
"r363",
"r391",
"r516",
"r685"
]
},
"grdn_RightToReceivePerShareInCash": {
"xbrltype": "perShareItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "RightToReceivePerShareInCash",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Right To Receive Per Share In Cash",
"terseLabel": "Right to receive per share cash",
"documentation": "Right to receive per share cash."
}
}
},
"auth_ref": []
},
"ecd_Rule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrAdoptedFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Adopted"
}
}
},
"auth_ref": [
"r635"
]
},
"ecd_Rule10b51ArrTrmntdFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrTrmntdFlag",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Terminated"
}
}
},
"auth_ref": [
"r635"
]
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockNameOfTransactionDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Sale of Stock [Domain]",
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
}
}
},
"auth_ref": []
},
"us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Sale of Stock, Number of Shares Issued in Transaction",
"terseLabel": "Sale of Stock, Number of Shares Issued in Transaction",
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
}
}
},
"auth_ref": []
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Antidilutive Security, Excluded EPS Calculation [Table]",
"documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
}
}
},
"auth_ref": [
"r26"
]
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Summary of Diluted Shares Outstanding as the Effect would have been Anti-Dilutive",
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
}
}
},
"auth_ref": [
"r26"
]
},
"us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/AcquisitionsSummaryOfPreliminaryRecognitionOfTheAssetsAndLiabilitiesOfTheAcquisitionsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Business Acquisitions, by Acquisition [Table]",
"documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
}
}
},
"auth_ref": [
"r33",
"r34",
"r319"
]
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
"documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
}
}
},
"auth_ref": [
"r324"
]
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Summary of Basic Net Income Per Share of Class A and Class B Common Stock",
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
}
}
},
"auth_ref": [
"r662"
]
},
"us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
"documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
}
}
},
"auth_ref": [
"r25",
"r27",
"r156",
"r157",
"r159"
]
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
}
}
},
"auth_ref": [
"r30"
]
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationTables"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"terseLabel": "Summary of Share-based Compensation Expense",
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
}
}
},
"auth_ref": [
"r30"
]
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/FairValueMeasurementsTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Summary of Liabilities Measured at Fair Value on a Recurring Basis on the Company's Consolidated Balance Sheets",
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
}
}
},
"auth_ref": [
"r720",
"r721"
]
},
"us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
"terseLabel": "Summary of Preliminary Recognition of the Assets and Liabilities of the Acquisitions",
"documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
}
}
},
"auth_ref": [
"r87"
]
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
"documentation": "Disclosure of information about share-based payment arrangement."
}
}
},
"auth_ref": [
"r260",
"r262",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"grdn_ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Unamortized Share Based Compensation Incentive Awards [Line Items]",
"terseLabel": "Schedule of Unamortized Share Based Compensation Incentive Awards [Line Items]",
"documentation": "Schedule of unamortized share based compensation incentive awards."
}
}
},
"auth_ref": []
},
"grdn_ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTable",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Unamortized Share Based Compensation Incentive Awards [Table]",
"documentation": "Schedule of unamortized share based compensation incentive awards."
}
}
},
"auth_ref": []
},
"grdn_ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Unamortized Share Based Compensation Incentive Awards [Text Block]",
"terseLabel": "Schedule of Unamortized Share Based Compensation Incentive Awards",
"documentation": "Schedule of unamortized share based compensation incentive awards."
}
}
},
"auth_ref": []
},
"grdn_ScheduleOfWeightedAverageNumberOfSharesLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ScheduleOfWeightedAverageNumberOfSharesLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Weighted Average Number Of Shares [Line Items]"
}
}
},
"auth_ref": []
},
"grdn_ScheduleOfWeightedAverageNumberOfSharesTable": {
"xbrltype": "stringItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ScheduleOfWeightedAverageNumberOfSharesTable",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule Of Weighted Average Number Of Shares [Table]"
}
}
},
"auth_ref": []
},
"us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareTables"
],
"lang": {
"en-us": {
"role": {
"label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
"terseLabel": "Summary of Basic and Diluted Net Income Per Share of Class A and Class B Common Stock",
"documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
}
}
},
"auth_ref": [
"r24"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "Security12bTitle",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r560"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "SecurityExchangeName",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r562"
]
},
"us-gaap_SegmentDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Segments [Domain]",
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
}
}
},
"auth_ref": [
"r98",
"r99",
"r100",
"r101",
"r166",
"r171",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r196",
"r197",
"r198",
"r202",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r227",
"r233",
"r234",
"r407",
"r408",
"r409",
"r410",
"r411",
"r412",
"r413",
"r414",
"r415",
"r416",
"r417",
"r513",
"r516",
"r517",
"r521",
"r548",
"r730",
"r732",
"r733",
"r734",
"r735",
"r736",
"r737",
"r738",
"r739",
"r740",
"r741",
"r742",
"r743",
"r744",
"r745",
"r746",
"r747",
"r748",
"r749",
"r750",
"r751",
"r752",
"r753",
"r754",
"r755",
"r756",
"r757",
"r758",
"r759"
]
},
"us-gaap_SegmentReportingAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingAbstract",
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingDisclosureTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/Segments"
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting Disclosure [Text Block]",
"terseLabel": "Segments",
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
}
}
},
"auth_ref": [
"r101",
"r166",
"r170",
"r171",
"r172",
"r173",
"r174",
"r186",
"r188",
"r189",
"r194",
"r195",
"r196",
"r197",
"r198",
"r199",
"r200",
"r202",
"r512",
"r514",
"r515",
"r516",
"r518",
"r519",
"r520"
]
},
"us-gaap_SegmentReportingOtherItemAmount": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingOtherItemAmount",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting, Other Segment Item, Amount",
"terseLabel": "Other segment items",
"documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
}
}
},
"auth_ref": [
"r166",
"r188",
"r189",
"r196",
"r516"
]
},
"us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": []
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SellingGeneralAndAdministrativeExpense",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0,
"order": 7.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Selling, General and Administrative Expense",
"terseLabel": "Selling, general, and administrative expenses",
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
}
}
},
"auth_ref": [
"r70"
]
},
"us-gaap_ShareBasedCompensation": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensation",
"crdr": "debit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0,
"order": 4.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Noncash Expense",
"terseLabel": "Share-based compensation expense",
"documentation": "Amount of noncash expense for share-based payment arrangement."
}
}
},
"auth_ref": [
"r6"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r260",
"r262",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
"terseLabel": "Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted",
"documentation": "Net number of non-option equity instruments granted to participants."
}
}
},
"auth_ref": [
"r11"
]
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationScheduleOfUnamortizedShareBasedCompensationIncentiveAwardsDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "All Award Types",
"terseLabel": "All Award Types",
"documentation": "Award under share-based payment arrangement."
}
}
},
"auth_ref": [
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedPaymentArrangementNonemployeeMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement, Nonemployee [Member]",
"terseLabel": "Share-Based Payment Arrangement, Nonemployee [Member]",
"documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
}
}
},
"auth_ref": [
"r260",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289"
]
},
"grdn_ShareContributionPriorToCorporateReorganisationValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ShareContributionPriorToCorporateReorganisationValue",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Share Contribution Prior To Corporate Reorganisation Value",
"terseLabel": "Contributions prior to Corporate Reorganization",
"documentation": "Share contribution prior to corporate reorganisation value."
}
}
},
"auth_ref": []
},
"grdn_ShareDistributionPriorToCorporateReorganizationValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ShareDistributionPriorToCorporateReorganizationValue",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Share Distribution Prior To Corporate Reorganization Value",
"terseLabel": "Distributions prior to Corporate Reorganization",
"documentation": "Share distribution prior to corporate reorganization value."
}
}
},
"auth_ref": []
},
"grdn_ShareDistributionValue": {
"xbrltype": "monetaryItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "ShareDistributionValue",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Share Distribution Value",
"terseLabel": "Distributions",
"documentation": "Share distribution value."
}
}
},
"auth_ref": []
},
"us-gaap_SharesIssued": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharesIssued",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Shares, Issued",
"terseLabel": "Shares, issued",
"documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
}
}
},
"auth_ref": [
"r10"
]
},
"us-gaap_SharesIssuedPricePerShare": {
"xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharesIssuedPricePerShare",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Shares Issued, Price Per Share",
"terseLabel": "Shares issued, price per share",
"documentation": "Per share or per unit amount of equity securities issued."
}
}
},
"auth_ref": []
},
"us-gaap_SharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharesOutstanding",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Shares, Outstanding",
"periodEndLabel": "Ending Balance (Shares)",
"periodStartLabel": "Beginning Balance (Shares)",
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
}
}
},
"auth_ref": []
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SignificantAccountingPoliciesTextBlock",
"presentation": [
"http://www.guardianpharmacy.com/role/SummaryOfSignificantAccountingPolicies"
],
"lang": {
"en-us": {
"role": {
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Summary of Significant Accounting Policies",
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
}
}
},
"auth_ref": [
"r80",
"r136"
]
},
"us-gaap_StatementBusinessSegmentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementBusinessSegmentsAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/SegmentsSummaryOfOperatingSegmentRevenueNetIncomeDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Segments [Axis]",
"documentation": "Information by business segments."
}
}
},
"auth_ref": [
"r98",
"r99",
"r100",
"r101",
"r108",
"r166",
"r171",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r187",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r196",
"r197",
"r198",
"r202",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r227",
"r230",
"r233",
"r234",
"r407",
"r408",
"r409",
"r410",
"r411",
"r412",
"r413",
"r414",
"r415",
"r416",
"r417",
"r513",
"r516",
"r517",
"r521",
"r548",
"r730",
"r732",
"r733",
"r734",
"r735",
"r736",
"r737",
"r738",
"r739",
"r740",
"r741",
"r742",
"r743",
"r744",
"r745",
"r746",
"r747",
"r748",
"r749",
"r750",
"r751",
"r752",
"r753",
"r754",
"r755",
"r756",
"r757",
"r758",
"r759"
]
},
"us-gaap_StatementClassOfStockAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementClassOfStockAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfDilutedSharesOutstandingAsTheEffectWouldHaveBeenAntiDilutiveDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations",
"http://www.guardianpharmacy.com/role/CoverPage",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ShareBasedCompensationAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Class of Stock [Axis]",
"documentation": "Information by the different classes of stock of the entity."
}
}
},
"auth_ref": [
"r105",
"r116",
"r117",
"r118",
"r137",
"r156",
"r157",
"r159",
"r161",
"r168",
"r169",
"r204",
"r237",
"r239",
"r240",
"r241",
"r244",
"r245",
"r247",
"r248",
"r249",
"r250",
"r251",
"r363",
"r428",
"r429",
"r430",
"r431",
"r436",
"r437",
"r438",
"r439",
"r440",
"r441",
"r442",
"r443",
"r444",
"r445",
"r446",
"r447",
"r456",
"r477",
"r495",
"r498",
"r499",
"r500",
"r501",
"r502",
"r647",
"r654",
"r661"
]
},
"us-gaap_StatementEquityComponentsAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementEquityComponentsAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Equity Components [Axis]",
"documentation": "Information by component of equity."
}
}
},
"auth_ref": [
"r10",
"r57",
"r60",
"r61",
"r106",
"r124",
"r125",
"r126",
"r139",
"r140",
"r141",
"r143",
"r148",
"r150",
"r152",
"r167",
"r205",
"r206",
"r228",
"r252",
"r306",
"r307",
"r314",
"r315",
"r316",
"r318",
"r322",
"r323",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r372",
"r380",
"r404",
"r420",
"r421",
"r422",
"r436",
"r495"
]
},
"us-gaap_StatementLineItems": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementLineItems",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"auth_ref": [
"r139",
"r140",
"r141",
"r167",
"r372",
"r384",
"r427",
"r447",
"r448",
"r449",
"r450",
"r451",
"r452",
"r453",
"r456",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r465",
"r466",
"r467",
"r469",
"r470",
"r471",
"r472",
"r473",
"r475",
"r478",
"r479",
"r481",
"r482",
"r483",
"r484",
"r485",
"r486",
"r487",
"r488",
"r489",
"r490",
"r491",
"r492",
"r495",
"r552"
]
},
"us-gaap_StatementOfCashFlowsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfCashFlowsAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfFinancialPositionAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfStockholdersEquityAbstract",
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"auth_ref": []
},
"us-gaap_StatementTable": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementTable",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheetsParenthetical",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Statement [Table]",
"documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
}
}
},
"auth_ref": [
"r139",
"r140",
"r141",
"r167",
"r203",
"r372",
"r384",
"r427",
"r447",
"r448",
"r449",
"r450",
"r451",
"r452",
"r453",
"r456",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r465",
"r466",
"r467",
"r469",
"r470",
"r471",
"r472",
"r473",
"r475",
"r478",
"r479",
"r481",
"r482",
"r483",
"r484",
"r485",
"r486",
"r487",
"r488",
"r489",
"r490",
"r491",
"r492",
"r495",
"r552"
]
},
"ecd_StkPrcOrTsrEstimationMethodTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "StkPrcOrTsrEstimationMethodTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Price or TSR Estimation Method [Text Block]",
"terseLabel": "Stock Price or TSR Estimation Method"
}
}
},
"auth_ref": [
"r569",
"r579",
"r589",
"r621"
]
},
"us-gaap_StockAppreciationRightsSARSMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockAppreciationRightsSARSMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Appreciation Rights (SARs) [Member]",
"terseLabel": "Stock Appreciation Rights (SARs)",
"documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
}
}
},
"auth_ref": []
},
"grdn_StockIssuedDuringPeriodShareBasedCompensationForfeited": {
"xbrltype": "sharesItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "StockIssuedDuringPeriodShareBasedCompensationForfeited",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Issued During Period Share Based Compensation Forfeited",
"terseLabel": "Share-based compensation forfeitures (Shares)",
"documentation": "Stock issued during period share based compensation forfeited."
}
}
},
"auth_ref": []
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Issued During Period, Shares, New Issues",
"terseLabel": "Issuance of Class\u00a0A common stock, net of costs (Shares)",
"definitionGuidance": "Issuance of Class\u00a0B common stock associated with acquisition (Shares)",
"verboseLabel": "Stock issued during period, shares, new issues",
"documentation": "Number of new stock issued during the period."
}
}
},
"auth_ref": [
"r10",
"r56",
"r57",
"r83",
"r428",
"r495",
"r499"
]
},
"us-gaap_StockIssuedDuringPeriodSharesOther": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesOther",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Issued During Period, Shares, Other",
"terseLabel": "Stock Issued During Period, Shares, Other",
"documentation": "Number of shares of stock issued attributable to transactions classified as other."
}
}
},
"auth_ref": []
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueNewIssues",
"crdr": "credit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity",
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Stock Issued During Period, Value, New Issues",
"terseLabel": "Issuance of Class\u00a0A common stock, net of costs",
"definitionGuidance": "Issuance of Class B common stock associated with acquisition",
"verboseLabel": "Stock issued during period, value, new issues",
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
}
}
},
"auth_ref": [
"r10",
"r56",
"r57",
"r83",
"r436",
"r495",
"r499",
"r558"
]
},
"us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
"crdr": "debit",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
"negatedLabel": "Share-based compensation forfeitures",
"documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
}
}
},
"auth_ref": [
"r85"
]
},
"us-gaap_StockholdersEquityAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets"
],
"lang": {
"en-us": {
"role": {
"label": "Equity, Attributable to Parent [Abstract]",
"terseLabel": "Equity:"
}
}
},
"auth_ref": []
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"crdr": "credit",
"calculation": {
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0,
"order": 20.0
}
},
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedBalanceSheets",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfChangesInMembersEquityAndStockholdersEquity"
],
"lang": {
"en-us": {
"role": {
"label": "Equity, Including Portion Attributable to Noncontrolling Interest",
"totalLabel": "Total equity",
"periodStartLabel": "Beginning Balance",
"periodEndLabel": "Ending Balance",
"documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
}
}
},
"auth_ref": [
"r42",
"r43",
"r45",
"r106",
"r107",
"r125",
"r139",
"r140",
"r141",
"r143",
"r148",
"r150",
"r205",
"r206",
"r228",
"r252",
"r306",
"r307",
"r314",
"r315",
"r316",
"r318",
"r322",
"r323",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r364",
"r365",
"r369",
"r371",
"r380",
"r421",
"r422",
"r434",
"r458",
"r474",
"r496",
"r497",
"r503",
"r558",
"r656",
"r670",
"r727",
"r762"
]
},
"us-gaap_StockholdersEquityNoteStockSplit": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityNoteStockSplit",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Note, Stock Split",
"terseLabel": "Stockholders' equity note, stock split",
"documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
}
}
},
"auth_ref": [
"r84"
]
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsidiarySaleOfStockAxis",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Sale of Stock [Axis]",
"documentation": "Information by type of sale of the entity's stock."
}
}
},
"auth_ref": []
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SupplementalCashFlowInformationAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfCashFlows"
],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Supplemental disclosure of cash flow information"
}
}
},
"auth_ref": []
},
"ecd_TabularListTableTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TabularListTableTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Tabular List [Table Text Block]",
"terseLabel": "Tabular List, Table"
}
}
},
"auth_ref": [
"r615"
]
},
"ecd_TotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Total Shareholder Return Amount",
"terseLabel": "Total Shareholder Return Amount"
}
}
},
"auth_ref": [
"r607"
]
},
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Total Shareholder Return Vs Peer Group [Text Block]",
"terseLabel": "Total Shareholder Return Vs Peer Group"
}
}
},
"auth_ref": [
"r614"
]
},
"us-gaap_TrademarksMember": {
"xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TrademarksMember",
"presentation": [
"http://www.guardianpharmacy.com/role/AcquisitionsAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Trademarks [Member]",
"documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
}
}
},
"auth_ref": [
"r38",
"r522",
"r673",
"r674",
"r675",
"r676",
"r677",
"r678",
"r679",
"r680",
"r681",
"r682"
]
},
"ecd_TradingArrAxis": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrAxis",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:"
}
}
},
"auth_ref": [
"r634"
]
},
"ecd_TradingArrByIndTable": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangements, by Individual [Table]",
"terseLabel": "Trading Arrangements, by Individual"
}
}
},
"auth_ref": [
"r636"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "TradingSymbol",
"presentation": [
"http://www.guardianpharmacy.com/role/CoverPage"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"ecd_TrdArrAdoptionDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrAdoptionDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Adoption Date",
"terseLabel": "Adoption Date"
}
}
},
"auth_ref": [
"r637"
]
},
"ecd_TrdArrDuration": {
"xbrltype": "durationItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrDuration",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Duration",
"terseLabel": "Arrangement Duration"
}
}
},
"auth_ref": [
"r638"
]
},
"ecd_TrdArrExpirationDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrExpirationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Expiration Date",
"terseLabel": "Expiration Date"
}
}
},
"auth_ref": [
"r638"
]
},
"ecd_TrdArrIndName": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrIndName",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Individual Name",
"terseLabel": "Name"
}
}
},
"auth_ref": [
"r636"
]
},
"ecd_TrdArrIndTitle": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrIndTitle",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Individual Title",
"terseLabel": "Title"
}
}
},
"auth_ref": [
"r636"
]
},
"ecd_TrdArrSecuritiesAggAvailAmt": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrSecuritiesAggAvailAmt",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement, Securities Aggregate Available Amount",
"terseLabel": "Aggregate Available"
}
}
},
"auth_ref": [
"r639"
]
},
"ecd_TrdArrTerminationDate": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrTerminationDate",
"presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Arrangement Termination Date",
"terseLabel": "Termination Date"
}
}
},
"auth_ref": [
"r637"
]
},
"grdn_UnderwrittenSharesMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "UnderwrittenSharesMember",
"presentation": [
"http://www.guardianpharmacy.com/role/OrganizationAndBackgroundAdditionalInformationDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Underwritten Shares [Member]",
"documentation": "UnderwrittenShares."
}
}
},
"auth_ref": []
},
"ecd_UndrlygSecurityMktPriceChngPct": {
"xbrltype": "pureItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change"
}
}
},
"auth_ref": [
"r633"
]
},
"grdn_UnvestedClassAAndBCommonStockMember": {
"xbrltype": "domainItemType",
"nsuri": "http://www.guardianpharmacy.com/20250930",
"localname": "UnvestedClassAAndBCommonStockMember",
"presentation": [
"http://www.guardianpharmacy.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Unvested Class A And B Common Stock [Member]",
"terseLabel": "Unvested Class\u00a0A and B common stock",
"documentation": "Unvested class\u00a0a and b common stock"
}
}
},
"auth_ref": []
},
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
}
}
},
"auth_ref": [
"r603"
]
},
"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
"terseLabel": "Dilutive Restricted Stock Units and Class\u00a0A and B Common Stock",
"documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
}
}
},
"auth_ref": [
"r662"
]
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"verboseLabel": "Diluted",
"terseLabel": "Weighted average shares of Class\u00a0A and Class\u00a0B common stock outstanding used to calculate diluted net income per share",
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
}
}
},
"auth_ref": [
"r155",
"r161"
]
},
"us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesIssuedBasic",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Issued, Basic",
"terseLabel": "Number of shares used in basic computation",
"documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
}
}
},
"auth_ref": [
"r22",
"r23"
]
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
"terseLabel": "Denominator:"
}
}
},
"auth_ref": []
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail",
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Basic",
"verboseLabel": "Basic",
"terseLabel": "Weighted average number of shares of Class\u00a0A and Class\u00a0B common stock outstanding",
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
}
}
},
"auth_ref": [
"r154",
"r161"
]
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/BasicAndDilutedNetIncomePerShareSummaryOfBasicAndDilutedNetIncomePerShareOfClassAAndClassBCommonStockDetail"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
"terseLabel": "Denominator:"
}
}
},
"auth_ref": []
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
"presentation": [
"http://www.guardianpharmacy.com/role/ConsolidatedStatementsOfOperations"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
"terseLabel": "Weighted-average Class A and Class B common shares outstanding"
}
}
},
"auth_ref": []
},
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
"xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
"presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"
],
"lang": {
"en-us": {
"role": {
"label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
"terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
}
}
},
"auth_ref": [
"r601"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "30",
"Paragraph": "7",
"SubTopic": "30",
"Topic": "805",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
},
"r1": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "30",
"Paragraph": "8",
"SubTopic": "30",
"Topic": "805",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
},
"r2": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"SubTopic": "230",
"Topic": "830",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
},
"r3": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "14",
"Subparagraph": "(a)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
},
"r4": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "15",
"Subparagraph": "(f)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
},
"r5": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(g)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
},
"r6": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(a)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
},
"r7": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(b)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
},
"r8": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"SubTopic": "10",
"Topic": "360",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
},
"r9": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)",
"SubTopic": "30",
"Topic": "805",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
},
"r10": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"SubTopic": "10",
"Topic": "505",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
},
"r11": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)",
"SubTopic": "10",
"Topic": "718",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r12": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(g)(1)",
"SubTopic": "10",
"Topic": "805",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
},
"r13": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(22))",
"SubTopic": "10",
"Topic": "210",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r14": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "14",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
},
"r15": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "14",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
},
"r16": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
},
"r17": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
},
"r18": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
},
"r19": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
},
"r20": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
},
"r21": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "230",
"SubTopic": "10",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
},
"r22": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "45",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
},
"r23": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "45",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
},
"r24": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r25": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r26": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r27": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "260",
"SubTopic": "10",
"Section": "55",
"Paragraph": "52",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
},
"r28": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "280",
"SubTopic": "10",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r29": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "280",
"SubTopic": "10",
"Section": "50",
"Paragraph": "31",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
},
"r30": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r31": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "20",
"Section": "55",
"Paragraph": "12",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
},
"r32": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "718",
"SubTopic": "20",
"Section": "55",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
},
"r33": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "10",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
},
"r34": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "10",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
},
"r35": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "10",
"Section": "55",
"Paragraph": "37",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
},
"r36": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "20",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
},
"r37": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "20",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(e)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
},
"r38": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "20",
"Section": "55",
"Paragraph": "14",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
},
"r39": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "20",
"Section": "55",
"Paragraph": "20",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
},
"r40": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "30",
"Section": "25",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
},
"r41": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "805",
"SubTopic": "30",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
},
"r42": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "810",
"SubTopic": "10",
"Section": "45",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
},
"r43": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "810",
"SubTopic": "10",
"Section": "45",
"Paragraph": "16",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
},
"r44": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "810",
"SubTopic": "10",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
},
"r45": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "810",
"SubTopic": "10",
"Section": "55",
"Paragraph": "4I",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
},
"r46": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification",
"Topic": "810",
"SubTopic": "10",
"Section": "55",
"Paragraph": "4J",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
},
"r47": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "205",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/205/tableOfContent"
},
"r48": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(19)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r49": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r50": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(20))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r51": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(21))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r52": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(23))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r53": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(24))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r54": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(25))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r55": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(26))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r56": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r57": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(29))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r58": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r59": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r60": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(30))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r61": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(31))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r62": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(32))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r63": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r64": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(10))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r65": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r66": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(2)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r67": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(2)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r68": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r69": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(20))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r70": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r71": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r72": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r73": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "12",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
},
"r74": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "15",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
},
"r75": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "15",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
},
"r76": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
},
"r77": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
},
"r78": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
},
"r79": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
},
"r80": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "235",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/235/tableOfContent"
},
"r81": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "440",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/440/tableOfContent"
},
"r82": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 4.F)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
},
"r83": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.3-04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
},
"r84": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "4",
"Subparagraph": "(SAB Topic 4.C)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
},
"r85": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r86": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "805",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/805/tableOfContent"
},
"r87": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "805",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Section": "50",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
},
"r88": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "805",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
},
"r89": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "810",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/810/tableOfContent"
},
"r90": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "19",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
},
"r91": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1A",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
},
"r92": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(11))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
},
"r93": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
},
"r94": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
},
"r95": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(23))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
},
"r96": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(15))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
},
"r97": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
},
"r98": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r99": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r100": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r101": {
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r102": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "13",
"Subparagraph": "(c)",
"SubTopic": "10",
"Topic": "230",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
},
"r103": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Subparagraph": "(a)",
"SubTopic": "20",
"Topic": "740",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
},
"r104": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h))",
"SubTopic": "10",
"Topic": "235",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r105": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Name": "Regulation S-K (SK)",
"Number": "229",
"Section": "1402",
"Paragraph": "a",
"Publisher": "SEC"
},
"r106": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "105",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
},
"r107": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "105",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
},
"r108": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "205",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
},
"r109": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "205",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
},
"r110": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
},
"r111": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
},
"r112": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r113": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(15))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r114": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r115": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(18))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r116": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r117": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(28))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r118": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(29))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r119": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r120": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(8))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r121": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
},
"r122": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
},
"r123": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
},
"r124": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
},
"r125": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
},
"r126": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
},
"r127": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r128": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(25))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r129": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r130": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "17",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
},
"r131": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
},
"r132": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
},
"r133": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
},
"r134": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
},
"r135": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
},
"r136": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
},
"r137": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r138": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r139": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "23",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
},
"r140": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
},
"r141": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
},
"r142": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
},
"r143": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
},
"r144": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
},
"r145": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
},
"r146": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
},
"r147": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
},
"r148": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
},
"r149": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
},
"r150": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
},
"r151": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "8",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
},
"r152": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
},
"r153": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/260/tableOfContent"
},
"r154": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
},
"r155": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "16",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
},
"r156": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
},
"r157": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
},
"r158": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "60B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
},
"r159": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "60B",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
},
"r160": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
},
"r161": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r162": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r163": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
},
"r164": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
},
"r165": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
},
"r166": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "270",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
},
"r167": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "272",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
},
"r168": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "272",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
},
"r169": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "272",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
},
"r170": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/280/tableOfContent"
},
"r171": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
},
"r172": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "21",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
},
"r173": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "21",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
},
"r174": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r175": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r176": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r177": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r178": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r179": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r180": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r181": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r182": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r183": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Subparagraph": "(j)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r184": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "25",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
},
"r185": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "25",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
},
"r186": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "26",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
},
"r187": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "26A",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
},
"r188": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "26B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
},
"r189": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "26C",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
},
"r190": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r191": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r192": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r193": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r194": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "31",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
},
"r195": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r196": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(ee)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r197": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r198": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "34",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
},
"r199": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "40",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
},
"r200": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "41",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
},
"r201": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "41",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
},
"r202": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "42",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
},
"r203": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
},
"r204": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "323",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
},
"r205": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "4",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
},
"r206": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "5",
"Subparagraph": "(c)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
},
"r207": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
},
"r208": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
},
"r209": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r210": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r211": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r212": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r213": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r214": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r215": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r216": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r217": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r218": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
},
"r219": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r220": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r221": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r222": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r223": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r224": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r225": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r226": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r227": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
},
"r228": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350",
"SubTopic": "60",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
},
"r229": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "360",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
},
"r230": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "360",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
},
"r231": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "405",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(e)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
},
"r232": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "420",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
},
"r233": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "420",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
},
"r234": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "420",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4.d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
},
"r235": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "440",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
},
"r236": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "440",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
},
"r237": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r238": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r239": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r240": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r241": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
},
"r242": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
},
"r243": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
},
"r244": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
},
"r245": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
},
"r246": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1D",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
},
"r247": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
},
"r248": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
},
"r249": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
},
"r250": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "14",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
},
"r251": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
},
"r252": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.3-04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
},
"r253": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r254": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r255": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r256": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r257": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r258": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r259": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/718/tableOfContent"
},
"r260": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "1D",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
},
"r261": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
},
"r262": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
},
"r263": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r264": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r265": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r266": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r267": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r268": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r269": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r270": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r271": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r272": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r273": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r274": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r275": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r276": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r277": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r278": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r279": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r280": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r281": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r282": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r283": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r284": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r285": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r286": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r287": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r288": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r289": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(v)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r290": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r291": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r292": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r293": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r294": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(l)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r295": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
},
"r296": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/740/tableOfContent"
},
"r297": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
},
"r298": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
},
"r299": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
},
"r300": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
},
"r301": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
},
"r302": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "12C",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
},
"r303": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "14",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
},
"r304": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "17",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
},
"r305": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "21",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
},
"r306": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
},
"r307": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(d)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
},
"r308": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.1.Q1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
},
"r309": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.5.Q1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
},
"r310": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
},
"r311": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
},
"r312": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "270",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
},
"r313": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
},
"r314": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "323",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
},
"r315": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "323",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
},
"r316": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "323",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
},
"r317": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "323",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(g)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
},
"r318": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740",
"SubTopic": "323",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(g)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
},
"r319": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
},
"r320": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
},
"r321": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(c)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
},
"r322": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805",
"SubTopic": "60",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
},
"r323": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805",
"SubTopic": "60",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
},
"r324": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "808",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
},
"r325": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "19",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
},
"r326": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
},
"r327": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "25",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
},
"r328": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1A",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
},
"r329": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1A",
"Subparagraph": "(c)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
},
"r330": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
},
"r331": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
},
"r332": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r333": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r334": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r335": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r336": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(h)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r337": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "6",
"Subparagraph": "(i)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
},
"r338": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
},
"r339": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
},
"r340": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
},
"r341": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "54B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
},
"r342": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r343": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r344": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r345": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r346": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r347": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r348": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r349": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r350": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r351": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r352": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r353": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r354": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r355": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2E",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
},
"r356": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
},
"r357": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
},
"r358": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r359": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r360": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r361": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r362": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r363": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "825",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "28",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
},
"r364": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "17",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
},
"r365": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
},
"r366": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
},
"r367": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
},
"r368": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "20",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
},
"r369": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
},
"r370": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
},
"r371": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "8",
"Subparagraph": "(c)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
},
"r372": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "35",
"Paragraph": "12A",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
},
"r373": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
},
"r374": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
},
"r375": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
},
"r376": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(g)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
},
"r377": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
},
"r378": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
},
"r379": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3"
},
"r380": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "848",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(a)(3)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
},
"r381": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
},
"r382": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
},
"r383": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(bb)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
},
"r384": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SAB Topic 11.L)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
},
"r385": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "926",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
},
"r386": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "928",
"SubTopic": "340",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
},
"r387": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "940",
"SubTopic": "820",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
},
"r388": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
},
"r389": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(27))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
},
"r390": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-04(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
},
"r391": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
},
"r392": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942",
"SubTopic": "360",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
},
"r393": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r394": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r395": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r396": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r397": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(24))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r398": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r399": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
},
"r400": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(11))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r401": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(16))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r402": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r403": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r404": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r405": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r406": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
},
"r407": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column A))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r408": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column B))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r409": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column C))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r410": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column D))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r411": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column E))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r412": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column F))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r413": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column G))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r414": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column H))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r415": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column I))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r416": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column J))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r417": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "235",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-16(Column K))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
},
"r418": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
},
"r419": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "9",
"Subparagraph": "(a)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
},
"r420": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
},
"r421": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(f)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
},
"r422": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(f)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
},
"r423": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(g)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
},
"r424": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "2",
"Subparagraph": "(h)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
},
"r425": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
},
"r426": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
},
"r427": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
},
"r428": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
},
"r429": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
},
"r430": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
},
"r431": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
},
"r432": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
},
"r433": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "13",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
},
"r434": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
},
"r435": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
},
"r436": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
},
"r437": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
},
"r438": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "27",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
},
"r439": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r440": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r441": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r442": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r443": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r444": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r445": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(g)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r446": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
},
"r447": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
},
"r448": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r449": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r450": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r451": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r452": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r453": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r454": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r455": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r456": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r457": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r458": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r459": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r460": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r461": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r462": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r463": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r464": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r465": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r466": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r467": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r468": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r469": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r470": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r471": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r472": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r473": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
},
"r474": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
},
"r475": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
},
"r476": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "7",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
},
"r477": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
},
"r478": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r479": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r480": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(g)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r481": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r482": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r483": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r484": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r485": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r486": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r487": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r488": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r489": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r490": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r491": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r492": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r493": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
},
"r494": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
},
"r495": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
},
"r496": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
},
"r497": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
},
"r498": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
},
"r499": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
},
"r500": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
},
"r501": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
},
"r502": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
},
"r503": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946",
"SubTopic": "505",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
},
"r504": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954",
"SubTopic": "440",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
},
"r505": {
"role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "985",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
},
"r506": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
},
"r507": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
},
"r508": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
},
"r509": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "52",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
},
"r510": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r511": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "31",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
},
"r512": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "47",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
},
"r513": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "47",
"Subparagraph": "(bb)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
},
"r514": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "47",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
},
"r515": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "47",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
},
"r516": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "48",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
},
"r517": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "49",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
},
"r518": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "54",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
},
"r519": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "54",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
},
"r520": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "54",
"Subparagraph": "(e)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
},
"r521": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
},
"r522": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "40",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
},
"r523": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69B",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
},
"r524": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "69C",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
},
"r525": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r526": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
},
"r527": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "17",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
},
"r528": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "80",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "11",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
},
"r529": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715",
"SubTopic": "80",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
},
"r530": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r531": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "231",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
},
"r532": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "4J",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
},
"r533": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "810",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "4K",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
},
"r534": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "100",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
},
"r535": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "100",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
},
"r536": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "102",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
},
"r537": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "103",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
},
"r538": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "107",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
},
"r539": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
},
"r540": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "4",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
},
"r541": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "4",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
},
"r542": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "4",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
},
"r543": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "5",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5"
},
"r544": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "6",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
},
"r545": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "6",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
},
"r546": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "845",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "05",
"Paragraph": "6",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
},
"r547": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
},
"r548": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "9C",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
},
"r549": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
},
"r550": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
},
"r551": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
},
"r552": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "310",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
},
"r553": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
},
"r554": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
},
"r555": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
},
"r556": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "320",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
},
"r557": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "830",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "10",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
},
"r558": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "830",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "11",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
},
"r559": {
"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946",
"SubTopic": "830",
"Name": "Accounting Standards Codification",
"Section": "55",
"Paragraph": "12",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
},
"r560": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r561": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r562": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r563": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r564": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "16",
"Subsection": "J",
"Paragraph": "a"
},
"r565": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1"
},
"r566": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i"
},
"r567": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "A"
},
"r568": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "B"
},
"r569": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "C"
},
"r570": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "D"
},
"r571": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "E"
},
"r572": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r573": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "1",
"Subparagraph": "iii"
},
"r574": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Section": "6",
"Subsection": "F",
"Paragraph": "2"
},
"r575": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a"
},
"r576": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1"
},
"r577": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "i"
},
"r578": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "ii"
},
"r579": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iii"
},
"r580": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iv"
},
"r581": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "v"
},
"r582": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "2"
},
"r583": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "a",
"Subparagraph": "3"
},
"r584": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Section": "19",
"Paragraph": "b"
},
"r585": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a"
},
"r586": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1"
},
"r587": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "i"
},
"r588": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "ii"
},
"r589": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iii"
},
"r590": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "iv"
},
"r591": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "1",
"Sentence": "v"
},
"r592": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "2"
},
"r593": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "a",
"Subparagraph": "3"
},
"r594": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form N-CSR",
"Section": "18",
"Paragraph": "b"
},
"r595": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r596": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v"
},
"r597": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "1"
},
"r598": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "ii"
},
"r599": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii"
},
"r600": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Subclause": "ii"
},
"r601": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "i"
},
"r602": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "ii"
},
"r603": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "iii"
},
"r604": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "iv"
},
"r605": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "v"
},
"r606": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1",
"Subclause": "vi"
},
"r607": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iv"
},
"r608": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "vi"
},
"r609": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "3"
},
"r610": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "4"
},
"r611": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "i"
},
"r612": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "ii"
},
"r613": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "iii"
},
"r614": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "5",
"Subparagraph": "iv"
},
"r615": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "6"
},
"r616": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "v",
"Paragraph": "6",
"Subparagraph": "i"
},
"r617": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1"
},
"r618": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i"
},
"r619": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "A"
},
"r620": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "B"
},
"r621": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "C"
},
"r622": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "D"
},
"r623": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "i",
"Sentence": "E"
},
"r624": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "ii"
},
"r625": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "1",
"Subparagraph": "iii"
},
"r626": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "w",
"Paragraph": "2"
},
"r627": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "1"
},
"r628": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2"
},
"r629": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "A"
},
"r630": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "C"
},
"r631": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "D"
},
"r632": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "E"
},
"r633": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "402",
"Subsection": "x",
"Paragraph": "2",
"Subparagraph": "ii",
"Sentence": "F"
},
"r634": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a"
},
"r635": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "1"
},
"r636": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "A"
},
"r637": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "B"
},
"r638": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "C"
},
"r639": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "a",
"Paragraph": "2",
"Subparagraph": "D"
},
"r640": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Number": "229",
"Section": "408",
"Subsection": "b",
"Paragraph": "1"
},
"r641": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Number": "229",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "C",
"Clause": "1"
},
"r642": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "A",
"Number": "229"
},
"r643": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Number": "229"
},
"r644": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-K",
"Section": "402",
"Subsection": "v",
"Paragraph": "2",
"Subparagraph": "iii",
"Sentence": "B",
"Clause": "1",
"Subclause": "i",
"Number": "229"
},
"r645": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r646": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
},
"r647": {
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
"Topic": "272",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "3",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
},
"r648": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(6))",
"SubTopic": "10",
"Topic": "220",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r649": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
},
"r650": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03(2))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r651": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "2",
"Subparagraph": "(SX 210.5-03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
},
"r652": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "28",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
},
"r653": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "230",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2A",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
},
"r654": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(d))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r655": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(f))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r656": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "235",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
},
"r657": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "23",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
},
"r658": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "24",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
},
"r659": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
},
"r660": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "250",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
},
"r661": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "55",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
},
"r662": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "260",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
},
"r663": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "270",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
},
"r664": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "15",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
},
"r665": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
},
"r666": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "30",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
},
"r667": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(ee)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r668": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "280",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "32",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
},
"r669": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "310",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
},
"r670": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "323",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
},
"r671": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r672": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "20",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(h)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
},
"r673": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
},
"r674": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r675": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r676": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r677": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r678": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "1",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
},
"r679": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r680": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r681": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r682": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "350",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
},
"r683": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "405",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/405-30/tableOfContent"
},
"r684": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450",
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/450/tableOfContent"
},
"r685": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r686": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "470",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
},
"r687": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r688": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r689": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r690": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r691": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r692": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r693": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r694": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r695": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r696": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r697": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r698": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r699": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r700": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r701": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r702": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r703": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r704": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r705": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(d)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r706": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r707": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(e)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r708": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r709": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(ii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r710": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iii)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r711": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(iv)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r712": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(f)(2)(v)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r713": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
},
"r714": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "22",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
},
"r715": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "23",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
},
"r716": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "805",
"SubTopic": "50",
"Name": "Accounting Standards Codification",
"Section": "25",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
},
"r717": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "805",
"SubTopic": "50",
"Name": "Accounting Standards Codification",
"Section": "30",
"Paragraph": "1",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
},
"r718": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "805",
"SubTopic": "50",
"Name": "Accounting Standards Codification",
"Section": "30",
"Paragraph": "2",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
},
"r719": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "815",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "65",
"Paragraph": "1",
"Subparagraph": "(e)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
},
"r720": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r721": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r722": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r723": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r724": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
},
"r725": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2E",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
},
"r726": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
},
"r727": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "825",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "28",
"Subparagraph": "(f)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
},
"r728": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
},
"r729": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "852",
"SubTopic": "10",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
},
"r730": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "30",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
},
"r731": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "310",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "3",
"Subparagraph": "(a)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
},
"r732": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
},
"r733": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4B",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
},
"r734": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4C",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
},
"r735": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4D",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
},
"r736": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "4G",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
},
"r737": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
},
"r738": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
},
"r739": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
},
"r740": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "5",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
},
"r741": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r742": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r743": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r744": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r745": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(4)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r746": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(5)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r747": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(b)(6)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r748": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "6",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
},
"r749": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r750": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(b)(1)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r751": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(b)(2)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r752": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(b)(3)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r753": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r754": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7A",
"Subparagraph": "(d)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
},
"r755": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7B",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
},
"r756": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7B",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
},
"r757": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "40",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "7B",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
},
"r758": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "80",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(b)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
},
"r759": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944",
"SubTopic": "80",
"Name": "Accounting Standards Codification",
"Section": "50",
"Paragraph": "2",
"Subparagraph": "(c)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
},
"r760": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "205",
"Name": "Accounting Standards Codification",
"Section": "45",
"Paragraph": "4",
"Subparagraph": "(a)",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
},
"r761": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "210",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "1",
"Subparagraph": "(SX 210.6-04(18))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
},
"r762": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
},
"r763": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "946",
"SubTopic": "220",
"Name": "Accounting Standards Codification",
"Section": "S99",
"Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))",
"Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
}
}
}